we O O
report O O
the O O
case O O
of O O
a O O
14-year-old O O
female O O
with O O
acute O O
promyelocytic O O
leukemia O O
who O O
developed O O
symptomatic B-ADR B-ADR
cardiomyopathy I-ADR I-ADR
only O O
4 O O
months O O
into O O
treatment O O
with O O
a O O
combination O O
of O O
daunomycin O B-DRUG
and O O
all-trans O B-DRUG
retinoic O I-DRUG
acid O I-DRUG
( O O
atra B-DRUG O

hyperammonemia B-ADR B-ADR
secondary O O
to O O
valproic B-DRUG B-DRUG
acid I-DRUG I-DRUG
as O O
a O O
cause O O
of O O
lethargy O B-ADR
in O O
a O O
postictal O O
patient O O

despite O O
minimal O O
short-term O O
side O O
effects O O
and O O
apparent O O
efficacy O O
, O O
chronic O O
treatment O O
of O O
mg O O
with O O
mm B-DRUG B-DRUG
may O O
be O O
associated O O
with O O
increased O O
risk O O
of O O
lymphoproliferative B-ADR B-ADR
disorders I-ADR I-ADR

despite O O
a O O
hematologic O O
response O O
in O O
all O O
3 O O
patients O O
, O O
none O O
of O O
them O O
achieved O O
cytogenetic O B-ADR
remission O I-ADR
, O O
and O O
all O O
progressed O O
to O O
blast B-ADR B-ADR
crisis I-ADR I-ADR
at O O
7 O O
to O O
10 O O
months O O
of O O
imatinib B-DRUG B-DRUG
therapy O O

however O O
, O O
given O O
the O O
clinically O O
significant O O
result O O
to O O
the O O
interaction O O
between O O
tolazoline B-DRUG B-DRUG
and O O
cimetidine O B-DRUG
we O O
report O O
, O O
the O O
use O O
of O O
cimetidine O B-DRUG
in O O
tolazoline B-DRUG B-DRUG
induced O O
upper B-ADR B-ADR
gastrointestinal I-ADR I-ADR
hemorrhage I-ADR I-ADR
should O O
deserve O O
more O O
attention O O

an O O
association O O
of O O
granulocytopenia O O
, O O
eosinophilia O O
, O O
skin O B-ADR
reaction O I-ADR
and O O
hepatitis B-ADR O
during O O
propylthiouracil B-DRUG B-DRUG
( O O
ptu O B-DRUG
) O O
therapy O O
for O O
thyrotoxicosis O O
in O O
a O O
47 O O
year O O
old O O
black O O
female O O
is O O
reported O O

visceral B-ADR O
leishmaniasis I-ADR O
and O O
macrophagic O B-ADR
activation O I-ADR
syndrome O I-ADR
in O O
a O O
patient O O
with O O
rheumatoid O O
arthritis O O
under O O
treatment O O
with O O
adalimumab B-DRUG B-DRUG

we O O
report O O
here O O
a O O
rare O O
case O O
of O O
ritodrine-hydrochloride-induced O O
rhabdomyolysis B-ADR B-ADR
in O O
a O O
pregnant O O
patient O O
with O O
myotonic O O
dystrophy O O

development O O
of O O
sarcoidosis B-ADR B-ADR
during O O
interferon B-DRUG B-DRUG
alpha I-DRUG I-DRUG
2b I-DRUG O
and O O
ribavirin O B-DRUG
combination O O
therapy O O
for O O
chronic O O
hepatitis O O
c O O
-- O O
a O O
case O O
report O O
and O O
review O O
of O O
the O O
literature O O

recently O O
, O O
her O O
serum O B-ADR
theophylline B-ADR I-ADR
levels I-ADR I-ADR
had I-ADR I-ADR
increased I-ADR I-ADR
to I-ADR O
the I-ADR O
toxic I-ADR B-ADR
range I-ADR I-ADR
( O O
133.2 O O
micromol O O
/ O O
l O O
[ O O
24 O O
microg O O
/ O O
ml O O
]) O O
shortly O O
after O O
the O O
addition O O
of O O
zafirlukast O B-DRUG
( O O
accolate O O
, O O
zeneca O O
pharmaceuticals O O
, O O
wilmington O O
, O O
del O O
) O O
to O O
her O O
regimen O O

a O O
young O O
woman O O
developed O O
galactorrhea B-ADR B-ADR
during O O
treatment O O
with O O
a O O
new O O
dibenzoxazepine B-DRUG O
antidepressant O O
, O O
amoxapine O B-DRUG

concomitant O O
irradiation O O
apparently O O
enhanced O O
the O O
skin B-ADR O
toxicity I-ADR O
of O O
aminoglutethimide B-DRUG B-DRUG
or O O
possibly O O
aminoglutethimide B-DRUG B-DRUG
had O O
a O O
radiosensitizing O O
role O O
in O O
this O O
patient O O

laryngeal B-ADR B-ADR
dyspnea I-ADR I-ADR
in O O
relation O O
to O O
an O O
interaction O O
between O O
acenocoumarol O B-DRUG
and O O
topical O O
econazole B-DRUG B-DRUG
lotion O O

anterior B-ADR B-ADR
lumbosacral I-ADR I-ADR
radiculopathy I-ADR I-ADR
after O O
intrathecal O O
methotrexate B-DRUG B-DRUG
treatment O O

we O O
report O O
four O O
cases O O
of O O
severe B-ADR B-ADR
corneal I-ADR I-ADR
ulceration I-ADR I-ADR
in O O
methamphetamine B-DRUG B-DRUG
abusers O O

bilateral O O
acoustic O O
( O O
viii O O
) O O
nerve O O
palsy O O
in O O
this O O
patient O O
was O O
most O O
likely O O
a O O
manifestation O O
of O O
vincristine B-DRUG B-DRUG
neurotoxicity B-ADR B-ADR

we O O
present O O
three O O
cases O O
from O O
the O O
provincial O O
toxicology O O
center O O
of O O
british O O
columbia O O
, O O
canada O O
in O O
which O O
suicidal B-ADR B-ADR
overdose I-ADR I-ADR
deaths I-ADR I-ADR
were O O
associated O O
with O O
quetiapine B-DRUG B-DRUG

we O O
describe O O
a O O
case O O
of O O
significant O O
elevation B-ADR B-ADR
of I-ADR I-ADR
serum I-ADR I-ADR
transaminases I-ADR I-ADR
in O O
a O O
patient O O
treated O O
with O O
6-tg B-DRUG B-DRUG
for O O
a O O
flare O O
of O O
crohn O O
's O O
disease O O

after O O
intravitreal O O
injection O O
of O O
triamcinolone B-DRUG B-DRUG
acetonide I-DRUG I-DRUG
, O O
cataract B-ADR B-ADR
may O O
rapidly O O
develop O O
in O O
eyes O O
that O O
have O O
been O O
intensively O O
treated O O
, O O
topically O O
and O O
systemically O O
, O O
by O O
corticosteroids O O
for O O
several O O
years O O

warfarin-associated O O
bleeding B-ADR B-ADR
complication O I-ADR
saved O O
life O O

we O O
introduce O O
a O O
case O O
of O O
a O O
sixty O O
years O O
old O O
woman O O
with O O
several O O
previous O O
episodes O O
of O O
rhinitis B-ADR O
, O O
conjunctivitis O O
and O O
perspiration O O
immediately O O
after O O
the O O
administration O O
of O O
salmon O B-DRUG
calcitonin B-DRUG I-DRUG
with O O
nasal O O
spray O O
or O O
intramuscular O O
administration O O
( O O
calsynar O B-DRUG

the O O
clinical O O
findings O O
and O O
laboratory O O
studies O O
suggested O O
an O O
autoimmune B-ADR B-ADR
cell-mediated I-ADR I-ADR
hypersensitivity I-ADR I-ADR
reaction O I-ADR
triggered O O
by O O
phenobarbital B-DRUG B-DRUG

patients O O
treated O O
with O O
l-asparaginase B-DRUG B-DRUG
may O O
present O O
with O O
hemorrhagic O O
and O O
thrombotic B-ADR B-ADR
cerebrovascular I-ADR I-ADR
events I-ADR I-ADR

both O O
colchicine B-DRUG B-DRUG
and O O
statin O B-DRUG
therapy O O
may O O
be O O
associated O O
with O O
myopathy B-ADR O
, O O
which O O
usually O O
occurs O O
after O O
several O O
months O O
of O O
therapy O O

methods O O
: O O
the O O
patient O O
required O O
insulin B-DRUG O
desensitization O O
for O O
severe B-ADR O
urticaria I-ADR O
, O O
angioedema O O
, O O
and O O
occasional O O
wheezing O O
resulting O O
from O O
her O O
insulin B-DRUG O
dose O O

multiple O O
pulmonary O O
nodules O O
: O O
an O O
unusual O O
presentation O O
of O O
fludarabine B-DRUG B-DRUG
pulmonary B-ADR B-ADR
toxicity I-ADR I-ADR
: O O
case O O
report O O
and O O
review O O
of O O
literature O O

reversible O B-ADR
nonthrombocytopenic B-ADR I-ADR
palpable I-ADR I-ADR
purpura I-ADR I-ADR
associated O O
with O O
metoclopramide B-DRUG B-DRUG

several O O
cases O O
of O O
lithium-induced O O
creutzfeldt-jakob B-ADR B-ADR
syndrome I-ADR I-ADR
have O O
been O O
reported O O
to O O
date O O
; O O
all O O
of O O
them O O
were O O
elderly O O
patients O O
and O O
a O O
half O O
had O O
" O O
therapeutic O O
" O O
lithium B-DRUG B-DRUG
serum O O
levels O O

methods O O
: O O
five O O
cases O O
of O O
contact B-ADR B-ADR
dermatitis I-ADR I-ADR
due O O
to O O
budesonide B-DRUG B-DRUG
, O O
a O O
nonhalogenated O O
steroid O O
, O O
are O O
described O O

amphotericin O B-DRUG
b O I-DRUG
( O O
amb B-DRUG O
) O O
is O O
effective O O
, O O
but O O
its O O
use O O
is O O
limited O O
by O O
toxicity O O
: O O
renal O O
impairment O O
, O O
anaemia O O
, O O
fever O O
, O O
malaise B-ADR O
, O O
and O O
hypokalaemia O O
are O O
common O O

we O O
report O O
two O O
young O O
patients O O
with O O
cystic O O
fibrosis O O
who O O
presented O O
with O O
acute B-ADR B-ADR
renal I-ADR I-ADR
insufficiency I-ADR I-ADR
after O O
2-3 O O
weeks O O
of O O
oral O O
ciprofloxacin B-DRUG B-DRUG
therapy O O

we O O
report O O
a O O
case O O
of O O
codeine B-ADR B-DRUG
intoxication I-ADR O
in O O
the O O
neonate O O
, O O
in O O
which O O
the O O
drug O O
was O O
prescribed O O
for O O
cough O O
control O O
during O O
an O O
emergency O O
department O O
visit O O

rapamycin O O
/ O O
sirolimus-induced O O
pneumonitis B-ADR B-ADR
has O O
been O O
described O O
previously O O
in O O
renal O O
transplant O O
recipients O O
, O O
and O O
this O O
report O O
describes O O
a O O
stable O O
heart-lung O O
transplant O O
recipient O O
who O O
developed O O
a O O
pulmonary O B-ADR
infiltrate O I-ADR
that O O
reversed O O
after O O
ceasing O O
sr O B-DRUG
therapy O O

the O O
authors O O
suggest O O
that O O
in O O
patients O O
with O O
corneal B-ADR O
ulcers I-ADR O
refractory I-ADR O
to I-ADR O
conventional I-ADR O
treatment I-ADR O
who O O
are O O
receiving O O
colchicine B-DRUG B-DRUG
, O O
cessation O O
of O O
colchicine B-DRUG B-DRUG
therapy O O
should O O
be O O
considered O O

proliferation B-ADR O
of I-ADR O
abnormal I-ADR O
bone I-ADR O
marrow I-ADR O
histiocytes I-ADR O
, O O
an O O
undesired O O
effect O O
of O O
granulocyte B-DRUG O
macrophage-colony-stimulating I-DRUG O
factor I-DRUG O
therapy O O
in O O
a O O
patient O O
with O O
hurler O O
's O O
syndrome O O
undergoing O O
bone O O
marrow O O
transplantation O O

under O O
the O O
suspicion O O
of O O
amiodarone-induced O O
acute B-ADR B-ADR
pancreatitis I-ADR I-ADR
, O O
amiodarone B-DRUG B-DRUG
was O O
substituted O O
by O O
propafenone O B-DRUG

a O O
well-recognized O O
complication O O
of O O
ethambutol O B-DRUG
use O O
is O O
optic O O
neuropathy O O
, O O
but O O
the O O
potential O O
ocular B-ADR B-ADR
toxicity I-ADR I-ADR
of O O
isoniazid B-DRUG B-DRUG
is O O
often O O
overlooked O O

while O O
both O O
amiodarone B-DRUG B-DRUG
and O O
digoxin O B-DRUG
can O O
cause O O
permanent O O
visual O O
changes O O
, O O
the O O
ocular B-ADR B-ADR
effects I-ADR I-ADR
are O O
often O O
reversible O O

the O O
patient O O
was O O
found O O
to O O
have O O
no B-ADR O
motile I-ADR O
sperm I-ADR O
with O O
a O O
normal O O
sperm O O
count O O
, O O
while O O
taking O O
a O O
dose O O
of O O
400 O O
mg O O
/ O O
day O O
of O O
carbamazepine B-DRUG B-DRUG

these O O
cases O O
suggest O O
the O O
possibility O O
that O O
, O O
in O O
some O O
patients O O
, O O
leukopenia B-ADR O
or O O
agranulocytosis O B-ADR
during O O
olanzapine B-DRUG B-DRUG
treatment O O
might O O
be O O
dose-related O O

although O O
gabapentin B-DRUG B-DRUG
withdrawal O O
has O O
been O O
previously O O
reported O O
and O O
usually O O
consists O O
of O O
anxiety O O
, O O
diaphoresis O O
, O O
and O O
palpitations O O
, O O
this O O
is O O
the O O
first O O
reported O O
patient O O
with O O
generalized B-ADR B-ADR
seizures I-ADR I-ADR
and O O
status O B-ADR
epilepticus O I-ADR
secondary O O
to O O
gabapentin B-DRUG B-DRUG
withdrawal O O

a O O
fatal B-ADR B-ADR
pancytopenia I-ADR I-ADR
occurred O O
in O O
a O O
patient O O
with O O
an O O
history O O
of O O
depression O O
with O O
hypomanic O O
rebounds O O
, O O
admitted O O
for O O
a O O
manic O O
episode O O
and O O
treated O O
with O O
levomepromazine O B-DRUG
, O O
diazepam O O
and O O
lithium B-DRUG B-DRUG
carbonate I-DRUG I-DRUG

case O O
summary O O
: O O
a O O
65-year-old O O
patient O O
chronically O O
treated O O
with O O
the O O
selective O O
serotonin O O
reuptake O O
inhibitor O O
( O O
ssri O O
) O O
citalopram O B-DRUG
developed O O
confusion O O
, O O
agitation B-ADR O
, O O
tachycardia O O
, O O
tremors O O
, O O
myoclonic O B-ADR
jerks O I-ADR
and O O
unsteady O O
gait O O
, O O
consistent O O
with O O
serotonin O O
syndrome O O
, O O
following O O
initiation O O
of O O
fentanyl B-DRUG B-DRUG
, O O
and O O
all O O
symptoms O O
and O O
signs O O
resolved O O
following O O
discontinuation O O
of O O
fentanyl B-DRUG B-DRUG

a O O
57-year-old O O
woman O O
developed O O
pulmonary B-ADR B-ADR
sarcoidosis I-ADR I-ADR
during O O
therapy O O
with O O
interferon B-DRUG B-DRUG
beta I-DRUG I-DRUG
for O O
advanced O O
renal O O
cell O O
carcinoma O O
metastatic O O
to O O
mediastinal O O
lymph O O
nodes O O

we O O
report O O
a O O
43-year-old O O
woman O O
who O O
developed O O
sore O O
throat O O
, O O
swelling O B-ADR
of O I-ADR
the O I-ADR
lips O I-ADR
and O O
oral O O
cavity O O
and O O
dysphagia B-ADR O
, O O
2 O O
weeks O O
after O O
the O O
use O O
of O O
budesonide O B-DRUG
spray O O
( O O
budefat B-DRUG O
) O O
for O O
treatment O O
of O O
bronchial O O
asthma O O

this O O
case O O
extends O O
the O O
spectrum O O
of O O
fludarabine B-DRUG B-DRUG
pulmonary O B-ADR
toxicity O I-ADR
to O O
include O O
pulmonary B-ADR B-ADR
nodules I-ADR I-ADR

we O O
report O O
a O O
case O O
of O O
zidovudine B-DRUG B-DRUG
induced O O
anaemia B-ADR O
and O O
bone O B-ADR
marrow O I-ADR
aplasia O I-ADR
in O O
a O O
patient O O
infected O O
with O O
hiv O O

it O O
is O O
believed O O
that O O
this O O
is O O
the O O
first O O
reported O O
case O O
of O O
reversible O O
azathioprine-induced O O
cholestasis B-ADR B-ADR
associated O O
with O O
histological O O
evidence O O
of O O
bile O B-ADR
duct O I-ADR
injury O I-ADR

emergence O O
of O O
philadelphia B-ADR O
positive I-ADR O
chronic I-ADR B-ADR
myeloid I-ADR I-ADR
leukaemia I-ADR I-ADR
during O O
treatment O O
with O O
hydroxyurea B-DRUG B-DRUG
for O O
philadelphia O O
negative O O
essential O O
thrombocythaemia O O

following O O
7 O O
days O O
of O O
tigecycline B-DRUG B-DRUG
she O O
developed O O
severe B-ADR O
abdominal I-ADR O
pain I-ADR O
and O O
elevated O O
pancreatic O O
enzymes O O
suggesting O O
acute O B-ADR
pancreatitis O I-ADR

we O O
describe O O
children O O
and O O
adolescents O O
with O O
chronic O O
hematologic O O
and O O
oncologic O O
diseases O O
who O O
exhibited O O
drug-seeking O O
behavior O O
or O O
anticholinergic B-ADR B-ADR
symptoms I-ADR I-ADR
with O O
the O O
use O O
of O O
diphenhydramine B-DRUG B-DRUG

we O O
describe O O
a O O
case O O
of O O
disseminated O O
muscular O O
cysticercosis O O
followed O O
by O O
myositis O O
( O O
fever B-ADR O
, O O
diffuse O O
myalgia O O
, O O
weakness O O
of O O
the O O
lower O O
limbs O O
, O O
and O O
inflammatory O O
reaction O O
around O O
dying O O
cysticerci O O
) O O
induced O O
by O O
praziquantel B-DRUG B-DRUG
therapy O O
, O O
an O O
event O O
not O O
described O O
previously O O

a O O
child O O
in O O
whom O O
a O O
phenobarbital B-DRUG B-DRUG
hypersensitivity O O
drug O O
reaction O O
developed O O
which O O
consisted O O
of O O
fever O O
, O O
a O O
pruritic O B-ADR
desquamating O I-ADR
erythrodermic O I-ADR
rash O I-ADR
, O O
alopecia O O
, O O
icterus B-ADR O
, O O
protein-losing O O
enteropathy O O
, O O
myositis O O
, O O
and O O
nephritis O O
, O O
is O O
described O O

mi B-ADR B-ADR
related O O
to O O
the O O
use O O
of O O
activated O O
and O O
non-activated O O
pccs B-DRUG O
predominantly O O
affects O O
young O O
patients O O
who O O
often O O
have O O
no O O
preceding O O
history O O
of O O
, O O
or O O
risk O O
factors O O
for O O
, O O
mi B-ADR B-ADR
and O O
tends O O
to O O
be O O
associated O O
with O O
large O O
cumulative O O
doses O O
of O O
concentrate O O

a O O
74-year-old O O
hypercholestrerolaemic O O
woman O O
taking O O
cerivastatin B-DRUG B-DRUG
( O O
0.15 O O
mg O O
/ O O
day O O
) O O
for O O
22 O O
days O O
complained O O
of O O
general O B-ADR
muscle O I-ADR
weakness O I-ADR
and O O
muscle B-ADR B-ADR
pain I-ADR I-ADR

we O O
report O O
2 O O
cases O O
of O O
maculopapular B-ADR B-ADR
eruption I-ADR I-ADR
and O O
fever O O
in O O
patients O O
infected O O
with O O
human O O
immunodeficiency O O
virus O O
( O O
hiv O O
) O O
on O O
the O O
2nd O O
day O O
of O O
first O O
administration O O
of O O
ritonavir B-DRUG B-DRUG
, O O
a O O
protease O O
inhibitor O O

falling B-ADR B-ADR
backward I-ADR I-ADR
in O O
two O O
elderly O O
patients O O
taking O O
bupropion B-DRUG B-DRUG

conclusions O O
: O O
this O O
case O O
report O O
showed O O
that O O
the O O
clinical O O
appearance O O
of O O
hashimoto B-ADR B-ADR
's I-ADR I-ADR
disease I-ADR I-ADR
after O O
ifn-alpha B-DRUG B-DRUG
therapy O O
for O O
chronic O O
c O O
hepatitis O O
in O O
our O O
patient O O
was O O
associated O O
with O O
a O O
specific O O
genetic O O
predisposition O O
( O O
dr5 O O
) O O
for O O
this O O
pathology O O

a O O
16-year-old O O
boy O O
developed O O
fever B-ADR O
, O O
generalized O O
rigidity O O
, O O
leukocytosis O O
, O O
and O O
increased O O
serum O O
transaminase O O
and O O
creatine O O
kinase O O
levels O O
while O O
receiving O O
treatment O O
with O O
olanzapine B-DRUG B-DRUG
and O O
lithium O B-DRUG

treatment O O
of O O
chronic O O
hepatitis O O
c O O
with O O
interferon B-DRUG B-DRUG
alpha I-DRUG I-DRUG
( O O
ifn-alpha O B-DRUG
) O O
is O O
relatively O O
contraindicated O O
in O O
patients O O
with O O
psychiatric O O
disorders O O
because O O
of O O
possible O O
severe O O
psychiatric B-ADR B-ADR
side I-ADR I-ADR
effects I-ADR I-ADR

itch B-ADR B-ADR
and O O
skin O B-ADR
rash O I-ADR
from O O
chocolate O B-DRUG
during O O
fluoxetine O B-DRUG
and O O
sertraline B-DRUG B-DRUG
treatment O O
: O O
case O O
report O O

central B-ADR B-ADR
pontine I-ADR I-ADR
myelinolysis I-ADR I-ADR
manifested O O
by O O
temporary O O
blindness O O
: O O
a O O
possible O O
complication O O
of O O
lithium B-DRUG B-DRUG
toxicity O O

our O O
report O O
suggested O O
that O O
cbdca B-DRUG B-DRUG
hypersensitivity B-ADR B-ADR
was O O
correlated O O
with O O
the O O
total O O
dose O O
of O O
previously O O
administered O O
platinum O O
agents O O
and O O
that O O
cbdca B-DRUG B-DRUG
should O O
be O O
excluded O O
in O O
patients O O
who O O
have O O
received O O
multiple O O
platinum-based O O
chemotherapy O O
, O O
even O O
in O O
platinum-sensitive O O
cases O O
, O O
because O O
cbdca B-DRUG B-DRUG
hypersensitivity B-ADR B-ADR
can O O
occur O O
even O O
with O O
low-dose O O
cbdca B-DRUG B-DRUG
administration O O

a O O
10-year-old O O
asthmatic O O
boy O O
began O O
to O O
suffer O O
from O O
urticarial O B-ADR
rash O I-ADR
and O O
moderately B-ADR O
severe I-ADR B-ADR
bronchospasm I-ADR I-ADR
after O O
8 O O
weeks' O O
treatment O O
with O O
disodium B-DRUG B-DRUG
cromoglycate I-DRUG I-DRUG

diagnosis O O
of O O
hypothyroidism B-ADR B-ADR
during O O
treatment O O
can O O
be O O
difficult O O
because O O
of O O
the O O
common O O
side O O
effects O O
of O O
alpha B-DRUG B-DRUG
interferon I-DRUG I-DRUG

acute B-ADR B-ADR
leukopenia I-ADR I-ADR
associated O O
with O O
silver B-DRUG B-DRUG
sulfadiazine I-DRUG I-DRUG
therapy O O

four O O
days O O
after O O
intravenous O O
zoledronic B-DRUG B-DRUG
acid I-DRUG I-DRUG
, O O
the O O
patient O O
presented O O
to O O
emergency O O
room O O
with O O
complaints O O
of O O
carpopedal B-ADR B-ADR
spasm I-ADR I-ADR
and O O
bronchospasm O B-ADR

calcification O O
and O O
ossification B-ADR B-ADR
of I-ADR I-ADR
the I-ADR I-ADR
spinal I-ADR I-ADR
arachnoid I-ADR I-ADR
after O O
intrathecal O O
administration O O
of O O
depo-medrol B-DRUG B-DRUG

conclusion O O
: O O
the O O
new O O
quinolone O O
derivatives O O
( O O
levofloxacin O O
, O O
sparfloxacin O O
, O O
grepafloxacin O O
, O O
trovafloxacin O O
, O O
gatifloxacin O O
and O O
moxifloxacin B-DRUG O
) O O
, O O
also O O
called O O
gyrase O O
inhibitors O O
, O O
are O O
known O O
for O O
their O O
potential O O
to O O
cause O O
central O O
nervous O O
system-related O O
adverse O O
effects O O
, O O
including O O
headache B-ADR O
, O O
dizziness O O
and O O
insomnia O O

this O O
paper O O
reports O O
on O O
a O O
6.9-year-old O O
autistic O O
male O O
who O O
developed O O
repeated O O
episodes O O
of O O
acute B-ADR B-ADR
dystonic I-ADR I-ADR
reactions I-ADR I-ADR
associated O O
with O O
pimozide B-DRUG B-DRUG
administration O O
at O O
the O O
doses O O
of O O
0.096 O O
mg O O
/ O O
kg O O
/ O O
day O O
and O O
0.032 O O
mg O O
/ O O
kg O O
/ O O
day O O
and O O
32 O O
hours O O
following O O
pimozide B-DRUG B-DRUG
withdrawal O O
, O O
as O O
well O O
as O O
during O O
subsequent O O
thioridazine O B-DRUG
administration O O

the O O
authors' O O
results O O
suggest O O
that O O
l-dopa B-DRUG B-DRUG
may O O
cause O O
daytime B-ADR B-ADR
somnolence I-ADR I-ADR
in O O
some O O
patients O O
with O O
parkinson O O
's O O
disease O O

fulminant B-ADR B-ADR
hepatic I-ADR I-ADR
failure I-ADR I-ADR
developed O O
in O O
a O O
24-year-old O O
black O O
woman O O
who O O
had O O
been O O
treated O O
with O O
propylthiouracil B-DRUG B-DRUG
and O O
propranolol O B-DRUG
for O O
hyperthyroidism O O

pentazocine-induced O O
fibrous B-ADR B-ADR
myopathy I-ADR I-ADR
and O O
localized O B-ADR
neuropathy O I-ADR

painful B-ADR O
erosion I-ADR O
of I-ADR O
psoriatic I-ADR B-ADR
plaques I-ADR I-ADR
is O O
a O O
less O O
common O O
sign O O
of O O
methotrexate B-DRUG B-DRUG
toxicity O O
that O O
may O O
precede O O
evidence O O
of O O
bone O B-ADR
marrow O I-ADR
suppression O I-ADR

aims O O
: O O
to O O
present O O
a O O
case O O
of O O
piloerection B-ADR B-ADR
after O O
replacing O O
fluvoxamine O B-DRUG
maleate O I-DRUG
with O O
milnacipran B-DRUG B-DRUG
hydrochloride I-DRUG I-DRUG
, O O
and O O
to O O
analyse O O
this O O
effect O O
based O O
on O O
receptor O O
occupancy O O
theory O O

since O O
1979 O O
, O O
over O O
30 O O
published O O
case O O
reports O O
have O O
documented O O
the O O
relationship O O
between O O
phenylpropanolamine B-DRUG B-DRUG
and O O
stroke B-ADR O

myasthenia B-ADR B-ADR
gravis I-ADR I-ADR
during O O
low-dose O O
ifn-alpha B-DRUG B-DRUG
therapy O O
for O O
chronic O O
hepatitis O O
c O O

cardiac B-ADR B-ADR
arrest I-ADR I-ADR
associated O O
with O O
sulprostone B-DRUG B-DRUG
use O O
during O O
caesarean O O
section O O

in O O
a O O
series O O
of O O
104 O O
cases O O
of O O
intentional O O
or O O
inadvertent O O
use O O
of O O
zidovudine B-DRUG B-DRUG
at O O
differing O O
gestations O O
in O O
pregnancy O O
, O O
there O O
were O O
eight O O
spontaneous O O
first O O
trimester O O
abortions O O
, O O
eight O O
therapeutic O O
terminations O O
, O O
and O O
eight O O
cases O O
of O O
fetal B-ADR B-ADR
abnormality I-ADR I-ADR
occurring O O
among O O
a O O
total O O
of O O
88 O O
cases O O
where O O
the O O
pregnancy O O
progressed O O

objective O O
: O O
to O O
test O O
the O O
hypothesis O O
that O O
tumor O O
necrosis O O
factor O O
( O O
tnf O O
)- O O
alpha O O
may O O
mediate O O
the O O
loss O O
and O O
the O O
dedifferentiation O O
of O O
subcutaneous O O
fat O O
tissue O O
in O O
the O O
insulin-induced O O
lipoatrophies B-ADR B-ADR
of O O
a O O
diabetic O O
patient O O
who O O
presented O O
extensive O O
lesions O O

ceftriaxone O B-DRUG
was O O
approved O O
in O O
1997 O O
for O O
the O O
treatment O O
of O O
otitis O O
media O O
despite O O
previous O O
studies O O
that O O
documented O O
an O O
association O O
of O O
ceftriaxone B-DRUG B-DRUG
with O O
elevated B-ADR O
hepato-biliary I-ADR O
enzymes I-ADR O
and O O
transient O B-ADR
biliary O I-ADR
stasis O I-ADR

calcipotriol B-DRUG O
( O O
daivonex O O
r O O
; O O
leo O O
pharmaceuticals O O
, O O
zurich O O
, O O
switzerland O O
) O O
may O O
cause O O
irritation B-ADR O
of I-ADR O
the I-ADR O
skin I-ADR O
, O O
whereas O O
allergic O B-ADR
reactions O I-ADR
are O O
less O O
common O O

conversely O O
, O O
diffuse O B-ADR
interstitial O I-ADR
pulmonary O I-ADR
fibrosis O I-ADR
should O O
be O O
considered O O
in O O
the O O
differential O O
diagnosis O O
of O O
patients O O
receiving O O
methotrexate B-DRUG B-DRUG
who O O
develop O O
bilateral B-ADR B-ADR
pulmonary I-ADR I-ADR
infiltrates I-ADR I-ADR
seen O O
on O O
chest O B-ADR
roentgenograms O I-ADR

the O O
current O O
report O O
describes O O
a O O
man O O
who O O
was O O
prescribed O O
zonisamide B-DRUG B-DRUG
for O O
epilepsy O O
and O O
subsequently O O
developed O O
widespread O O
skin O O
rash O O
, O O
acute O O
kidney O O
injury O O
, O O
high-grade O O
fever O O
, O O
eosinophilia O O
, O O
liver O O
dysfunction O O
, O O
lymphadenopathy B-ADR O
and O O
an O O
increase O O
in O O
antihuman O O
herpesvirus-6 O O
immunoglobulin O O
g O O
titer O O

approximately O O
15 O O
min O O
after O O
the O O
first O O
administration O O
of O O
nebulised O O
morphine B-DRUG B-DRUG
the O O
patient O O
became O O
markedly O O
bradypneic O O
( O O
respiratory O O
rate O O
: O O
4-5 O O
bpm O O
) O O
, O O
hypotensive B-ADR O
( O O
bp O O
70 O O
/ O O
40 O O
mmhg O O
) O O
, O O
and O O
responded O O
only O O
partially O O
to O O
command O O

common O O
adverse O O
events O O
( O O
frequency O O
10 O O
%) O O
of O O
lacosamide B-DRUG B-DRUG
doses O O
up O O
to O O
600 O O
mg O O
/ O O
day O O
include O O
nonspecific O O
central O O
nervous O O
system O O
effects O O
( O O
e.g. O O
, O O
dizziness O O
, O O
ataxia O O
, O O
diplopia O O
, O O
and O O
somnolence B-ADR O

pheripheral B-ADR B-ADR
edema I-ADR I-ADR
was O O
observed O O
in O O
five O O
female O O
patients O O
after O O
taking O O
proton O O
pump O O
inhibitors O O
omeprazole O O
, O O
lansoprazole O O
, O O
or O O
pantoprazole B-DRUG B-DRUG
for O O
7-15 O O
days O O
for O O
peptic O O
acid O O
diseases O O
in O O
recommended O O
standard O O
doses O O

a O O
7-year-old O O
girl O O
developed O O
diabetes O O
mellitus O O
and O O
exocrine B-ADR B-ADR
pancreatic I-ADR I-ADR
insufficiency I-ADR I-ADR
after O O
3.5 O O
years O O
of O O
almost O O
continuous O O
treatment O O
with O O
azathioprine O B-DRUG
and O O
/ O O
or O O
prednisone B-DRUG B-DRUG
for O O
idiopathic O O
auto-immune O O
haemolytic O O
anaemia O O

case O O
summary O O
: O O
a O O
65-year-old O O
patient O O
chronically O O
treated O O
with O O
the O O
selective O O
serotonin O O
reuptake O O
inhibitor O O
( O O
ssri O O
) O O
citalopram O B-DRUG
developed O O
confusion O O
, O O
agitation O O
, O O
tachycardia B-ADR O
, O O
tremors O O
, O O
myoclonic O B-ADR
jerks O I-ADR
and O O
unsteady O O
gait O O
, O O
consistent O O
with O O
serotonin O O
syndrome O O
, O O
following O O
initiation O O
of O O
fentanyl B-DRUG B-DRUG
, O O
and O O
all O O
symptoms O O
and O O
signs O O
resolved O O
following O O
discontinuation O O
of O O
fentanyl B-DRUG B-DRUG

development O O
of O O
tics B-ADR B-ADR
in O O
a O O
thirteen-year-old O O
male O O
following O O
atomoxetine B-DRUG B-DRUG
use O O

herein O O
we O O
report O O
four O O
patients O O
who O O
underwent O O
liver O O
transplantation O O
and O O
developed O O
neutropenia B-ADR B-ADR
while O O
receiving O O
mmf B-DRUG B-DRUG

we O O
report O O
the O O
first O O
case O O
of O O
polymorphic B-ADR B-ADR
ventricular I-ADR I-ADR
tachycardia I-ADR I-ADR
with O O
normal O O
qt O O
interval O O
associated O O
with O O
the O O
oral O O
use O O
of O O
levofloxacin B-DRUG B-DRUG
in O O
the O O
absence O O
of O O
other O O
etiologies O O
known O O
to O O
cause O O
these O O
arrhythmias O O

the O O
clinical O O
course O O
suggests O O
that O O
caffeine B-DRUG B-DRUG
, O O
which O O
is O O
present O O
in O O
oolong O O
tea O O
, O O
was O O
mainly O O
responsible O O
for O O
the O O
rhabdomyolysis O B-ADR
as O O
well O O
as O O
the O O
delirium B-ADR O
, O O
although O O
severe O O
hyponatremia O O
has O O
been O O
reported O O
to O O
cause O O
rhabdomyolysis O B-ADR
on O O
rare O O
occasions O O

fibrosis B-ADR B-ADR
of I-ADR I-ADR
corpus I-ADR I-ADR
cavernosum I-ADR I-ADR
after O O
intracavernous O O
injection O O
of O O
phentolamine O B-DRUG
/ O O
papaverine B-DRUG B-DRUG

myoclonus B-ADR B-ADR
associated O O
with O O
continuous O O
dobutamine B-DRUG B-DRUG
infusion O O
in O O
a O O
patient O O
with O O
end-stage O O
renal O O
disease O O

we O O
observed O O
3 O O
diabetic O O
patients O O
with O O
intolerable B-ADR O
dizziness I-ADR O
followed O O
by O O
nausea O O
and O O
vomiting O O
immediately O O
after O O
an O O
initial O O
administration O O
of O O
the O O
alpha-glucosidase O O
inhibitor O O
, O O
voglibose B-DRUG B-DRUG

we O O
describe O O
a O O
continuous O O
ambulatory O O
peritoneal O O
dialysis O O
( O O
capd O O
) O O
patient O O
that O O
developed O O
vancomycin-induced O O
agranulocytosis B-ADR B-ADR
during O O
treatment O O
for O O
methicillin-resistant O O
staphylococcus O O
aureus O O
( O O
mrsa O O
)- O O
associated O O
external O O
cuff O O
infection O O
and O O
pneumonia O O

objective O O
: O O
the O O
authors O O
described O O
a O O
case O O
of O O
interferon-induced O O
psychosis B-ADR B-ADR
as O O
a O O
framework O O
to O O
review O O
the O O
literature O O
and O O
discuss O O
the O O
decision O O
to O O
pursue O O
antiviral O O
treatment O O
in O O
psychiatrically O O
ill O O
patients O O
with O O
hepatitis O O
c O O

the O O
use O O
of O O
rituximab B-DRUG B-DRUG
has O O
been O O
uncommonly O O
associated O O
with O O
delayed B-ADR O
pulmonary I-ADR B-ADR
toxicity I-ADR I-ADR

four O O
cases O O
of O O
oesophageal B-ADR B-ADR
damage I-ADR I-ADR
associated O O
with O O
ingestion O O
of O O
the O O
urinary O O
anti-spasmodic O O
agent O O
emepronium B-DRUG B-DRUG
bromide I-DRUG I-DRUG
are O O
described O O

there O O
are O O
now O O
reports O O
of O O
liver B-ADR B-ADR
failure I-ADR I-ADR
following O O
treatment O O
of O O
childhood O O
cancers O O
with O O
amd B-DRUG B-DRUG

the O O
patient O O
continued O O
to O O
have O O
fever B-ADR O
and O O
autonomic O B-ADR
instability O I-ADR
without O O
evidence O O
of O O
infection O O
which O O
entirely O O
resolved O O
within O O
24 O O
hours O O
of O O
reinstitution O O
of O O
full O O
preadmission O O
dosing O O
of O O
oral O O
baclofen B-DRUG B-DRUG

herein O O
, O O
we O O
present O O
a O O
patient O O
with O O
severe O O
and O O
prolonged B-ADR B-ADR
hypoglycemia I-ADR I-ADR
after O O
long-acting O O
octreotide B-DRUG B-DRUG
treatment O O

cystoid B-ADR B-ADR
macular I-ADR I-ADR
edema I-ADR I-ADR
in O O
a O O
low-risk O O
patient O O
after O O
switching O O
from O O
latanoprost O B-DRUG
to O O
bimatoprost B-DRUG B-DRUG

mental B-ADR B-ADR
nerve I-ADR I-ADR
neuropathy I-ADR I-ADR
as O O
a O O
result O O
of O O
hepatitis B-DRUG O
b I-DRUG O
vaccination I-DRUG O

rapamycin B-DRUG O
/ O O
sirolimus O O
( O O
sr O O
) O O
, O O
trade O O
named O O
rapammune O O
( O O
wyeth-ayerst O O
, O O
sydney O O
, O O
australia O O
) O O
, O O
is O O
a O O
potent O O
immunosuppressive O O
drug O O
associated O O
with O O
myelosuppression O O
, O O
hypertension O O
, O O
hyperlipidemia B-ADR O
, O O
and O O
infection O O

in O O
one O O
instance O O
a O O
systemic B-ADR O
hypoglycemic I-ADR B-ADR
reaction I-ADR I-ADR
resulting O O
in O O
head O O
trauma O O
and O O
confusion O O
ended O O
in O O
an O O
emegency O B-ADR
hospital O I-ADR
admission O I-ADR
following O O
the O O
substitution O O
of O O
acetohexamide B-DRUG B-DRUG
for O O
acetazolamide O B-DRUG

caution O O
with O O
use O O
of O O
cimetidine O B-DRUG
in O O
tolazoline B-DRUG B-DRUG
induced O O
upper B-ADR B-ADR
gastrointestinal I-ADR I-ADR
bleeding I-ADR I-ADR

cefuroxime-induced O O
acute B-ADR B-ADR
renal I-ADR I-ADR
failure I-ADR I-ADR

mitomycin O O
c O O
( O O
mmc B-DRUG B-DRUG
) O O
is O O
an O O
alkylating O O
agent O O
that O O
has O O
been O O
recently O O
associated O O
with O O
the O O
hemolytic-uremic O O
syndrome O O
( O O
hus B-ADR B-ADR

although O O
combinations O O
of O O
belladonna O B-DRUG
, O O
ergotamine B-DRUG O
, O O
and O O
phenobarbital O B-DRUG
have O O
been O O
used O O
for O O
medical O O
treatment O O
of O O
menopausal O B-ADR
symptoms O I-ADR
since O O
the O O
1960s O O
, O O
this O O
is O O
the O O
first O O
known O O
case O O
report O O
of O O
its O O
association O O
with O O
anticonvulsant B-ADR O
hypersensitivity I-ADR B-ADR
syndrome I-ADR I-ADR

case O O
summary O O
: O O
a O O
65-year-old O O
patient O O
chronically O O
treated O O
with O O
the O O
selective O O
serotonin O O
reuptake O O
inhibitor O O
( O O
ssri O O
) O O
citalopram O B-DRUG
developed O O
confusion O O
, O O
agitation O O
, O O
tachycardia O O
, O O
tremors O O
, O O
myoclonic O B-ADR
jerks O I-ADR
and O O
unsteady B-ADR O
gait I-ADR O
, O O
consistent O O
with O O
serotonin O O
syndrome O O
, O O
following O O
initiation O O
of O O
fentanyl B-DRUG B-DRUG
, O O
and O O
all O O
symptoms O O
and O O
signs O O
resolved O O
following O O
discontinuation O O
of O O
fentanyl B-DRUG B-DRUG

we O O
report O O
the O O
case O O
of O O
a O O
young O O
man O O
, O O
affected O O
by O O
rheumatoid O O
arthritis O O
who O O
developed O O
a O O
rapid-onset O O
short-of-breath O O
, O O
hemoptysis B-ADR O
, O O
and O O
severe O B-ADR
weakness O I-ADR
, O O
about O O
2 O O
weeks O O
after O O
the O O
administration O O
of O O
leflunomide B-DRUG B-DRUG

three O O
of O O
these O O
patients O O
had O O
convulsions O B-ADR
attributed O O
to O O
imipenem B-DRUG B-DRUG
/ O O
cilastatin O B-DRUG
; O O
3.6 O O
% O O
of O O
the O O
patients O O
had O O
seizure B-ADR O
, O O
or O O
2 O O
% O O
of O O
imipenem B-DRUG O
/ O O
cilastatin O B-DRUG
administrations O O
was O O
followed O O
by O O
a O O
seizure B-ADR O
attack O O

basilar O O
invagination O O
and O O
mid-line B-ADR B-ADR
skeletal I-ADR I-ADR
abnormalities I-ADR I-ADR
due O O
to O O
in O O
utero O O
exposure O O
to O O
phenytoin B-DRUG B-DRUG

sensory B-ADR B-ADR
neuropathy I-ADR I-ADR
revealing O O
necrotizing O B-ADR
vasculitis O I-ADR
during O O
infliximab B-DRUG B-DRUG
therapy O O
for O O
rheumatoid O O
arthritis O O

disulfiram B-DRUG B-ADR
encephalopathy O I-ADR
as O O
a O O
cause O O
of O O
the O O
catatonia B-ADR B-ADR
syndrome I-ADR I-ADR

we O O
report O O
a O O
46-yr-old O O
woman O O
with O O
ovarian O O
carcinoma O O
who O O
developed O O
porphyria B-ADR B-ADR
cutanea I-ADR I-ADR
tarda I-ADR I-ADR
while O O
undergoing O O
treatment O O
with O O
cisplatin O B-DRUG
and O O
cyclophosphamide B-DRUG B-DRUG

probable O O
propafenone-induced O O
transient B-ADR B-ADR
global I-ADR I-ADR
amnesia I-ADR I-ADR

we O O
describe O O
a O O
patient O O
with O O
a O O
liver O O
abscess O O
due O O
to O O
entamoeba O O
histolytica O O
, O O
in O O
whom O O
metronidazole B-DRUG B-DRUG
therapy O O
( O O
total O O
dose O O
, O O
21 O O
g O O
over O O
14 O O
days O O
) O O
was O O
complicated O O
by O O
reversible O O
deafness O O
, O O
tinnitus O O
, O O
and O O
ataxia O O
and O O
who O O
relapsed O O
5 O O
months O O
later O O
with O O
a O O
splenic B-ADR O
abscess I-ADR O

a O O
case O O
of O O
high-grade B-ADR B-ADR
endometrial I-ADR I-ADR
stromal I-ADR I-ADR
sarcoma I-ADR I-ADR
, O O
confined O O
into O O
an O O
intrauterine O B-ADR
polypoid O I-ADR
growth O I-ADR
, O O
in O O
a O O
woman O O
with O O
a O O
history O O
of O O
breast O O
cancer O O
who O O
was O O
treated O O
with O O
adjuvant O O
tamoxifen B-DRUG B-DRUG

objective O O
: O O
to O O
report O O
a O O
case O O
of O O
rapidly O O
occurring O O
hyperglycemia B-ADR B-ADR
that O O
occurred O O
in O O
a O O
geriatric O O
patient O O
3 O O
days O O
after O O
treatment O O
with O O
olanzapine B-DRUG B-DRUG

in O O
eight O O
patients O O
, O O
a O O
mean O O
decrease B-ADR O
in I-ADR O
serum I-ADR O
na I-ADR O
+ O O
of O O
8.25 O O
+/- O O
3.2 O O
meq O O
/ O O
l O O
was O O
observed O O
after O O
a O O
single O O
200 O O
mg O O
intravenous O O
dose O O
of O O
lorcainide B-DRUG B-DRUG

of O O
particular O O
interest O O
in O O
this O O
patient O O
is O O
the O O
fluctuation B-ADR O
of I-ADR O
the I-ADR O
qt I-ADR O
interval I-ADR O
at O O
a O O
stable O O
dose O O
of O O
methadone B-DRUG B-DRUG
, O O
suggesting O O
that O O
a O O
single O O
normal O O
electrocardiogram O O
( O O
ecg O O
) O O
does O O
not O O
guarantee O O
that O O
the O O
patient O O
is O O
not O O
at O O
risk O O
of O O
ventricular O B-ADR
arrhythmias O I-ADR

tiagabine B-DRUG B-DRUG
overdose O O
causes O O
an O O
unusual B-ADR O
array I-ADR O
of I-ADR O
neurological I-ADR B-ADR
symptoms I-ADR I-ADR
, O O
many O O
similar O O
to O O
reported O O
adverse O O
effects O O
during O O
therapeutic O O
use O O

symptomatic B-ADR B-ADR
hypoglycemia I-ADR I-ADR
secondary O O
to O O
a O O
glipizide-trimethoprim O O
/ O O
sulfamethoxazole B-DRUG O
drug O O
interaction O O

the O O
fetal O O
valproate B-DRUG B-DRUG
syndrome O O
( O O
fvs O O
) O O
is O O
characterized O O
by O O
distinctive O O
facial O O
appearance O O
, O O
major O O
and O O
minor O O
malformations O O
, O O
and O O
developmental B-ADR O
delay I-ADR O

however O O
, O O
acute B-ADR O
cardiomyopathy I-ADR O
and O O
pericarditis O O
secondary O O
to O O
methylphenidate B-DRUG B-DRUG
use O O
has O O
been O O
rarely O O
reported O O

drug-induced O O
eosinophilia B-ADR B-ADR
is O O
a O O
non-dose-dependent O O
side O O
effect O O
of O O
clozapine B-DRUG B-DRUG

purpose O O
: O O
to O O
describe O O
transient B-ADR O
structured I-ADR O
visual I-ADR B-ADR
hallucinations I-ADR I-ADR
in O O
a O O
patient O O
with O O
vascular O O
age-related O O
macular O O
degeneration O O
( O O
amd O O
) O O
, O O
following O O
an O O
intravitreal O O
avastin-injection O B-DRUG

flutamide B-ADR B-ADR
withdrawal I-ADR I-ADR
syndrome I-ADR I-ADR
is O O
characterized O O
by O O
a O O
decrease O O
in O O
prostate-specific O O
antigen O O
( O O
psa O O
) O O
after O O
flutamide B-DRUG B-DRUG
withdrawal O O
in O O
a O O
subset O O
of O O
patients O O
with O O
progressing O O
metastatic O O
carcinoma O O
of O O
the O O
prostate O O

data O O
synthesis O O
: O O
a O O
49-year-old O O
man O O
developed O O
symptoms O O
of O O
severe B-ADR O
psychosis I-ADR O
concomitant O O
with O O
ciprofloxacin B-DRUG B-DRUG
( O O
250 O O
mg O O
bid O O
) O O
treatment O O

two O O
patients O O
treated O O
with O O
5-fluorouracil B-DRUG B-DRUG
( O O
5-fu O B-DRUG
) O O
for O O
disseminated O O
adenocarcinoma O O
of O O
the O O
colon O O
developed O O
cerebellar B-ADR B-ADR
dysfunction I-ADR I-ADR
typical O O
of O O
5-fu O B-DRUG
neurotoxicity O B-ADR

a O O
7-year-old O O
with O O
congenital O O
toxoplasmosis O O
who O O
took O O
pyrimethamine O B-DRUG
and O O
sulfadiazine B-DRUG B-DRUG
for O O
reactivated O O
chorioretinitis O O
developed O O
fever O O
, O O
severe O O
cutaneous O O
involvement O O
, O O
swelling O O
, O O
abdominal O O
pain O O
and O O
transaminitis B-ADR O
, O O
persisting O O
weeks O O
after O O
withholding O O
medicines O O

naproxen B-DRUG B-DRUG
, O O
the O O
most O O
common O O
offender O O
, O O
has O O
been O O
associated O O
with O O
a O O
dimorphic O O
clinical O O
pattern O O
: O O
a O O
pct-like O O
presentation O O
and O O
one O O
simulating O O
erythropoietic B-ADR B-ADR
protoporphyria I-ADR I-ADR
in O O
the O O
pediatric O O
population O O

atrial B-ADR B-ADR
fibrillation I-ADR I-ADR
following O O
methylprednisolone B-DRUG B-DRUG
pulse O O
therapy O O

syncope B-ADR B-ADR
induced O O
by O O
propranolol B-DRUG B-DRUG
in O O
hypertrophic O B-ADR
cardiomyopathy O I-ADR

we O O
report O O
5 O O
cases O O
of O O
acute B-ADR B-ADR
reversible I-ADR I-ADR
renal I-ADR I-ADR
failure I-ADR I-ADR
coinciding O O
with O O
the O O
onset O O
of O O
treatment O O
with O O
captopril B-DRUG B-DRUG
in O O
patients O O
with O O
severe O O
drug-resistant O O
hypertension O O

a O O
patient O O
developed O O
restless B-ADR B-ADR
legs I-ADR I-ADR
symptoms I-ADR I-ADR
paralleling O O
the O O
course O O
of O O
interferon-alpha B-DRUG B-DRUG
( O O
ifn O B-DRUG
alpha O I-DRUG
) O O
therapy O O
for O O
chronic O O
hepatitis O O
c O O

a O O
72-year-old O O
woman O O
with O O
a O O
history O O
of O O
thyrotoxicosis O O
presented O O
with O O
sore B-ADR O
throat I-ADR O
and O O
fever O B-ADR
two O O
weeks O O
after O O
starting O O
carbimazole B-DRUG B-DRUG

physicians O O
should O O
be O O
aware O O
of O O
the O O
risk O O
of O O
severe O O
aiha B-ADR B-ADR
in O O
cll O O
patients O O
with O O
a O O
history O O
of O O
aiha B-ADR B-ADR
or O O
positivation O B-ADR
of O I-ADR
the O I-ADR
dat O I-ADR
during O O
previous O O
fludarabine B-DRUG B-DRUG
administration O O
, O O
or O O
in O O
case O O
of O O
secondary O O
fixation O O
of O O
complement O O
to O O
the O O
red O O
cell O O
membrane O O
occurring O O
during O O
fludarabine B-DRUG B-DRUG
treatment O O

a O O
wide O O
variety O O
of O O
adverse O O
central O B-ADR
nervous O I-ADR
system O I-ADR
effects O I-ADR
have O O
been O O
reported O O
in O O
association O O
with O O
propafenone B-DRUG B-DRUG
; O O
dizziness B-ADR O
is O O
the O O
most O O
common O O

severe O O
heparin B-DRUG B-DRUG
associated O O
thrombocytopenia B-ADR B-ADR
is O O
a O O
rare O O
complication O O
of O O
heparin B-DRUG B-DRUG
therapy O O

we O O
report O O
a O O
case O O
of O O
long O O
lasting O O
respiratory B-ADR B-ADR
depression I-ADR I-ADR
after O O
intravenous O O
administration O O
of O O
morphine B-DRUG B-DRUG
to O O
a O O
7 O O
year O O
old O O
girl O O
with O O
haemolytic O B-ADR
uraemic O I-ADR
syndrome O I-ADR

we O O
report O O
the O O
first O O
case O O
of O O
fulminant O O
adult B-ADR O
respiratory I-ADR O
distress I-ADR O
syndrome I-ADR O
( O O
ards O O
) O O
associated O O
with O O
pegylated O O
interferon O O
alpha-2a O O
( O O
pegifnalpha-2a B-DRUG O
) O O
and O O
ribavirin O B-DRUG
use O O
for O O
hepatitis O O
c O O
, O O
complicated O O
by O O
subsequent O O
and O O
ultimately O O
fatal O O
sepsis O O
and O O
multiorgan O B-ADR
failure O I-ADR

ophthalmologists O O
should O O
be O O
aware O O
of O O
the O O
ocular O O
side O O
effects O O
of O O
ifn B-DRUG B-DRUG
therapy O O
and O O
carefully O O
monitor O O
patients O O
for O O
the O O
possible O O
occurrence O O
of O O
hypoalbuminemia O O
and O O
thrombocytopenia B-ADR O

three O O
days O O
after O O
receiving O O
intravitreal O O
injection O O
of O O
bevacizumab B-DRUG B-DRUG
( O O
1.25 O O
mg O O
in O O
0.1 O O
ml O O
) O O
, O O
he O O
developed O O
acute B-ADR B-ADR
vision I-ADR I-ADR
loss I-ADR I-ADR
and O O
change O B-ADR
of O I-ADR
consciousness O I-ADR

leukaemoid B-ADR B-ADR
monocytosis I-ADR I-ADR
in O O
m4 O O
aml O O
following O O
chemotherapy O O
and O O
g-csf B-DRUG B-DRUG

ards B-ADR B-ADR
has O O
been O O
associated O O
with O O
the O O
administration O O
of O O
other O O
monoclonal O O
antibodies O O
, O O
such O O
as O O
infliximab O B-DRUG
, O O
gemtuzumab B-DRUG O
ozogamicin I-DRUG B-DRUG
, O O
and O O
okt3 O B-DRUG
and O O
is O O
believed O O
to O O
be O O
directly O O
mediated O O
by O O
release O O
of O O
proinflammatory O O
cytokines O O

disseminated O O
intravascular O O
coagulation O O
associated O O
with O O
acute O O
hemoglobinemia O O
or O O
hemoglobinuria B-ADR O
following O O
rh O O
( O O
0 O O
)( O O
d O O
) O O
immune O O
globulin O O
intravenous O O
administration O O
for O O
immune O O
thrombocytopenic O O
purpura O O

results O O
: O O
in O O
a O O
22-year-old O O
thai O O
woman O O
with O O
graves' O O
disease O O
, O O
tinnitus O O
, O O
hearing O O
impairment O O
in O O
the O O
left O O
ear O O
( O O
with O O
progression O O
to O O
the O O
right O O
ear O O
) O O
, O O
and O O
vertigo B-ADR B-ADR
developed O O
after O O
3 O O
years O O
of O O
therapy O O
with O O
ptu B-DRUG B-DRUG

cyclosporin B-DRUG B-DRUG
side O O
effects O O
included O O
hirsutism O O
, O O
hypertension O O
, O O
increased O O
blood O O
levels O O
of O O
urea O O
and O O
creatinine O O
, O O
and O O
abnormalities B-ADR O
in I-ADR O
liver I-ADR O
function I-ADR O
tests I-ADR O

regression O O
of O O
thyrotoxic B-ADR B-ADR
ophthalmopathy I-ADR I-ADR
following O O
lithium B-DRUG B-DRUG
withdrawal O O

objective O O
: O O
1 O O
) O O
to O O
describe O O
a O O
patient O O
with O O
rheumatoid O O
arthritis O O
receiving O O
adalimumab B-DRUG B-DRUG
who O O
developed O O
fever B-ADR O
, O O
pancytopenia O O
, O O
splenomegaly O O
, O O
and O O
extreme O O
hyperferritinemia O O

syncope B-ADR B-ADR
in O O
a O O
65-year-old O O
woman O O
after O O
nitrate B-DRUG B-DRUG
ingestion O O

we O O
discuss O O
a O O
patient O O
who O O
developed O O
severe B-ADR B-ADR
renal I-ADR I-ADR
tubular I-ADR I-ADR
dysfunction I-ADR I-ADR
secondary O O
to O O
short-term O O
therapy O O
with O O
amikacin B-DRUG B-DRUG
, O O
resulting O O
in O O
refractory O O
hypokalemia O O
, O O
hypocalcemia O O
, O O
hypomagnesemia O O
, O O
metabolic O B-ADR
alkalosis O I-ADR
, O O
and O O
polyuria O O

treatment-related O O
myelodysplastic B-ADR B-ADR
syndrome I-ADR I-ADR
after O O
temozolomide B-DRUG B-DRUG
for O O
recurrent O O
high-grade O O
glioma O O

pneumonitis O O
, O O
bilateral O O
pleural O O
effusions O O
, O O
echocardiographic O O
evidence O O
of O O
cardiac O O
tamponade O O
, O O
and O O
positive B-ADR O
autoantibodies I-ADR O
developed O O
in O O
a O O
43-year-old O O
man O O
, O O
who O O
was O O
receiving O O
long-term O O
sulfasalazine B-DRUG B-DRUG
therapy O O
for O O
chronic O O
ulcerative O O
colitis O O

in O O
the O O
absence O O
of O O
mucositis O O
or O O
diarrhea O O
, O O
severe O O
dermatologic O B-ADR
toxicity O I-ADR
following O O
a O O
single O O
low O O
dose O O
of O O
the O O
drug O O
suggests O O
an O O
' O O
allergic O O
' O O
or O O
acute B-ADR B-ADR
hypersensitivity I-ADR I-ADR
reaction I-ADR I-ADR
to O O
mtx B-DRUG B-DRUG
in O O
this O O
patient O O

methods O O
: O O
a O O
68-year-old O O
man O O
developed O O
intense B-ADR O
conjunctival I-ADR O
hyperemia I-ADR O
and O O
cystoid O B-ADR
macula O I-ADR
edema O I-ADR
after O O
switching O O
from O O
latanoprost B-DRUG B-DRUG
to O O
bimatoprost O B-DRUG
9 O O
months O O
after O O
cataract O O
surgery O O
in O O
an O O
eye O O
at O O
low-risk O O
for O O
this O O
cystoid O B-ADR
macular O I-ADR
edema O I-ADR

the O O
literature O O
on O O
thiabendazole-induced O O
cholestasis B-ADR B-ADR
and O O
its O O
association O O
with O O
sicca O B-ADR
complex O I-ADR
is O O
reviewed O O

two O O
patients O O
who O O
developed O O
decreased O B-ADR
visual O I-ADR
acuity O I-ADR
after O O
several O O
months O O
of O O
ethambutol B-DRUG B-DRUG
treatment O O
for O O
mycobacterium O O
avium-intracellulare O O
infection O O
had O O
bitemporal B-ADR O
visual I-ADR O
field I-ADR O
defects I-ADR O
that O O
suggested O O
optic O B-ADR
chiasm O I-ADR
damage O I-ADR

gelofusine B-ADR B-ADR
allergy I-ADR I-ADR
-- O O
the O O
need O O
for O O
identification O O
jewellery O O

in O O
one O O
patient O O
the O O
vasculitis O O
resolved O O
after O O
termination O O
of O O
the O O
ciprofloxacin B-DRUG B-DRUG
therapy O O
; O O
in O O
the O O
other O O
patient O O
the O O
ciprofloxacin-induced O O
hemorrhagic O B-ADR
vasculitis O I-ADR
was O O
superimposed O O
on O O
a O O
severe O O
forefoot O O
infection O O
, O O
leading O O
to O O
progressive B-ADR O
gangrene I-ADR O
and O O
a O O
below-knee O B-ADR
amputation O I-ADR

isonicotinic B-DRUG B-DRUG
acid I-DRUG I-DRUG
hydrazide I-DRUG O
induced O O
anagen O B-ADR
effluvium O I-ADR
and O O
associated O O
lichenoid B-ADR B-ADR
eruption I-ADR I-ADR

we O O
report O O
the O O
case O O
of O O
a O O
20-year-old O O
female O O
with O O
polyarteritis O O
nodosa O O
( O O
pan O O
) O O
who O O
developed O O
bilateral B-ADR B-ADR
sensorineural I-ADR I-ADR
hearing I-ADR I-ADR
loss I-ADR I-ADR
25 O O
minutes O O
after O O
receiving O O
30 O O
mg O O
of O O
intravenous O O
ketoralac B-DRUG B-DRUG

amphotericin O B-DRUG
b O I-DRUG
( O O
amb B-DRUG O
) O O
is O O
effective O O
, O O
but O O
its O O
use O O
is O O
limited O O
by O O
toxicity O O
: O O
renal O O
impairment O O
, O O
anaemia B-ADR O
, O O
fever O O
, O O
malaise O O
, O O
and O O
hypokalaemia O O
are O O
common O O

oxcarbazepine-associated O O
angioedema B-ADR B-ADR
manifested O O
by O O
swelling O B-ADR
of O I-ADR
the O I-ADR
face O I-ADR
, O O
eyes O O
, O O
lips O O
, O O
or O O
tongue O O
or O O
difficulty O O
swallowing O O
or O O
breathing O O
( O O
or O O
both O O
) O O
is O O
a O O
rare O O
but O O
potentially O O
life-threatening O O
reaction O O
for O O
which O O
early O O
recognition O O
and O O
management O O
are O O
vital O O

this O O
paper O O
reports O O
on O O
a O O
6.9-year-old O O
autistic O O
male O O
who O O
developed O O
repeated O O
episodes O O
of O O
acute B-ADR B-ADR
dystonic I-ADR I-ADR
reactions I-ADR I-ADR
associated O O
with O O
pimozide B-DRUG B-DRUG
administration O O
at O O
the O O
doses O O
of O O
0.096 O O
mg O O
/ O O
kg O O
/ O O
day O O
and O O
0.032 O O
mg O O
/ O O
kg O O
/ O O
day O O
and O O
32 O O
hours O O
following O O
pimozide B-DRUG B-DRUG
withdrawal O O
, O O
as O O
well O O
as O O
during O O
subsequent O O
thioridazine O B-DRUG
administration O O

a O O
patient O O
with O O
seropositive O O
rheumatoid O O
arthritis O O
developed O O
ascites B-ADR B-ADR
while O O
taking O O
weekly O O
doses O O
of O O
methotrexate O B-DRUG
( O O
mtx B-DRUG B-DRUG

we O O
introduce O O
a O O
case O O
of O O
a O O
sixty O O
years O O
old O O
woman O O
with O O
several O O
previous O O
episodes O O
of O O
rhinitis O O
, O O
conjunctivitis B-ADR O
and O O
perspiration O O
immediately O O
after O O
the O O
administration O O
of O O
salmon O B-DRUG
calcitonin B-DRUG I-DRUG
with O O
nasal O O
spray O O
or O O
intramuscular O O
administration O O
( O O
calsynar O B-DRUG

ticlopidine-induced O O
interstitial B-ADR B-ADR
pulmonary I-ADR I-ADR
disease I-ADR I-ADR
: O O
a O O
case O O
report O O

two O O
patients O O
with O O
ovarian O O
cancer O O
who O O
had O O
received O O
multiple O O
courses O O
of O O
cisplatin B-DRUG B-DRUG
without O O
complications O O
experienced O O
hypersensitivity O O
reactions O O
to O O
cisplatin B-DRUG B-DRUG
: O O
one O O
, O O
involving O O
intrahepatic O O
artery O O
infusion O O
, O O
manifested O O
general O O
erythema O O
, O O
dyspnea O O
, O O
and O O
hypotension O O
; O O
the O O
other O O
, O O
involving O O
intravenous O O
infusion O O
, O O
manifested O O
abdominal O O
pain O O
, O O
general O O
erythema O O
, O O
and O O
fever B-ADR O

sweet O O
's O O
syndrome O O
is O O
an O O
acute B-ADR B-ADR
febrile I-ADR I-ADR
neutrophilic I-ADR I-ADR
dermatosis I-ADR I-ADR
that O O
is O O
a O O
known O O
complication O O
of O O
the O O
administration O O
of O O
filgrastim B-DRUG B-DRUG
, O O
a O O
drug O O
that O O
causes O O
increased O B-ADR
neutrophil O I-ADR
proliferation O I-ADR
and O O
differentiation O O

we O O
suggest O O
that O O
objective O O
evaluation O O
of O O
retinal O O
function O O
with O O
electrophysiological O O
methods O O
should O O
be O O
performed O O
in O O
patients O O
with O O
visual B-ADR B-ADR
disturbance I-ADR I-ADR
during O O
treatment O O
with O O
rifabutin B-DRUG B-DRUG

transient O O
phenytoin B-DRUG B-DRUG
induced O O
iga O B-ADR
deficiency O I-ADR
and O O
permanent O O
ige B-ADR O
increase I-ADR O

one O O
patient O O
who O O
received O O
clindamycin B-DRUG B-DRUG
had O O
liver O O
biopsy O O
findings O O
of O O
marked O O
cholestasis O O
, O O
portal O O
inflammation O O
, O O
bile O O
duct O O
injury O O
and O O
bile B-ADR O
duct I-ADR O
paucity I-ADR O
( O O
ductopenia O B-ADR

phenobarbital B-DRUG B-DRUG
hepatotoxicity B-ADR B-ADR
in O O
an O O
8-month-old O O
infant O O

with O O
the O O
use O O
of O O
optical O O
coherence O O
tomography O O
( O O
oct O O
) O O
, O O
two O O
patients O O
with O O
ifn-associated O O
retinopathy O O
who O O
had O O
developed O O
macular O O
edema O O
and O O
reduced B-ADR O
visual I-ADR B-ADR
acuity I-ADR I-ADR
during O O
the O O
clinical O O
course O O
of O O
ifn B-DRUG B-DRUG
therapy O O
were O O
observed O O

a O O
22-year-old O O
black O O
man O O
developed O O
fever B-ADR O
, O O
chills O O
, O O
fatigue O O
, O O
night O O
sweats O O
, O O
tender O O
lymphadenopathy O O
, O O
and O O
a O O
generalized O O
, O O
pruritic O O
, O O
macular O B-ADR
eruption O I-ADR
3 O O
weeks O O
after O O
starting O O
minocycline B-DRUG B-DRUG
therapy O O
for O O
acne O O

bromocriptine-induced O O
schizophrenia B-ADR B-ADR

this O O
case O O
suggests O O
that O O
acyclovir O B-DRUG
when O O
given O O
intravenously O O
in O O
doses O O
of O O
10 O O
mg O O
/ O O
kg O O
may O O
result O O
in O O
increased B-ADR O
serum I-ADR O
lithium I-ADR B-DRUG
concentrations O O

increasing O O
the O O
olanzapine B-DRUG B-DRUG
dosage O O
severely O O
aggravated O O
the O O
symptoms O O
of O O
rls B-ADR B-ADR

a O O
66-year-old O O
japanese O O
woman O O
with O O
severe O O
scleroderma O O
developed O O
anemia B-ADR O
and O O
thrombocytopenia O O
due O O
to O O
d-penicillamine O B-DRUG
( O O
d-pen B-DRUG B-DRUG
) O O
treatment O O
, O O
although O O
the O O
leukopenia O B-ADR
was O O
not O O
markedly O O
severe O O

the O O
syndrome O O
of O O
irreversible O O
lithium-effectuated O O
neurotoxicity B-ADR B-ADR
( O O
silent O O

the O O
spectrum O O
of O O
renal B-ADR B-ADR
lesions I-ADR I-ADR
occurring O O
during O O
antituberculous O O
therapy O O
, O O
particularly O O
in O O
association O O
with O O
rifampin B-DRUG B-DRUG
, O O
may O O
be O O
wider O O
than O O
previously O O
suspected O O

since O O
the O O
bronchospasm B-ADR B-ADR
was O O
relieved O O
with O O
discontinuation O O
of O O
propranolol B-DRUG B-DRUG
and O O
supportive O O
bronchodilator O O
therapy O O
, O O
the O O
bronchospasm B-ADR B-ADR
was O O
believed O O
to O O
be O O
caused O O
by O O
propranolol B-DRUG B-DRUG

tacrolimus B-DRUG O
( O O
fk506 O O
) O O
, O O
an O O
immunosuppressant O O
, O O
has O O
been O O
associated O O
with O O
mutism B-ADR B-ADR
in O O
adults O O
after O O
liver O O
transplant O O

this O O
article O O
presents O O
a O O
patient O O
with O O
hypoparathyroidism O O
who O O
was O O
treated O O
with O O
calcium B-DRUG O
carbonate I-DRUG O
and O O
calcitriol O B-DRUG
resulting O O
in O O
two O O
admissions O O
to O O
the O O
hospital O O
for O O
milk-alkali B-ADR B-ADR
syndrome I-ADR I-ADR

doxycycline-induced O O
hypoglycemia B-ADR B-ADR
in O O
a O O
nondiabetic O O
young O O
man O O

fatal B-ADR B-ADR
acute I-ADR I-ADR
tubular I-ADR I-ADR
necrosis I-ADR I-ADR
occurred O O
in O O
1 O O
patient O O
in O O
whom O O
intravesical O O
formalin B-DRUG B-DRUG
was O O
used O O
to O O
control O O
massive O O
persistent O O
hemorrhage O O
from O O
radiation O O
cystitis O O

amiodarone B-DRUG B-DRUG
was O O
discontinued O O
, O O
and O O
thyrotoxicosis B-ADR B-ADR
gradually O O
abated O O

this O O
therapy O O
was O O
also O O
complicated O O
by O O
warfarin-induced O O
skin B-ADR B-ADR
necrosis I-ADR I-ADR

after O O
5 O O
days O O
of O O
treatment O O
with O O
il-2 B-DRUG B-DRUG
, O O
the O O
patient O O
developed O O
a O O
hemorrhagic O B-ADR
lesion O I-ADR
that O O
progressed O O
to O O
toxic O B-ADR
epidermal O I-ADR
necrolysis O I-ADR
, O O
as O O
well O O
as O O
grade O O
4 O O
pancytopenia B-ADR O

a O O
61-year-old O O
man O O
developed O O
clinical O O
lupus O O
syndrome O O
with O O
positive O O
antinuclear O O
antibody O O
, O O
positive O O
lupus O O
erythematosus O O
( O O
le O O
) O O
cell O O
preparation O O
, O O
and O O
diffuse B-ADR O
proliferative I-ADR B-ADR
glomerulonephritis I-ADR I-ADR
following O O
26 O O
months O O
of O O
procainamide B-DRUG B-DRUG
therapy O O

insulin-induced O O
cardiac B-ADR B-ADR
failure I-ADR I-ADR

physicians O O
should O O
be O O
cognizant O O
of O O
this O O
potential O O
complication O O
in O O
patients O O
receiving O O
thalidomide B-DRUG B-DRUG
or O O
thalidomide-like O O
drugs O O
who O O
present O O
with O O
fever B-ADR O
and O O
pulmonary O B-ADR
infiltrates O I-ADR
and O O
fail O O
to O O
improve O O
despite O O
treatment O O
with O O
broad-spectrum O O
antibiotics O O

treatment O O
of O O
lithium B-DRUG B-DRUG
tremor B-ADR O
with O O
metoprolol O B-DRUG

the O O
renal O O
biopsy O O
showed O O
focal B-ADR B-ADR
segmental I-ADR I-ADR
glomerulosclerosis I-ADR I-ADR
, O O
which O O
has O O
only O O
been O O
previously O O
reported O O
in O O
two O O
cases O O
of O O
cml O B-ADR
treated O O
with O O
ifnalpha B-DRUG B-DRUG

aseptic O B-ADR
meningitis O I-ADR
, O O
hemolytic O O
anemia O O
, O O
hepatitis B-ADR O
, O O
and O O
orthostatic O B-ADR
hypotension O I-ADR
in O O
a O O
patient O O
treated O O
with O O
trimethoprim-sulfamethoxazole O B-DRUG

a O O
64-year-old O O
man O O
presented O O
with O O
proteinuria B-ADR B-ADR
during O O
postoperative O O
interferon O O
( O O
ifn O B-DRUG
)- O O
beta O O
therapy O O
against O O
malignant O O
melanoma O O

a O O
dapsone B-DRUG B-DRUG
hypersensitivity O O
syndrome O O
, O O
consisting O O
of O O
fever O O
, O O
headache O O
, O O
nausea O O
, O O
vomiting B-ADR O
, O O
lymphadenopathy O O
, O O
hepatitis O O
, O O
hemolysis O O
, O O
leukopenia O O
, O O
and O O
mononucleosis O O
, O O
has O O
been O O
described O O
in O O
patients O O
treated O O
with O O
the O O
drug O O
for O O
leprosy O O

nicotinic B-DRUG O
acid-induced O O
fulminant B-ADR B-ADR
hepatic I-ADR I-ADR
failure I-ADR I-ADR

myelodysplasia B-ADR B-ADR
terminating O O
in O O
acute O O
myeloid O O
leukemia O O
in O O
a O O
hairy O O
cell O O
leukemia O O
patient O O
treated O O
with O O
2-deoxycoformycin B-DRUG B-DRUG

methods O O
: O O
double-blind O O
, O O
placebo-controlled O O
titrated O O
oral O O
challenges O O
with O O
pancreatic O O
enzymes O O
resulted O O
in O O
definite O O
vomiting B-ADR O
within O O
1 O O
to O O
1.5 O O
hours O O
after O O
challenges O O
with O O
viokase O B-DRUG
and O O
pancrease B-DRUG O
mt I-DRUG O
16 I-DRUG O
, O O
but O O
not O O
with O O
placebo O B-DRUG

magnesium B-DRUG B-ADR
tocolysis O I-ADR
as O O
the O O
cause O O
of O O
urinary B-ADR O
calculus I-ADR O
during O O
pregnancy O O

the O O
case O O
of O O
a O O
bipolar O O
patient O O
who O O
developed O O
thyrotoxicosis O O
with O O
severe B-ADR B-ADR
exophthalmos I-ADR I-ADR
while O O
on O O
lithium B-DRUG B-DRUG
therapy O O
is O O
described O O

baclofen B-DRUG B-DRUG
withdrawal O O
: O O
a O O
cause O O
of O O
prolonged O B-ADR
fever B-ADR I-ADR
in O O
the O O
intensive O O
care O O
unit O O

we O O
report O O
here O O
a O O
case O O
of O O
ten B-ADR B-ADR
after O O
administration O O
of O O
ciprofloxacin B-DRUG B-DRUG

conclusions O O
: O O
spontaneous B-ADR O
hemothorax I-ADR B-ADR
is O O
a O O
rare O O
phenomenon O O
in O O
conjunction O O
with O O
lmwh B-DRUG B-DRUG
but O O
should O O
be O O
considered O O
in O O
cases O O
of O O
acute O B-ADR
respiratory O I-ADR
distress O I-ADR
following O O
commencement O O
of O O
lmwh B-DRUG B-DRUG

the O O
present O O
report O O
suggests O O
that O O
clarithromycin O B-DRUG
coadministration O O
induces O O
increased B-ADR B-ADR
plasma I-ADR I-ADR
carbamazepine I-ADR I-ADR
concentrations O I-ADR
, O O
which O O
may O O
result O O
in O O
carbamazepine B-DRUG B-ADR
toxicity O I-ADR

we O O
report O O
the O O
first O O
case O O
of O O
an O O
acute O O
flare O O
of O O
eosinophilic B-ADR B-ADR
cystitis I-ADR I-ADR
in O O
a O O
51-year-old O O
woman O O
after O O
bladder O O
instillation O O
with O O
dimethyl B-DRUG B-DRUG
sulfoxide I-DRUG I-DRUG
( O O
dmso O B-DRUG
) O O
for O O
presumed O O
interstitial O O
cystitis O O

the O O
administration O O
of O O
" O O
sweet B-DRUG O
spirits I-DRUG O
of I-DRUG O
nitre I-DRUG B-DRUG
" O O
( O O
4 O B-DRUG
% O I-DRUG
ethyl O I-DRUG
nitrite O I-DRUG
ch3ch2ono O I-DRUG
in O I-DRUG
70 O I-DRUG
% O I-DRUG
ethyl O I-DRUG
alcohol O I-DRUG
) O O
was O O
followed O O
by O O
acute O O
methemoglobinemia O O
and O O
severe O B-ADR
anoxic O I-ADR
metabolic O I-ADR
acidosis O I-ADR
in O O
infant O O
twins O O
, O O
methylene O B-DRUG
blue O O
administration O O
reversed O O
methemoglobinemia O B-ADR
in O O
both O O
, O O
but O O
one O O
twin O O
died O O
from O O
the O O
consequences O O
of O O
hypoxemia B-ADR B-ADR

life-threatening O B-ADR
acute B-ADR I-ADR
hyponatraemia I-ADR I-ADR
induced O O
by O O
low O O
dose O O
cyclophosphamide B-DRUG O
and O O
indomethacin O B-DRUG

a O O
patient O O
suffering O O
from O O
heparin-associated O O
thrombocytopenia O O
( O O
hat O O
) O O
, O O
recurrent B-ADR O
arteriothromboses I-ADR O
, O O
and O O
acute O B-ADR
renal O I-ADR
failure O I-ADR
after O O
treatment O O
with O O
standard O O
heparin B-DRUG B-DRUG
is O O
described O O

tardive B-ADR B-ADR
dyskinesia I-ADR I-ADR
in O O
2 O O
patients O O
treated O O
with O O
ziprasidone B-DRUG B-DRUG

a O O
dapsone B-DRUG B-DRUG
hypersensitivity O O
syndrome O O
, O O
consisting O O
of O O
fever O O
, O O
headache O O
, O O
nausea O O
, O O
vomiting O O
, O O
lymphadenopathy O O
, O O
hepatitis O O
, O O
hemolysis O O
, O O
leukopenia O O
, O O
and O O
mononucleosis B-ADR O
, O O
has O O
been O O
described O O
in O O
patients O O
treated O O
with O O
the O O
drug O O
for O O
leprosy O O

renal B-ADR B-ADR
toxicities I-ADR I-ADR
have O O
been O O
reported O O
in O O
less O O
than O O
one O O
percent O O
of O O
the O O
patients O O
receiving O O
ciprofloxacin B-DRUG B-DRUG
therapy O O

dermatitis B-ADR B-ADR
to O O
captopril B-DRUG B-DRUG

its O O
overall O O
toxicity B-ADR O
is O O
considerably O O
less O O
compared O O
to O O
standard O O
induction O O
chemotherapy O O
; O O
however O O
, O O
it O O
is O O
associated O O
with O O
a O O
high O O
incidence O O
of O O
a O O
potentially O O
fatal O O
symptom O O
complex O O
referred O O
to O O
as O O
" O O
retinoic B-DRUG B-DRUG
acid I-DRUG I-DRUG
syndrome. O O
" O O
this O O
report O O
describes O O
a O O
patient O O
with O O
apl O O
who O O
developed O O
the O O
syndrome O O
a O O
few O O
weeks O O
after O O
initiating O O
induction O O
therapy O O
with O O
atra O B-DRUG
despite O O
being O O
treated O O
for O O
hyperleukocytosis O O

reversible O B-ADR
cholestasis O I-ADR
with O O
bile B-ADR B-ADR
duct I-ADR I-ADR
injury I-ADR I-ADR
following O O
azathioprine B-DRUG B-DRUG
therapy O O

it O O
also O O
highlights O O
a O O
current O O
major O O
etiologic O O
question O O
, O O
that O O
is O O
, O O
whether O O
and O O
to O O
what O O
degree O O
lead B-DRUG O
exposure O O
contributes O O
to O O
the O O
development O O
of O O
hypertension O O
, O O
and O O
raises O O
the O O
issue O O
of O O
whether O O
lead-induced B-ADR O
hypertension I-ADR B-ADR
constitutes O O
a O O
subset O O
of O O
hypertension O O
that O O
is O O
especially O O
amenable O O
to O O
therapy O O
with O O
dietary O O
calcium O O

a O O
patient O O
with O O
ulcerative O O
colitis O O
developed O O
skin O B-ADR
pigmentation O I-ADR
and O O
diffuse B-ADR B-ADR
pulmonary I-ADR I-ADR
shadowing I-ADR I-ADR
without O O
respiratory O O
symptomatology O O
, O O
while O O
taking O O
sulfasalazine B-DRUG B-DRUG

therefore O O
, O O
although O O
garenoxacin B-DRUG B-DRUG
reportedly O O
causes O O
fewer O O
adverse O O
reactions O O
for O O
cardiac B-ADR B-ADR
rhythms I-ADR I-ADR
than O O
third-generation O O
quinolone O O
antibiotics O O
, O O
one O O
must O O
be O O
cautious O O
of O O
the O O
interference O O
of O O
other O O
drugs O O
during O O
hypokalemia O O
in O O
order O O
to O O
prevent O O
tdp O B-DRUG

we O O
describe O O
a O O
case O O
of O O
disseminated O O
muscular O O
cysticercosis O O
followed O O
by O O
myositis O O
( O O
fever O O
, O O
diffuse O O
myalgia O O
, O O
weakness B-ADR O
of I-ADR O
the I-ADR O
lower I-ADR O
limbs I-ADR O
, O O
and O O
inflammatory O O
reaction O O
around O O
dying O O
cysticerci O O
) O O
induced O O
by O O
praziquantel B-DRUG B-DRUG
therapy O O
, O O
an O O
event O O
not O O
described O O
previously O O

objective O O
: O O
to O O
describe O O
the O O
development O O
of O O
valproate-related O O
reproductive B-ADR B-ADR
endocrine I-ADR I-ADR
disorders I-ADR I-ADR
in O O
women O O
with O O
epilepsy O O

visual B-ADR B-ADR
changes I-ADR I-ADR
secondary O O
to O O
initiation O O
of O O
amiodarone B-DRUG B-DRUG
: O O
a O O
case O O
report O O
and O O
review O O
involving O O
ocular O O
management O O
in O O
cardiac O O
polypharmacy O O

monitoring O O
of O O
liver O O
function O O
tests O O
should O O
be O O
mandatory O O
in O O
patients O O
receiving O O
high O O
doses O O
of O O
cyproterone B-DRUG B-DRUG
acetate I-DRUG I-DRUG
; O O
the O O
drug O O
should O O
be O O
withdrawn O O
immediately O O
if O O
abnormal B-ADR O
liver I-ADR O
function I-ADR O
tests I-ADR O
are O O
found O O

toxic B-ADR B-ADR
epidermal I-ADR I-ADR
necrolysis I-ADR I-ADR
associated O O
with O O
interleukin-2 B-DRUG B-DRUG

three O O
patients O O
received O O
respectively O O
190 O O
mg O O
, O O
175 O O
mg O O
, O O
and O O
196 O O
mg O O
of O O
methotrexate B-DRUG B-DRUG
and O O
developed O O
bilateral B-ADR B-ADR
pulmonary I-ADR I-ADR
infiltrates I-ADR I-ADR
without O O
evidence O O
of O O
peripheral O B-ADR
blood O I-ADR
eosinophilia O I-ADR

although O O
there O O
is O O
one O O
case O O
report O O
of O O
cholesterol B-ADR B-ADR
crystal I-ADR I-ADR
embolization I-ADR I-ADR
following O O
t-pa B-DRUG B-DRUG
therapy O O
with O O
only O O
extrarenal O O
manifestations O O
( O O
n O O
engl O O
j O O
med O O
321:1270 O O
, O O
1989 O O
) O O
, O O
this O O
is O O
the O O
first O O
reported O O
case O O
of O O
atheroembolic O B-ADR
acute O I-ADR
renal O I-ADR
failure O I-ADR
following O O
t-pa B-DRUG B-DRUG
therapy O O

the O O
case O O
history O O
and O O
toxicological O O
findings O O
of O O
an O O
infant O O
fatality B-ADR O
involving O O
pseudoephedrine O O
, O O
brompheniramine O O
, O O
and O O
dextromethorphan B-DRUG B-DRUG
are O O
presented O O

terlipressin-induced O O
ventricular B-ADR B-ADR
arrhythmia I-ADR I-ADR

methotrexate B-DRUG O
( O O
mtx O B-DRUG
) O O
is O O
a O O
commonly O O
used O O
second O O
line O O
agent O O
for O O
ra O O
, O O
and O O
there O O
have O O
been O O
several O O
recent O O
reports O O
of O O
epstein-barr O O
virus O O
( O O
ebv O O
)- O O
associated O O
polyclonal O O
b O O
cell O O
lymphoproliferative O O
disorder O O
in O O
mtx-treated O O
ra O O
patients O O

when O O
sasp O B-DRUG
was O O
changed O O
to O O
5-aminosalicylic O B-DRUG
acid O I-DRUG
( O O
5-asa B-DRUG O
) O O
, O O
his O O
skin O O
eruptions O O
were O O
resolved O O
, O O
however O O
, O O
he O O
developed O O
weakness O O
and O O
atrophy O O
in O O
his O O
right O O
arm O O
as O O
well O O
as O O
progressive O O
worsening B-ADR O
of I-ADR O
the I-ADR O
dysesthesia I-ADR O
in O O
his O O
legs O O
and O O
gait O O
disturbance O O

nitrendipine B-DRUG B-DRUG
is O O
an O O
experimental O O
calcium O O
channel O O
blocking O O
agent O O
that O O
also O O
appears O O
to O O
cause O O
the O O
side O O
effect O O
of O O
drug-induced O O
gingival B-ADR B-ADR
hyperplasia I-ADR I-ADR

an O O
association O O
of O O
granulocytopenia O O
, O O
eosinophilia O O
, O O
skin B-ADR B-ADR
reaction I-ADR I-ADR
and O O
hepatitis O O
during O O
propylthiouracil B-DRUG B-DRUG
( O O
ptu O B-DRUG
) O O
therapy O O
for O O
thyrotoxicosis O O
in O O
a O O
47 O O
year O O
old O O
black O O
female O O
is O O
reported O O

a O O
case O O
report O O
of O O
a O O
patient O O
with O O
probable O O
cisplatin B-DRUG B-DRUG
and O O
bleomycin-induced O O
tma B-ADR B-ADR
is O O
presented O O

all O O
developed O O
mucocutaneous B-ADR B-ADR
side I-ADR I-ADR
effects I-ADR I-ADR
within O O
20 O O
weeks O O
of O O
beginning O O
im O B-DRUG
gold B-DRUG I-DRUG
therapy O O
, O O
at O O
a O O
time O O
when O O
ra O B-DRUG
had O O
improved O O
markedly O O
compared O O
to O O
pretreatment O O
status O O

a O O
27-year-old O O
man O O
who O O
had O O
a O O
history O O
of O O
bronchial O O
asthma O O
, O O
eosinophilic O O
enteritis O O
, O O
and O O
eosinophilic O O
pneumonia O O
presented O O
with O O
fever O O
, O O
skin O O
eruptions O O
, O O
cervical O O
lymphadenopathy O O
, O O
hepatosplenomegaly O O
, O O
atypical O O
lymphocytosis O O
, O O
and O O
eosinophilia B-ADR O
two O O
weeks O O
after O O
receiving O O
trimethoprim O O
( O O
tmp O O
)- O O
sulfamethoxazole B-DRUG O
( O O
smx O O
) O O
treatment O O

life-threatening O B-ADR
acute B-ADR I-ADR
hyponatraemia I-ADR I-ADR
induced O O
by O O
low O O
dose O O
cyclophosphamide O O
and O O
indomethacin B-DRUG B-DRUG

hypersensitivity O O
to O O
aspirin B-DRUG B-DRUG
can O O
be O O
manifested O O
as O O
acute O O
asthma O O
, O O
urticaria O O
and O O
/ O O
or O O
angioedema O O
, O O
or O O
a O O
systemic B-ADR B-ADR
anaphylactoid I-ADR I-ADR
reaction I-ADR I-ADR

we O O
consider O O
asterixis B-ADR B-ADR
to O O
be O O
an O O
easily O O
overlooked O O
sign O O
of O O
neurotoxicity O B-ADR
, O O
which O O
may O O
occur O O
even O O
at O O
low O O
or O O
moderate O O
dosage O O
levels O O
, O O
if O O
certain O O
drugs O O
as O O
lithium O B-DRUG
or O O
clozapine B-DRUG B-DRUG
are O O
used O O
in O O
combination O O
with O O
cbz O B-DRUG

the O O
authors O O
intend O O
to O O
carry O O
out O O
a O O
case-control O O
study O O
on O O
patients O O
treated O O
with O O
tamoxifen B-DRUG B-DRUG
for O O
breast O O
carcinoma O O
to O O
reveal O O
the O O
possible O O
presence O O
of O O
endometrial B-ADR B-ADR
carcinoma I-ADR I-ADR

patients O O
from O O
endemic O O
areas O O
referred O O
to O O
transplant O O
centers O O
may O O
be O O
at O O
high O O
risk O O
for O O
disseminated B-ADR O
histoplasmosis I-ADR B-ADR
when O O
treated O O
with O O
long-term O O
prednisone B-DRUG B-DRUG
for O O
graft-versus-host O O
disease O O

uveitis B-ADR B-ADR
during O O
treatment O O
of O O
disseminated O O
mycobacterium O O
avium-intracellulare O O
complex O O
infection O O
with O O
the O O
combination O O
of O O
rifabutin B-DRUG B-DRUG
, O O
clarithromycin O O
and O O
ethambutol O B-DRUG

keratitis B-ADR B-ADR
in O O
methamphetamine B-DRUG B-DRUG
abusers O O

adverse O O
effects O O
of O O
amiodarone B-DRUG B-DRUG
including O O
pulmonary O O
toxicity O O
, O O
hepatotoxicity O O
, O O
aggravation B-ADR O
of I-ADR O
arrhythmia I-ADR O
, O O
and O O
thyroid O O
diseases O O
are O O
well O O
understood O O

seven O O
of O O
the O O
eight O O
cases O O
of O O
acute B-ADR B-ADR
leukemia I-ADR I-ADR
occurred O O
in O O
a O O
series O O
of O O
553 O O
patients O O
treated O O
with O O
treosulfan B-DRUG B-DRUG
for O O
ovarian O O
cancer O O
in O O
the O O
period O O
from O O
1970 O O
to O O
1977 O O
and O O
followed O O
closely O O
for O O
a O O
total O O
of O O
1159 O O
patient-years O O
up O O
to O O
february O O
1978 O O

early O O
peritoneal O O
dialysis O O
has O O
not O O
previously O O
been O O
reported O O
for O O
lisinopril B-DRUG B-DRUG
induced O O
multiorgan B-ADR B-ADR
failure I-ADR I-ADR

after O O
a O O
second O O
dose O O
of O O
metoclopramide B-DRUG B-DRUG
, O O
these O O
symptoms O O
recurred O O
and O O
were O O
associated O O
with O O
confusion O O
, O O
agitation O O
, O O
fever O O
, O O
diaphoresis B-ADR O
, O O
tachypnea O O
, O O
tachycardia O O
, O O
and O O
hypertension O O

a O O
56-year-old O O
woman O O
with O O
scleroderma O O
developed O O
rapidly O O
progressive O O
glomerulonephritis O O
with O O
epithelial O O
crescents O O
associated O O
with O O
hemoptysis B-ADR B-ADR
after O O
27 O O
months O O
of O O
d-penicillamine B-DRUG B-DRUG
therapy O O
and O O
a O O
cumulative O O
dose O O
of O O
1,200 O O
g O O

it O O
occasionally O O
accompanies O O
the O O
heparin-associated O O
thrombocytopenia O O
and O O
thrombosis B-ADR B-ADR
syndrome I-ADR I-ADR

tremor B-ADR B-ADR
: O O
a O O
newly O O
described O O
adverse O O
event O O
with O O
long-term O O
itraconazole B-DRUG B-DRUG
therapy O O

these O O
are O O
the O O
first O O
reported O O
patients O O
to O O
show O O
mferg O B-ADR
abnormalities O I-ADR
that O O
correspond O O
to O O
bitemporal B-ADR O
visual I-ADR B-ADR
field I-ADR I-ADR
defects I-ADR I-ADR
and O O
add O O
to O O
the O O
growing O O
evidence O O
that O O
ethambutol B-DRUG B-DRUG
damages O B-ADR
the O I-ADR
retina O I-ADR

methotrexate-induced O O
leukoencephalopathy B-ADR B-ADR
is O O
treatable O O
with O O
high-dose O O
folinic O B-DRUG
acid O I-DRUG
: O O
a O O
case O O
report O O
and O O
analysis O O
of O O
the O O
literature O O

study O O
design O O
: O O
case O O
report O O
of O O
a O O
31-year-old O O
woman O O
who O O
presented O O
with O O
toxic B-ADR B-ADR
myelopathy I-ADR I-ADR
due O O
to O O
intrathecal O O
administration O O
of O O
doxorubicin B-DRUG B-DRUG

typically O O
, O O
drug-induced O O
neutropenia B-ADR B-ADR
occurs O O
in O O
a O O
patient O O
receiving O O
a O O
semisynthetic O O
penicillin B-DRUG B-DRUG
for O O
two O O
weeks O O
or O O
more O O

there O O
is O O
no O O
consensus O O
on O O
the O O
treatment O O
of O O
ticlopidine-induced O O
marrow B-ADR B-ADR
aplasia I-ADR I-ADR

the O O
possibility O O
of O O
phenytoin B-DRUG B-DRUG
hypersensitivity O O
reactions O O
should O O
be O O
considered O O
when O O
patients O O
receiving O O
phenytoin B-DRUG B-DRUG
have O O
unusual O O
symptoms O O
, O O
particularly O O
fever O O
, O O
rash B-ADR O
, O O
and O O
lymphadenopathy O O

hepatotoxicity B-ADR B-ADR
associated O O
with O O
choline B-DRUG B-DRUG
magnesium I-DRUG I-DRUG
trisalicylate I-DRUG I-DRUG
: O O
case O O
report O O
and O O
review O O
of O O
salicylate-induced O O
hepatotoxicity O B-ADR

three O O
patients O O
, O O
in O O
whom O O
tumour O O
overkill O O
by O O
cytotoxic O O
treatment O O
, O O
including O O
high O O
dose O O
methotrexate O B-DRUG
with O O
folinic B-DRUG B-DRUG
acid I-DRUG I-DRUG
rescue O O
, O O
resulted O O
in O O
the O O
' O O
phosphate B-ADR O
shower I-ADR O
syndrome I-ADR O
' O O
( O O
hyper-uricaemia O O
, O O
hyperkalaemia O O
and O O
hyperphosphataemia O O
with O O
hypocalcaemia O O
and O O
tetany O O
, O O
with O O
metabolic O O
acidosis O O
and O O
acute O O
renal O O
impairment O O
) O O
are O O
described O O

however O O
, O O
follow-up O O
revealed O O
that O O
gestational O B-ADR
diabetes O I-ADR
when O O
associated O O
with O O
norethisterone B-DRUG B-DRUG
had O O
a O O
lesser O O
risk O O
of O O
emerging O O
diabetes B-ADR O
mellitus I-ADR O
and O O
impaired O B-ADR
glucose O I-ADR
tolerance O I-ADR

angioedema B-ADR B-ADR
and O O
maculopapular O B-ADR
eruptions O I-ADR
associated O O
with O O
carbamazepine B-DRUG B-DRUG
administration O O

during O O
analysis O O
of O O
28 O O
patients O O
receiving O O
cap B-DRUG B-DRUG
with O O
concomitant O O
radiation O O
( O O
xrt O O
) O O
for O O
pancreatic O O
cancer O O
( O O
resected O O
or O O
locally O O
advanced O O
) O O
, O O
two O O
patients O O
developed O O
signs O O
and O O
symptoms O O
consistent O O
with O O
peripheral B-ADR B-ADR
neuropathy I-ADR I-ADR

unaccountable O O
severe O B-ADR
hypercalcemia B-ADR I-ADR
in O O
a O O
patient O O
treated O O
for O O
hypoparathyroidism O O
with O O
dihydrotachysterol B-DRUG B-DRUG

purple O B-ADR
glove O I-ADR
syndrome O I-ADR
, O O
named O O
for O O
its O O
distinctive O O
purple O O
discoloration O O
and O O
swelling B-ADR B-ADR
of I-ADR I-ADR
the I-ADR I-ADR
hands I-ADR I-ADR
in O O
the O O
distribution O O
of O O
a O O
glove O O
, O O
is O O
an O O
uncommon O O
complication O O
of O O
intravenous O O
phenytoin B-DRUG B-DRUG
administration O O
through O O
small O B-ADR
dorsal O I-ADR
veins O I-ADR
of O I-ADR
the O I-ADR
hands O I-ADR

to O O
our O O
knowledge O O
, O O
these O O
cases O O
are O O
the O O
first O O
published O O
reports O O
of O O
lovastatin-induced O O
rhabdomyolysis B-ADR B-ADR
associated O O
with O O
azithromycin O B-DRUG
and O O
clarithromycin B-DRUG B-DRUG

rofecoxib B-DRUG B-DRUG
, O O
used O O
for O O
dysmenorrhea O O
, O O
caused O O
a O O
herpetiform B-ADR O
fixed I-ADR O
drug I-ADR O
eruption I-ADR O
predominantly O O
involving O O
the O O
lips O O
with O O
classic O O
clinical O O
and O O
histological O O
findings O O
in O O
a O O
red-brown O B-ADR
lesion O I-ADR
on O O
the O O
dorsal O O
hand O O

in O O
one O O
instance O O
a O O
systemic O O
hypoglycemic O B-ADR
reaction O I-ADR
resulting O O
in O O
head B-ADR O
trauma I-ADR O
and O O
confusion O O
ended O O
in O O
an O O
emegency O B-ADR
hospital O I-ADR
admission O I-ADR
following O O
the O O
substitution O O
of O O
acetohexamide B-DRUG B-DRUG
for O O
acetazolamide O B-DRUG

intracranial B-ADR B-ADR
haemorrhage I-ADR I-ADR
from O O
a O O
meningioma O O
in O O
a O O
patient O O
receiving O O
aspirin B-DRUG B-DRUG
prophylaxis O O
: O O
a O O
case O O
report O O

the O O
occurrence O O
of O O
neuromuscular B-ADR O
blockade I-ADR O
and O O
the O O
resulting O O
potentiation O O
of O O
muscle O O
relaxants O O
during O O
magnesium B-DRUG B-DRUG
sulfate I-DRUG I-DRUG
( O O
mgso4 O B-DRUG
) O O
administration O O
is O O
well O O
known O O

the O O
patient O O
was O O
enrolled O O
in O O
a O O
weight-loss O O
clinic O O
, O O
and O O
his O O
diabetes O O
medications O O
were O O
adjusted.subsequently O O
, O O
olanzapine B-DRUG B-DRUG
was O O
discontinued O O
because O O
of O O
weight B-ADR O
gain I-ADR O
and O O
uncontrolled O O
diabetes O O

we O O
report O O
the O O
case O O
of O O
a O O
17-year-old O O
male O O
who O O
developed O O
chest O O
pain O O
, O O
elevated B-ADR O
cardiac I-ADR O
biomarkers I-ADR O
, O O
and O O
acute O B-ADR
left O I-ADR
ventricular O I-ADR
dysfunction O I-ADR
following O O
a O O
single O O
dose O O
of O O
methylphenidate B-DRUG B-DRUG

adriamycin-induced O O
cardiomyopathy O B-ADR
aggravated O O
by O O
cis-platinum B-DRUG B-ADR
nephrotoxicity B-ADR I-ADR
requiring O O
dialysis O O

noncardiogenic B-ADR B-ADR
pulmonary I-ADR I-ADR
edema I-ADR I-ADR
during O O
intrabiliary O O
infusion O O
of O O
mono-octanoin B-DRUG B-DRUG

levofloxacin B-DRUG B-DRUG
induced O O
polymorphic B-ADR B-ADR
ventricular I-ADR I-ADR
tachycardia I-ADR I-ADR
with O O
normal O O
qt O O
interval O O

we O O
present O O
two O O
cases O O
of O O
nitrofurantoin-induced O O
pulmonary O B-ADR
toxicity O I-ADR
in O O
which O O
the O O
initial O O
hrct O O
showed O O
a O O
widespread O O
reticular O O
pattern O O
and O O
associated O O
distortion B-ADR O
of I-ADR O
the I-ADR O
lung I-ADR O
parenchyma I-ADR O
, O O
thought O O
to O O
represent O O
established O O
fibrosis O O

this O O
report O O
presents O O
a O O
case O O
of O O
acute B-ADR B-ADR
lung I-ADR I-ADR
injury I-ADR I-ADR
developing O O
within O O
hours O O
after O O
administration O O
of O O
mefloquine B-DRUG B-DRUG
for O O
a O O
low-level O O
plasmodium O O
falciparum O O
malaria O O
, O O
which O O
was O O
persistent O O
despite O O
halofantrine O B-DRUG
therapy O O

we O O
report O O
here O O
a O O
rare O O
case O O
of O O
pleuropericarditis B-ADR B-ADR
due O O
to O O
methotrexate B-DRUG B-DRUG

carboplatin B-DRUG B-DRUG
hypersensitivity O O
presenting O O
as O O
coronary B-ADR B-ADR
vasospasm I-ADR I-ADR
- O O
a O O
case O O
report O O

since O O
the O O
thrombocyte B-ADR B-ADR
count I-ADR I-ADR
started I-ADR I-ADR
to I-ADR I-ADR
increase I-ADR I-ADR
immediately O O
after O O
initiation O O
and O O
dropped O O
immediately O O
after O O
discontinuation O O
of O O
ciprofloxacin B-DRUG O
and O O
tazobactam O O
/ O O
piperacillin O B-DRUG
and O O
all O O
other O O
drugs O O
were O O
discontinued O O
already O O
before O O
or O O
were O O
started O O
after O O
the O O
nadir O O
of O O
the O O
thrombocyte O O
count O O
, O O
these O O
two O O
antibiotics O O
were O O
regarded O O
causative O O

we O O
report O O
a O O
44-year-old O O
woman O O
with O O
t-mds O O
( O O
refractory B-ADR O
anemia I-ADR O
with I-ADR O
excess I-ADR O
blasts I-ADR O
) O O
following O O
treatment O O
of O O
recurrent O O
anaplastic O O
astrocytoma O O
with O O
temozolomide B-DRUG B-DRUG
( O O
tmz O B-DRUG

i O O
saw O O
two O O
patients O O
with O O
kala-azar O B-DRUG
resistant O O
to O O
sodium O B-DRUG
stibogluconate O I-DRUG
who O O
developed O O
cardiac B-ADR B-ADR
arrest I-ADR I-ADR
after O O
amphotericin B-DRUG B-DRUG
infusion O O
( O O
in O O
spite O O
of O O
tolerating O O
a O O
test O O
dose O O

we O O
present O O
a O O
case O O
report O O
of O O
a O O
patient O O
who O O
developed O O
a O O
prolonged B-ADR O
qt I-ADR O
while O O
being O O
treated O O
with O O
oral O O
methadone B-DRUG B-DRUG
for O O
a O O
chronic O O
pain O O
syndrome O O

the O O
rash B-ADR B-ADR
seen O O
in O O
this O O
patient O O
, O O
who O O
was O O
treated O O
with O O
cephalexin B-DRUG B-DRUG
, O O
may O O
be O O
similar O O
to O O
the O O
rash B-ADR O
seen O O
with O O
ampicillin O B-DRUG
treatment O O
of O O
patients O O
with O O
infectious O O
mononucleosis O O

pamidronate O B-DRUG
therapy O O
should O O
be O O
considered O O
in O O
patients O O
with O O
hypercalcemia O O
secondary O O
to O O
acute B-ADR B-ADR
vitamin I-ADR I-ADR
d I-ADR I-ADR
poisoning I-ADR I-ADR

acute B-ADR B-ADR
syphilitic I-ADR I-ADR
posterior I-ADR I-ADR
placoid I-ADR I-ADR
chorioretinitis I-ADR I-ADR
following O O
intravitreal O O
triamcinolone B-DRUG B-DRUG
acetonide I-DRUG I-DRUG
injection O O

even O O
after O O
a O O
strict O O
warning O O
, O O
he O O
took O O
another O O
quinine B-DRUG B-DRUG
tablet O O
that O O
evening O O
, O O
which O O
triggered O O
his O O
fifth O O
episode O O
of O O
severe O O
thrombocytopenia B-ADR O
, O O
and O O
confirmed O O
the O O
etiology O O
of O O
quinine-induced O O
thrombocytopenia B-ADR B-ADR

disulfiram B-DRUG B-ADR
encephalopathy B-ADR I-ADR
as O O
a O O
cause O O
of O O
the O O
catatonia O B-ADR
syndrome O I-ADR

we O O
report O O
three O O
cases O O
of O O
amiodarone-induced O O
torsades B-ADR B-ADR
de I-ADR I-ADR
pointe I-ADR I-ADR

objective O O
: O O
to O O
report O O
a O O
case O O
of O O
carbamazepine B-ADR B-ADR
toxicity I-ADR I-ADR
following O O
the O O
administration O O
of O O
oxybutynin O B-DRUG
and O O
dantrolene B-DRUG B-DRUG

progressive B-ADR B-ADR
anemia I-ADR I-ADR
following O O
combination O O
therapy O O
with O O
interferon-alpha B-DRUG B-DRUG
and O O
interleukin-2 O B-DRUG
in O O
a O O
patient O O
with O O
metastatic O O
renal O O
cell O O
carcinoma O O

we O O
report O O
the O O
first O O
case O O
of O O
doxycycline-induced O O
hypoglycemia B-ADR B-ADR
in O O
a O O
young O O
nondiabetic O O
man O O

case O O
report O O
: O O
we O O
describe O O
here O O
a O O
case O O
of O O
a O O
60 O O
year O O
old O O
female O O
that O O
experienced O O
a O O
relapse O O
of O O
symptomatic B-ADR B-ADR
hyperlactatemia I-ADR I-ADR
after O O
being O O
switched O O
from O O
stavudine B-DRUG B-DRUG
to O O
zidovudine O B-DRUG
and O O
how O O
the O O
case O O
was O O
managed O O
at O O
the O O
infectious O O
diseases O O
institute O O
, O O
kampala O O
, O O
uganda O O

acute B-ADR B-ADR
renal I-ADR I-ADR
failure I-ADR I-ADR
during O O
lisinopril O B-DRUG
and O O
losartan B-DRUG B-DRUG
therapy O O
for O O
proteinuria O O

objective O O
: O O
we O O
report O O
a O O
patient O O
who O O
developed O O
neutropenia O O
on O O
clozapine B-DRUG B-DRUG
, O O
but O O
behind O O
the O O
cell O O
count O O
decrease O O
showed O O
to O O
be O O
a O O
diurnal B-ADR O
variation I-ADR O
of I-ADR O
the I-ADR O
white I-ADR O
blood I-ADR O
cells I-ADR O
( O O
wbc O O

results O O
: O O
both O O
cases O O
presented O O
here O O
describe O O
corneal B-ADR B-ADR
ulcers I-ADR I-ADR
that O O
persisted O O
and O O
showed O O
signs O O
of O O
worsening O O
during O O
weeks O O
of O O
frequent O O
topical O O
dosing O O
with O O
moxifloxacin B-DRUG B-DRUG

azathioprine-induced O O
myelosuppression B-ADR B-ADR
due O O
to O O
thiopurine O B-ADR
methyltransferase O I-ADR
deficiency O I-ADR
in O O
a O O
patient O O
with O O
autoimmune O O
hepatitis O O

we O O
report O O
the O O
first O O
case O O
of O O
an O O
acute O O
flare O O
of O O
eosinophilic B-ADR B-ADR
cystitis I-ADR I-ADR
in O O
a O O
51-year-old O O
woman O O
after O O
bladder O O
instillation O O
with O O
dimethyl O B-DRUG
sulfoxide O I-DRUG
( O O
dmso B-DRUG B-DRUG
) O O
for O O
presumed O O
interstitial O O
cystitis O O

second O O
cancers O O
including O O
various O O
types O O
of O O
hematological B-ADR B-ADR
malignancy I-ADR I-ADR
have O O
been O O
reported O O
in O O
patients O O
with O O
hairy O O
cell O O
leukemia O O
treated O O
with O O
chemotherapy O O
or O O
interferon B-DRUG B-DRUG
alfa I-DRUG I-DRUG

although O O
it O O
is O O
difficult O O
to O O
be O O
certain O O
of O O
the O O
direct O O
link O O
of O O
amiodarone B-DRUG B-DRUG
on O O
the O O
basis O O
of O O
a O O
single O O
case O O
, O O
it O O
is O O
reasonable O O
to O O
presume O O
that O O
this O O
histopathology O O
is O O
associated O O
with O O
amiodarone-induced O O
hypothyroidism B-ADR B-ADR
and O O
that O O
involution O O
changes O O
represent O O
the O O
hypofunctional O O
status O O
of O O
this O O
drug-induced O O
disorder O O

neurological B-ADR B-ADR
side I-ADR I-ADR
effects I-ADR I-ADR
in O O
two O O
patients O O
receiving O O
gold B-DRUG B-DRUG
injections O O
for O O
rheumatoid O O
arthritis O O

intravenous O O
diazepam B-DRUG B-DRUG
exacerbated O O
the O O
seizures B-ADR B-ADR

because O O
etoposide-induced O O
pulmonary B-ADR B-ADR
toxicity I-ADR I-ADR
is O O
an O O
uncommon O O
but O O
serious O O
adverse O O
event O O
, O O
clinicians O O
must O O
be O O
vigilant O O
about O O
the O O
possibility O O
of O O
it O O
, O O
so O O
that O O
the O O
optimal O O
treatment O O
can O O
start O O
as O O
soon O O
as O O
possible O O

paradoxical B-ADR B-ADR
cerebral I-ADR I-ADR
cortical I-ADR I-ADR
hyperexcitability I-ADR I-ADR
following O O
flupirtine B-DRUG B-DRUG
overdose O O

she O O
received O O
an O O
accidental O O
450-mg O O
bolus O O
injection O O
of O O
morphine B-DRUG B-DRUG
intrathecally O O
and O O
developed O O
hypertension O O
, O O
status O B-ADR
epilepticus O I-ADR
, O O
intracerebral B-ADR O
hemorrhage I-ADR O
, O O
and O O
respiratory O B-ADR
failure O I-ADR

recent O O
reports O O
have O O
shown O O
that O O
decadron O B-DRUG
( O O
dexamethasone O O
; O O
merck O O
sharp O O
& O O
dohme O O
, O O
west O O
point O O
, O O
pa O B-DRUG
) O O
has O O
a O O
significant O O
antiemetic O O
effect O O
on O O
cisplatin-induced O O
vomiting B-ADR B-ADR

fatal B-ADR B-ADR
pulmonary I-ADR I-ADR
fibrosis I-ADR I-ADR
associated O O
with O O
bcnu B-DRUG B-DRUG
: O O
the O O
relative O O
role O O
of O O
platelet-derived O O
growth O O
factor-b O O
, O O
insulin-like O O
growth O O
factor O O
i O O
, O O
transforming O O
growth O O
factor-beta1 O O
and O O
cyclooxygenase-2 O B-DRUG

prolongation B-ADR O
of I-ADR O
the I-ADR O
qt I-ADR O
interval I-ADR O
observed O O
in O O
a O O
japanese O O
patient O O
with O O
vivax O O
malaria O O
following O O
treatment O O
with O O
halofantrine B-DRUG B-DRUG

anticonvulsant B-ADR B-ADR
hypersensitivity I-ADR I-ADR
syndrome I-ADR I-ADR
associated O O
with O O
bellamine B-DRUG B-DRUG
s I-DRUG I-DRUG
, O O
a O O
therapy O O
for O O
menopausal O O
symptoms O O

background O O
: O O
reproductive O O
endocrine O O
disorders O O
characterized O O
by O O
menstrual O O
disorders O O
, O O
polycystic O B-ADR
ovaries O I-ADR
, O O
and O O
hyperandrogenism B-ADR O
seem O O
to O O
be O O
common O O
among O O
women O O
treated O O
with O O
sodium B-DRUG B-DRUG
valproate I-DRUG I-DRUG
for O O
epilepsy O O

interstitial B-ADR B-ADR
pneumonitis I-ADR I-ADR
associated O O
with O O
sirolimus B-DRUG B-DRUG
: O O
a O O
dilemma O O
for O O
lung O O
transplantation O O

we O O
present O O
four O O
cases O O
in O O
which O O
the O O
use O O
of O O
heparin B-DRUG B-DRUG
was O O
associated O O
with O O
hyperkalemia B-ADR O
and O O
discuss O O
the O O
pathophysiology O O

first O O
case O O
of O O
ivermectin-induced O O
severe B-ADR B-ADR
hepatitis I-ADR I-ADR

a O O
patient O O
suffering O O
from O O
heparin-associated O O
thrombocytopenia O O
( O O
hat O O
) O O
, O O
recurrent O O
arteriothromboses O O
, O O
and O O
acute B-ADR B-ADR
renal I-ADR I-ADR
failure I-ADR I-ADR
after O O
treatment O O
with O O
standard O O
heparin B-DRUG B-DRUG
is O O
described O O

encephalopathy O O
and O O
seizures B-ADR B-ADR
induced O O
by O O
intravesical O B-ADR
alum B-DRUG I-ADR
irrigations O I-ADR

we O O
report O O
a O O
patient O O
with O O
pulmonary O O
adenocarcinoma O O
complicated O O
by O O
the O O
syndrome B-ADR O
of I-ADR O
inappropriate I-ADR O
secretion I-ADR O
of I-ADR O
antidiuretic I-ADR O
hormone I-ADR O
( O O
siadh O B-ADR
) O O
following O O
systemic O O
chemotherapy O O
with O O
cisplatin O O
( O O
cddp O O
) O O
and O O
vindesine O O
( O O
vds B-DRUG O

the O O
first O O
patient O O
is O O
undergoing O O
hemodialysis O O
and O O
, O O
though O O
responding O O
to O O
sunitinib B-DRUG B-DRUG
, O O
is O O
having O O
significant O O
fatigue B-ADR O
and O O
hypertension O O

clinical B-ADR O
, I-ADR O
spectroscopic I-ADR O
, I-ADR O
and I-ADR O
imaging I-ADR O
abnormalities I-ADR O
resolved O O
with O O
discontinuation O O
of O O
metronidazole B-DRUG B-DRUG

case O O
report O O
: O O
dapsone B-DRUG B-DRUG
hypersensitivity B-ADR B-ADR
syndrome I-ADR I-ADR
associated O O
with O O
treatment O O
of O O
the O O
bite O O
of O O
a O O
brown O O
recluse O O
spider O O

a O O
teenage O O
girl O O
with O O
crescentic O O
glomerulonephritis O O
had O O
antineutrophil B-ADR O
cytoplasmic I-ADR O
antibody I-ADR O
( O O
anca O O
) O O
detected O O
after O O
she O O
had O O
received O O
propylthiouracil B-DRUG B-DRUG
( O O
ptu O B-DRUG
) O O
for O O
hyperthyroidism O O
without O O
cutaneous O O
vasculitis O O

a O O
patient O O
with O O
a O O
large O O
hydatid O O
cyst O O
of O O
the O O
left O O
lobe O O
of O O
the O O
liver O O
developed O O
metabolic B-ADR B-ADR
acidosis I-ADR I-ADR
following O O
rather O O
liberal O O
use O O
of O O
cetrimide-chlorhexidine O B-DRUG
solution O O
as O O
a O O
scolicidal O O
agent O O

less O O
common O O
adverse O O
events O O
to O O
dapsone B-DRUG B-DRUG
include O O
the O O
idiosyncratic O O
reactions O O
of O O
leukopenia O O
and O O
agranulocytosis B-ADR O
, O O
cutaneous O O
eruptions O O
, O O
peripheral O O
neuropathy O O
, O O
psychosis O O
, O O
toxic O O
hepatitis O O
, O O
cholestatic O O
jaundice O O
, O O
nephrotic O O
syndrome O O
, O O
renal O O
papillary O O
necrosis O O
, O O
severe O O
hypoalbuminemia O O
without O O
proteinuria O O
, O O
an O O
infectious O O
mononucleosis-like O O
syndrome O O
, O O
and O O
minor O O
neurological O O
and O O
gastrointestinal O O
complaints O O

although O O
visual B-ADR O
hallucinations I-ADR O
have O O
not O O
been O O
reported O O
as O O
an O O
adverse O O
effect O O
of O O
this O O
agent O O
, O O
we O O
describe O O
three O O
patients O O
who O O
experienced O O
complex O O
visual B-ADR O
hallucinations I-ADR O
and O O
altered O O
mental O B-ADR
status O I-ADR
after O O
zonisamide B-DRUG B-DRUG
treatment O O
was O O
begun O O
or O O
its O O
dosage O O
increased O O

data O O
synthesis O O
: O O
genetic O O
deficiencies O O
in O O
dpd O O
, O O
the O O
rate-limiting O O
enzyme O O
responsible O O
for O O
5-fu B-DRUG B-DRUG
catabolism O O
, O O
may O O
occur O O
in O O
3 O O
% O O
or O O
more O O
of O O
patients O O
with O O
cancer O O
putting O O
them O O
at O O
increased O O
risk O O
for O O
unusually O O
severe O O
adverse O O
reactions O O
( O O
e.g. O O
, O O
diarrhea O O
, O O
stomatitis O O
, O O
mucositis O O
, O O
myelosuppression B-ADR O
, O O
neurotoxicity O O
) O O
to O O
standard O O
doses O O
of O O
5-fu B-DRUG B-DRUG

sixteen O O
hours O O
after O O
the O O
first O O
administration O O
of O O
ifn B-DRUG B-DRUG
, O O
ifn B-DRUG B-DRUG
was O O
suspended O O
by O O
the O O
symptoms O O
of O O
congestive B-ADR B-ADR
heart I-ADR I-ADR
failure I-ADR I-ADR
( O O
chf O B-ADR

transient B-ADR O
left I-ADR O
homonymous I-ADR O
hemianopsia I-ADR O
and O O
encephalopathy O O
following O O
treatment O O
of O O
testicular O O
carcinoma O O
with O O
cisplatinum O O
, O O
vinblastine B-DRUG O
, O O
and O O
bleomycin O B-DRUG

two O O
patients O O
treated O O
with O O
alprazolam B-DRUG B-DRUG
had O O
histories O O
suggestive O O
of O O
a O O
bipolar O O
disorder O O
and O O
developed O O
lithium-responsive O B-ADR
manic B-ADR I-ADR
episodes I-ADR I-ADR

it O O
is O O
tempting O O
to O O
speculate O O
that O O
interferon B-DRUG B-DRUG
alpha I-DRUG I-DRUG
may O O
be O O
involved O O
in O O
the O O
pathogenesis O O
of O O
lichen B-ADR B-ADR
nitidus I-ADR I-ADR

results O O
: O O
brimonidine B-DRUG B-DRUG
was O O
observed O O
to O O
cause O O
iop B-ADR O
elevation I-ADR O
, O O
confirmed O O
on O O
rechallenge O O
, O O
scoring O O
8 O O
( O O
strong O O
probability O O
) O O
on O O
an O O
adverse O O
drug O O
reaction O O
probability O O
score O O

they O O
continued O O
to O O
rise O O
for O O
five O O
more O O
days O O
before O O
salicylate B-DRUG B-DRUG
hepatotoxicity B-ADR B-ADR
was O O
suspected O O

a O O
52-year-old O O
, O O
white O O
female O O
developed O O
low-grade O O
fever O O
, O O
cough O O
, O O
and O O
dyspnea B-ADR O
after O O
8 O O
weeks O O
treatment O O
with O O
sodium B-DRUG B-DRUG
aurothiomalate I-DRUG I-DRUG
for O O
rheumatoid O O
arthritis O O

piloerection B-ADR B-ADR
induced O O
by O O
replacing O O
fluvoxamine O B-DRUG
with O O
milnacipran B-DRUG B-DRUG

ifosfamide-induced O O
nonconvulsive B-ADR B-ADR
status I-ADR I-ADR
epilepticus I-ADR I-ADR

vancomycin-induced O O
vasculitis B-ADR B-ADR

correction O O
of O O
serum O O
electrolyte O O
imbalance O O
prevents O O
cardiac B-ADR B-ADR
arrhythmia I-ADR I-ADR
during O O
amphotericin B-DRUG B-DRUG
b I-DRUG I-DRUG
administration O O

the O O
sub-conjunctival B-ADR B-ADR
haematoma I-ADR I-ADR
in O O
a O O
patient O O
receiving O O
warfarin B-DRUG B-DRUG
can O O
pose O O
a O O
significant O O
management O O
challenge O O

purpose O O
: O O
we O O
report O O
an O O
unusual O O
paradoxical B-ADR O
effect I-ADR O
of O O
brimonidine B-DRUG B-DRUG

conclusions O O
: O O
in O O
these O O
3 O O
cases O O
, O O
the O O
unique O O
positive O O
ocular O O
finding O O
was O O
corneal B-ADR B-ADR
endothelial I-ADR I-ADR
deposits I-ADR I-ADR
, O O
which O O
may O O
be O O
related O O
to O O
the O O
use O O
of O O
rifabutin B-DRUG B-DRUG

this O O
is O O
the O O
first O O
report O O
of O O
an O O
adverse B-ADR O
effect I-ADR O
of I-ADR O
fetal I-ADR B-ADR
renal I-ADR I-ADR
circulation I-ADR I-ADR
by O O
maternal O O
ingestion O O
of O O
nimesulide B-DRUG B-DRUG

we O O
report O O
a O O
case O O
of O O
acne B-ADR B-ADR
fulminans I-ADR I-ADR
occurring O O
during O O
treatment O O
with O O
13-cis-retinoic B-DRUG B-DRUG
acid I-DRUG I-DRUG
for O O
cystic O O
acne O O

severe O B-ADR
adenovirus O I-ADR
pneumonia O I-ADR
( O O
avp B-ADR B-ADR
) O O
following O O
infliximab B-DRUG B-DRUG
infusion O O
for O O
the O O
treatment O O
of O O
crohn O O
's O O
disease O O

we O O
describe O O
a O O
patient O O
with O O
extranodal O O
non-hodgkin O O
lymphoma O O
who O O
developed O O
systemic B-ADR B-ADR
candidiasis I-ADR I-ADR
after O O
treatment O O
with O O
a O O
cyclophosphamide-based O O
chemotherapy O O
regimen O O

thus O O
, O O
an O O
immunological O O
mechanism O O
might O O
be O O
involved O O
in O O
the O O
mechanism O O
of O O
pirmenol-induced O O
qt O B-ADR
prolongation O I-ADR
and O O
t B-ADR B-ADR
wave I-ADR I-ADR
inversion I-ADR I-ADR
on O O
the O O
electrocardiogram O O

lichen O B-ADR
planus O I-ADR
and O O
acne B-ADR B-ADR
provoked O O
by O O
gold B-DRUG B-DRUG

in O O
these O O
patients O O
, O O
long-acting O O
octreotide B-DRUG B-DRUG
may O O
trigger O O
serious B-ADR B-ADR
hypoglycemia I-ADR I-ADR

moreover O O
, O O
treatment O O
with O O
immunosuppressive O O
drugs O O
such O O
as O O
cyclosporine B-DRUG O
, O O
cisplatin O O
, O O
tacrolimus O O
, O O
and O O
interferon-alpha O B-DRUG
can O O
induce O O
a O O
condition O O
resembling O O
rpls B-ADR B-ADR

dose-dependent O O
olanzapine-associated O O
leukopenia B-ADR B-ADR
: O O
three O O
case O O
reports O O

neuropathy B-ADR B-ADR
is O O
a O O
significant O O
side O O
effect O O
of O O
thalidomide B-DRUG B-DRUG
therapy O O
, O O
which O O
may O O
limit O O
its O O
clinical O O
use O O

conclusions O O
: O O
the O O
increasing O O
prevalence O O
of O O
type O O
2 O O
diabetes O O
and O O
its O O
treatment O O
with O O
metformin B-DRUG B-DRUG
might O O
result O O
in O O
more O O
cases O O
of O O
lactic B-ADR B-ADR
acidosis I-ADR I-ADR

one O O
patient O O
with O O
systemic O O
lupus O O
erythematosus O O
developed O O
erythema B-ADR B-ADR
multiforme I-ADR I-ADR
after O O
taking O O
griseofulvin B-DRUG B-DRUG

a O O
34-year-old O O
lady O O
developed O O
a O O
constellation O O
of O O
dermatitis O O
, O O
fever O O
, O O
lymphadenopathy O O
and O O
hepatitis B-ADR O
, O O
beginning O O
on O O
the O O
17th O O
day O O
of O O
a O O
course O O
of O O
oral O O
sulphasalazine B-DRUG B-DRUG
for O O
sero-negative O O
rheumatoid O O
arthritis O O

pleuropulmonary B-ADR B-ADR
changes I-ADR I-ADR
during O O
treatment O O
of O O
parkinson O O
's O O
disease O O
with O O
a O O
long-acting O O
ergot O O
derivative O O
, O O
cabergoline B-DRUG B-DRUG

conclusions O O
: O O
it O O
is O O
probable O O
that O O
foscarnet B-DRUG B-DRUG
contributed O O
to O O
the O O
electrolyte B-ADR O
disorders I-ADR O
and O O
symptomatology O O
in O O
this O O
patient O O

haemolytic-uraemic B-ADR B-ADR
syndrome I-ADR I-ADR
complicating O O
long-term O O
mitomycin B-DRUG O
c I-DRUG O
and O O
5-fluorouracil O B-DRUG
therapy O O
for O O
gastric O O
carcinoma O O

we O O
report O O
( O O
to O O
our O O
knowledge O O
, O O
for O O
the O O
first O O
time O O
in O O
a O O
child O O
) O O
the O O
emergence O O
of O O
psychosis B-ADR B-ADR
in O O
a O O
12-year O O
old O O
white O O
girl O O
with O O
an O O
increased O O
efavirenz B-DRUG B-DRUG
concentration O O
and O O
heterozygous O O
gene O O
polymorphism O O
of O O
the O O
cyp2b6-g516t O O

when O O
cyanamide-treated O O
alcoholics O O
relapse O O
into O O
drinking O O
, O O
more O O
severe O B-ADR
inflammation B-ADR I-ADR
develops O O
in O O
the O O
liver O O

the O O
nz O B-DRUG
pharmacovigilance O O
centre O O
has O O
received O O
7 O O
additional O O
reports O O
of O O
severe B-ADR B-ADR
infections I-ADR I-ADR
in O O
patients O O
with O O
ra O O
taking O O
leflunomide B-DRUG B-DRUG

we O O
describe O O
six O O
patients O O
who O O
developed O O
tardive B-ADR B-ADR
dyskinesia I-ADR I-ADR
after O O
treatment O O
with O O
sulpiride B-DRUG B-DRUG
for O O
depression O O
or O O
gastrointestinal O O
symptoms O O

on O O
the O O
second O O
day O O
of O O
hospitalization O O
, O O
it O O
was O O
noted O O
that O O
the O O
patient O O
's O O
dyspnea O O
and O O
sinus B-ADR B-ADR
bradycardia I-ADR I-ADR
could O O
be O O
related O O
to O O
a O O
recent O O
increase O O
in O O
his O O
timolol B-DRUG B-DRUG
dosage O O

isoniazid-induced O O
anaphylaxis B-ADR B-ADR

a O O
37-year-old O O
woman O O
with O O
relapsing O O
invasive O O
vertebral O O
aspergillosis O O
received O O
intravenous O O
vrc B-DRUG O
and O O
developed O O
angio-oedema B-ADR B-ADR
10 O O
days O O
after O O
starting O O
therapy O O

discussion O O
: O O
the O O
occurrence O O
of O O
priapism B-ADR B-ADR
in O O
our O O
patient O O
was O O
related O O
to O O
zuclopenthixol B-DRUG B-DRUG

ethambutol B-DRUG B-DRUG
toxicity O O
manifesting O O
as O O
acute B-ADR B-ADR
onset I-ADR I-ADR
psychosis I-ADR I-ADR

methods O O
: O O
a O O
68-year-old O O
man O O
developed O O
intense O O
conjunctival O O
hyperemia O O
and O O
cystoid O B-ADR
macula O I-ADR
edema O I-ADR
after O O
switching O O
from O O
latanoprost B-DRUG B-DRUG
to O O
bimatoprost O B-DRUG
9 O O
months O O
after O O
cataract O O
surgery O O
in O O
an O O
eye O O
at O O
low-risk O O
for O O
this O O
cystoid B-ADR B-ADR
macular I-ADR I-ADR
edema I-ADR I-ADR

we O O
describe O O
a O O
case O O
of O O
disseminated O O
muscular O O
cysticercosis O O
followed O O
by O O
myositis O O
( O O
fever O O
, O O
diffuse B-ADR O
myalgia I-ADR O
, O O
weakness O O
of O O
the O O
lower O O
limbs O O
, O O
and O O
inflammatory O O
reaction O O
around O O
dying O O
cysticerci O O
) O O
induced O O
by O O
praziquantel B-DRUG B-DRUG
therapy O O
, O O
an O O
event O O
not O O
described O O
previously O O

carbamazepine B-ADR B-ADR
toxicity I-ADR I-ADR
induced O O
by O O
clarithromycin B-DRUG B-DRUG
coadministration O O
in O O
psychiatric O O
patients O O

he O O
had O O
been O O
taking O O
trimethoprim-sulfamethoxazole O B-DRUG
for O O
approximately O O
eight O O
days O O
when O O
he O O
revisited O O
his O O
family O O
physician O O
, O O
complaining O O
of O O
headaches O O
, O O
dizziness O O
, O O
difficulty O O
with O O
speech O O
, O O
weakness O O
, O O
and O O
itching B-ADR O
on I-ADR O
the I-ADR O
trunk I-ADR O
of O O
his O O
body O O
and O O
legs O O
, O O
where O O
a O O
maculopapular O B-ADR
rash O I-ADR
was O O
noted O O

paroxysmal B-ADR B-ADR
supraventricular I-ADR I-ADR
tachycardia I-ADR I-ADR
during O O
treatment O O
with O O
cisplatin O B-DRUG
and O O
etoposide B-DRUG B-DRUG
combination O O

cutaneous B-ADR B-ADR
sarcoidosis I-ADR I-ADR
during O O
interferon B-DRUG B-DRUG
alfa I-DRUG I-DRUG
and O O
ribavirin O B-DRUG
treatment O O
of O O
hepatitis O O
c O O
virus O O
infection O O
: O O
two O O
cases O O

we O O
present O O
the O O
case O O
of O O
a O O
patient O O
who O O
had O O
undergone O O
cholecystectomy O O
previously O O
, O O
but O O
in O O
whom O O
morphine B-DRUG B-DRUG
given O O
in O O
the O O
emergency O O
department O O
precipitated O O
pain B-ADR O
consistent O O
with O O
biliary O B-ADR
colic O I-ADR
; O O
the O O
pain B-ADR B-ADR
resolved O O
promptly O O
after O O
administration O O
of O O
naloxone O B-DRUG

our O O
cases O O
constitute O O
the O O
most O O
severe O O
cases O O
of O O
benzarone B-DRUG B-DRUG
hepatotoxicity O B-ADR
reported O O
so O O
far O O
, O O
and O O
comprise O O
the O O
first O O
cases O O
of O O
( O O
sub O O
) O O
fulminant O O
hepatitis O O
and O O
cirrhosis B-ADR O
related O O
to O O
benzarone B-DRUG B-DRUG

restless B-ADR B-ADR
legs I-ADR I-ADR
syndrome I-ADR I-ADR
and O O
periodic O B-ADR
limb O I-ADR
movements O I-ADR
during O O
sleep O O
probably O O
associated O O
with O O
olanzapine B-DRUG B-DRUG

despite O O
a O O
very O O
low O O
complication O O
rate O O
, O O
several O O
severe B-ADR O
arterial I-ADR B-ADR
thrombotic I-ADR I-ADR
events I-ADR I-ADR
have O O
been O O
reported O O
following O O
thrombin B-DRUG B-DRUG
injection O O
of O O
pseudoaneurysms O B-ADR

we O O
report O O
a O O
case O O
of O O
a O O
young O O
woman O O
with O O
sle O O
and O O
thrombocytopenia O O
, O O
who O O
developed O O
severe O O
perspiration O O
, O O
headache O O
, O O
and O O
seizure B-ADR O
after O O
receiving O O
cyclosporine B-DRUG B-DRUG

less O O
common O O
adverse O O
events O O
to O O
dapsone B-DRUG B-DRUG
include O O
the O O
idiosyncratic O O
reactions O O
of O O
leukopenia B-ADR O
and O O
agranulocytosis O O
, O O
cutaneous O O
eruptions O O
, O O
peripheral O O
neuropathy O O
, O O
psychosis O O
, O O
toxic O O
hepatitis O O
, O O
cholestatic O O
jaundice O O
, O O
nephrotic O O
syndrome O O
, O O
renal O O
papillary O O
necrosis O O
, O O
severe O O
hypoalbuminemia O O
without O O
proteinuria O O
, O O
an O O
infectious O O
mononucleosis-like O O
syndrome O O
, O O
and O O
minor O O
neurological O O
and O O
gastrointestinal O O
complaints O O

eleven O O
patients O O
developed O O
infection O O
requiring O O
hospitalization O O
while O O
taking O O
leflunomide B-DRUG B-DRUG
including O O
: O O
lower B-ADR O
respiratory I-ADR O
tract I-ADR O
infections I-ADR O
( O O
3 O O
) O O
, O O
cellulitis O O
( O O
2 O O
) O O
, O O
disseminated O O
herpes O O
zoster O O
( O O
2 O O
) O O
, O O
probable O O
tb O O
liver O O
( O O
1 O O
) O O
, O O
abdominal O O
sepsis O O
( O O
1 O O
) O O
, O O
mycotic O O
aneurysm O O
( O O
1 O O
) O O
and O O
gastroenteritis O O
( O O
1 O O

niflumic B-DRUG B-DRUG
acid-induced O O
skeletal B-ADR B-ADR
fluorosis I-ADR I-ADR
: O O
iatrogenic O O
disease O O
or O O
therapeutic O O
perspective O O
for O O
osteoporosis O O

possible O O
recurrence O O
of O O
amiodarone B-DRUG B-DRUG
pulmonary B-ADR B-ADR
toxicity I-ADR I-ADR
following O O
corticosteroid O O
therapy O O

to O O
our O O
knowledge O O
, O O
this O O
is O O
the O O
first O O
case O O
report O O
that O O
demonstrates O O
the O O
occurrence O O
of O O
fever B-ADR O
with O O
low-dose O O
amifostine B-DRUG B-DRUG
therapy O O
without O O
the O O
manifestation O O
of O O
accompanying O O
rash O O
or O O
hypotension O O

myoglobinuria O B-ADR
and O O
acute B-ADR B-ADR
renal I-ADR I-ADR
failure I-ADR I-ADR
associated O O
with O O
intravenous O O
vasopressin B-DRUG B-DRUG
infusion O O

with O O
itraconazole B-DRUG B-DRUG
, O O
hepatotoxic B-ADR B-ADR
reactions O I-ADR
have O O
only O O
very O O
rarely O O
been O O
reported O O
, O O
and O O
histologic O O
data O O
are O O
lacking O O

he O O
had O O
an O O
immediate O O
hypersensitivity O O
reaction O O
during O O
the O O
initiation O O
of O O
the O O
mtx B-DRUG B-DRUG
infusion O O
with O O
diffuse O O
urticaria O O
, O O
facial O O
swelling O O
, O O
cough B-ADR O
, O O
and O O
chest O O
tightness O O

the O O
authors O O
describe O O
a O O
case O O
of O O
valvular B-ADR B-ADR
heart I-ADR I-ADR
disease I-ADR I-ADR
in O O
a O O
48-year-old O O
woman O O
receiving O O
benfluorex B-DRUG B-DRUG
( O O
150 O O
mg O O
t.i.d. O O
for O O
8 O O
years O O
) O O
and O O
leading O O
to O O
surgical O O
mitral O O
valve O O
replacement O O

in O O
patients O O
with O O
swallowing O O
dysfunction O O
and O O
pneumonia O O
, O O
a O O
history O O
of O O
mineral B-DRUG B-DRUG
oil I-DRUG I-DRUG
use O O
should O O
be O O
obtained O O
and O O
a O O
diagnosis O O
of O O
elp B-ADR B-ADR
should O O
be O O
considered O O
in O O
the O O
differential O O
diagnoses O O
if O O
mineral B-DRUG B-DRUG
oil I-DRUG I-DRUG
use O O
has O O
occurred O O

persisent B-ADR B-ADR
ocular I-ADR I-ADR
hypertension I-ADR I-ADR
following O O
intravitreal O O
ranibizumab B-DRUG B-DRUG

poorly O O
controlled O O
hypertension O B-ADR
in O O
a O O
painter O O
with O O
chronic O B-ADR
lead B-ADR I-ADR
toxicity I-ADR I-ADR

we O O
report O O
here O O
a O O
26-year-old O O
female O O
with O O
diffuse O O
large O O
b-cell O O
lymphoma O O
who O O
died O O
of O O
severe B-ADR O
pulmonary I-ADR B-ADR
fibrosis I-ADR I-ADR
81 O O
days O O
after O O
the O O
administration O O
of O O
high-dose O O
bcnu B-DRUG B-DRUG
( O O
600 O O
mg O O
/ O O
m2 O O

we O O
report O O
the O O
case O O
of O O
a O O
patient O O
who O O
developed O O
polyserositis B-ADR O
( O O
pericardial O O
effusion O O
, O O
pleural O B-ADR
effusion O I-ADR
, O O
and O O
pericarditis O O
) O O
after O O
being O O
started O O
on O O
clozapine B-DRUG B-DRUG
, O O
and O O
whose O O
symptoms O O
remitted O O
upon O O
discontinuation O O
of O O
clozapine B-DRUG B-DRUG

however O O
, O O
recurrent O O
staphylococcus B-ADR B-ADR
aureus I-ADR I-ADR
sepsis I-ADR I-ADR
developed O O
during O O
cya B-DRUG B-DRUG
therapy O O

conclusions O O
: O O
this O O
case O O
describes O O
the O O
clinically O O
significant O O
increase B-ADR B-ADR
of I-ADR I-ADR
inr I-ADR I-ADR
in O O
an O O
elderly O O
patient O O
after O O
adding O O
a O O
chemotherapy O O
regimen O O
of O O
levamisole O B-DRUG
and O O
5-fu O B-DRUG
to O O
a O O
previous O O
regimen O O
of O O
warfarin B-DRUG B-DRUG
alone O O

a O O
14-year-old O O
girl O O
with O O
newly O O
diagnosed O O
sle O O
developed O O
a O O
pruritic B-ADR B-ADR
bullous I-ADR I-ADR
eruption I-ADR I-ADR
while O O
on O O
prednisone B-DRUG B-DRUG

pet O O
scintigraphy O O
of O O
etoposide-induced O O
pulmonary B-ADR B-ADR
toxicity I-ADR I-ADR

during O O
clarithromycin B-DRUG B-DRUG
coadministration O O
, O O
four O O
out O O
of O O
the O O
seven O O
patients O O
developed O O
moderate-to-severe O O
toxic B-ADR O
symptoms I-ADR O
of O O
carbamazepine O B-DRUG
, O O
such O O
as O O
drowsiness O O
, O O
dizziness O O
, O O
and O O
ataxia O O
, O O
which O O
resolved O O
within O O
5 O O
days O O
after O O
clarithromycin B-DRUG B-DRUG
discontinuation O O

anterior B-ADR B-ADR
ischemic I-ADR I-ADR
optic I-ADR I-ADR
neuropathy I-ADR I-ADR
secondary O O
to O O
interferon B-DRUG B-DRUG
alfa I-DRUG I-DRUG

a O O
patient O O
with O O
the O O
wolff-parkinson-white O O
syndrome O O
presented O O
with O O
incessant B-ADR O
orthodromic I-ADR B-ADR
atrioventricular I-ADR I-ADR
tachycardia I-ADR I-ADR
following O O
initiation O O
of O O
procainamide B-DRUG B-DRUG
therapy O O

the O O
day O O
after O O
clozapine O B-DRUG
was O O
stopped O O
, O O
while O O
he O O
was O O
still O O
receiving O O
clomipramine B-DRUG B-DRUG
150 O O
mg O O
/ O O
d O O
, O O
he O O
began O O
behaving O O
oddly O O
, O O
started O O
sweating O O
profusely O O
, O O
shivering B-ADR O
, O O
and O O
became O O
tremulous O O
, O O
agitated O O
, O O
and O O
confused O O

introduction O O
: O O
in O O
resource O O
limited O O
settings O O
patients O O
on O O
antiretroviral O O
treatment O O
who O O
develop O O
stavudine B-DRUG B-DRUG
induced O O
hyperlactatemia B-ADR B-ADR
are O O
often O O
switched O O
to O O
zidovudine O B-DRUG
on O O
the O O
basis O O
of O O
published O O
studies O O
that O O
demonstrate O O
that O O
this O O
agent O O
can O O
be O O
a O O
safe O O
alternative O O

fluphenazine-induced O O
neuroleptic B-ADR B-ADR
malignant I-ADR I-ADR
syndrome I-ADR I-ADR
in O O
a O O
schizophrenic O O
patient O O

flare O O
of O O
kaposi B-ADR O
's I-ADR O
sarcoma I-ADR O
( O O
ks O O
) O O
is O O
well O O
described O O
in O O
immunosuppressed O O
patients O O
treated O O
with O O
corticosteroids O O
and O O
rituximab B-DRUG B-DRUG
, O O
but O O
has O O
not O O
yet O O
been O O
reported O O
during O O
treatment O O
with O O
imatinib O B-DRUG

physicians O O
should O O
be O O
aware O O
of O O
the O O
possible O O
association O O
between O O
the O O
use O O
of O O
alteplase B-DRUG B-DRUG
and O O
the O O
development O O
of O O
subfascial B-ADR B-ADR
hemorrhage I-ADR I-ADR

though O O
hypotension O O
, O O
dry O O
mouth O O
, O O
and O O
constipation B-ADR O
are O O
well-documented O O
possible O O
adverse O O
effects O O
, O O
the O O
possibility O O
of O O
clonidine-induced O O
bradycardia O B-ADR
is O O
less O O
well O O
recognized O O
and O O
is O O
rare O O

scrotal B-ADR B-ADR
ulceration I-ADR I-ADR
induced O O
by O O
all-trans O B-DRUG
retinoic B-DRUG I-DRUG
acid I-DRUG I-DRUG
in O O
a O O
patient O O
with O O
acute O O
promyelocytic O O
leukemia O O

rituximab-based O O
therapy O O
for O O
gemcitabine-induced O O
hemolytic B-ADR B-ADR
uremic I-ADR I-ADR
syndrome I-ADR I-ADR
in O O
a O O
patient O O
with O O
metastatic O O
pancreatic O O
adenocarcinoma O O
: O O
a O O
case O O
report O O

the O O
harlequin B-ADR B-ADR
color I-ADR I-ADR
change I-ADR I-ADR
and O O
association O O
with O O
prostaglandin B-DRUG B-DRUG
e1 I-DRUG I-DRUG

we O O
report O O
the O O
case O O
of O O
a O O
60-year-old O O
woman O O
who O O
developed O O
erythema B-ADR O
and O O
erosions O O
in O O
the O O
axilla O O
and O O
groin O O
while O O
on O O
pld B-DRUG B-DRUG
for O O
breast O O
cancer O O

a O O
65-year-old O O
woman O O
with O O
angina O O
pectoris O O
presented O O
with O O
syncope B-ADR B-ADR
after O O
sublingual O O
ingestion O O
of O O
isosorbide B-DRUG B-DRUG
dinitrate I-DRUG I-DRUG
( O O
5 O O
mg O O

we O O
report O O
3 O O
cases O O
of O O
hiv-1 O O
infected O O
patients O O
who O O
experienced O O
symptomatic O B-ADR
angiolipomas B-ADR I-ADR
shortly O O
after O O
starting O O
antiretroviral O O
therapy O O
including O O
the O O
protease O O
inhibitor O O
indinavir B-DRUG B-DRUG

objective O O
: O O
to O O
report O O
a O O
case O O
of O O
toxin-positive B-ADR O
clostridium I-ADR O
difficile-induced I-ADR O
colitis I-ADR B-ADR
( O O
cdic O B-ADR
) O O
after O O
use O O
of O O
clindamycin B-DRUG B-DRUG
phosphate I-DRUG I-DRUG
vaginal O O
cream O O

since O O
this O O
amount O O
of O O
fab O B-DRUG
was O O
insufficient O O
to O O
bind O O
all O O
dgtx B-DRUG B-DRUG
present O O
in O O
the O O
serum O O
, O O
cardiac B-ADR B-ADR
dgtx I-ADR I-ADR
toxicity I-ADR I-ADR
( O O
total O B-ADR
av-block O I-ADR
) O O
persisted O O

this O O
case O O
report O O
describes O O
the O O
development O O
of O O
asymptomatic O O
visual O B-ADR
field O I-ADR
defects O I-ADR
( O O
vfds B-ADR O
) O O
in O O
a O O
psychiatric O O
patient O O
with O O
bipolar O O
disorder O O
receiving O O
adjunctive O O
tiagabine B-DRUG B-DRUG
treatment O O

based O O
upon O O
the O O
observed O O
fall O O
of O O
the O O
filtration O O
fraction O O
, O O
the O O
rise O O
in O O
the O O
relative O O
clearance O O
of O O
99tc-dimercaptosuccinic O B-DRUG
acid O I-DRUG
and O O
the O O
increase O O
in O O
proteinuria O O
, O O
we O O
suggest O O
that O O
in O O
this O O
case O O
the O O
tubules O O
and O O
/ O O
or O O
interstitium O O
are O O
the O O
main O O
targets O O
for O O
cyclosporine B-DRUG B-DRUG
a I-DRUG O
nephrotoxicity B-ADR B-ADR

after O O
having O O
received O O
gemcitabine B-DRUG B-DRUG
on O O
day O O
1 O O
of O O
the O O
second O O
course O O
, O O
the O O
patient O O
developed O O
dry O O
cough O O
, O O
subfebrile O O
temperatures O O
and O O
dyspnea B-ADR O
within O O
48 O O
h O O

3. O O
thus O O
, O O
the O O
decreased B-ADR B-ADR
plasma I-ADR I-ADR
cortisol I-ADR I-ADR
level I-ADR I-ADR
during O O
alprazolam B-DRUG B-DRUG
treatment O O
of O O
panic O B-ADR
disorder O I-ADR
was O O
suggested O O
to O O
be O O
caused O O
not O O
by O O
symptom O O
alleviation O O
due O O
to O O
alprazolam B-DRUG B-DRUG
but O O
by O O
alprazolam B-DRUG B-DRUG
administration O O
itself O O

hepatotoxicity B-ADR B-ADR
resolved O O
once O O
erlotinib B-DRUG B-DRUG
was O O
discontinued O O
and O O
serum O O
transaminases O O
returned O O
to O O
baseline O O
normal O O
values O O

aplastic O B-ADR
anemia O I-ADR
and O O
agranulocytosis B-ADR B-ADR
in O O
patients O O
using O O
methazolamide B-DRUG B-DRUG
for O O
glaucoma O O

thus O O
, O O
the O O
eosinophilia B-ADR B-ADR
myalgia I-ADR I-ADR
syndrome I-ADR I-ADR
can O O
be O O
associated O O
with O O
parenteral O O
tryptophan B-DRUG B-DRUG
administration O O

nephrotic B-ADR B-ADR
syndrome I-ADR I-ADR
related O O
to O O
systemic O B-ADR
lupus O I-ADR
erythematosus O I-ADR
after O O
griseofulvin B-DRUG B-DRUG
therapy O O

a O O
16-year-old O O
boy O O
developed O O
fever O O
, O O
generalized B-ADR O
rigidity I-ADR O
, O O
leukocytosis O O
, O O
and O O
increased O O
serum O O
transaminase O O
and O O
creatine O O
kinase O O
levels O O
while O O
receiving O O
treatment O O
with O O
olanzapine O B-DRUG
and O O
lithium B-DRUG B-DRUG

thus O O
, O O
an O O
immunological O O
mechanism O O
might O O
be O O
involved O O
in O O
the O O
mechanism O O
of O O
pirmenol-induced O O
qt B-ADR B-ADR
prolongation I-ADR I-ADR
and O O
t O B-ADR
wave O I-ADR
inversion O I-ADR
on O O
the O O
electrocardiogram O O

it O O
was O O
hypothesized O O
that O O
valproic B-DRUG B-DRUG
acid I-DRUG I-DRUG
may O O
interfere O O
with O O
glucuronidation O O
of O O
lamotrigine O B-DRUG
, O O
leading O O
to O O
increased B-ADR O
serum I-ADR O
lamotrigine I-ADR B-DRUG
levels I-ADR O
, O O
or O O
perhaps O O
alter O O
the O O
drug O O
's O O
metabolism O O
, O O
resulting O O
in O O
accumulation O O
of O O
a O O
toxic O O
intermediate O O
metabolite O O

we O O
observed O O
ventricular B-ADR B-ADR
fibrillation I-ADR I-ADR
in O O
2 O O
patients O O
who O O
presented O O
to O O
the O O
emergency O O
department O O
with O O
pre-excited O O
atrial O B-ADR
fibrillation O I-ADR
and O O
were O O
given O O
12 O O
mg O O
of O O
adenosine B-DRUG B-DRUG

a O O
5-month-old O O
infant O O
became O O
lethargic B-ADR B-ADR
and O O
poorly O O
responsive O O
after O O
receiving O O
1 O O
drop O O
of O O
brimonidine B-DRUG B-DRUG
in O O
each O O
eye O O

ulcer B-ADR B-ADR
became I-ADR O
worse I-ADR O
after O O
tobramycin B-DRUG B-DRUG
and O O
gentamycin O B-DRUG
treatment O O
for O O
2 O O
days O O

it O O
is O O
thought O O
that O O
the O O
clinico-pathological O O
features O O
and O O
chronology O O
of O O
this O O
case O O
bore O O
the O O
hallmarks O O
of O O
the O O
so-called O O
" O O
3-week O O
sulphasalazine B-DRUG B-DRUG
syndrome O O
" O O
, O O
a O O
rare O O
, O O
but O O
often O O
fatal B-ADR O
, O O
immunoallergic O B-ADR
reaction O I-ADR
to O O
sulphasalazine B-DRUG B-DRUG

the O O
more O O
common O O
grade O O
3 O O
or O O
4 O O
adverse O O
effects O O
of O O
sunitinib B-DRUG B-DRUG
include O O
hypertension O O
, O O
fatigue O O
, O O
hand-foot B-ADR O
syndrome I-ADR O
, O O
elevated O O
lipase O O
and O O
lymphopenia O O

occurrence O O
of O O
withdrawal O B-ADR
dyskinesia B-ADR I-ADR
indicates O O
that O O
the O O
neuroleptic O B-ADR
effects O I-ADR
of O O
amoxapine B-DRUG B-DRUG
may O O
be O O
clinically O O
significant O O

acute B-ADR B-ADR
coronary I-ADR I-ADR
syndrome I-ADR I-ADR
induced O O
by O O
capecitabine B-DRUG B-DRUG
therapy O O

pancreatitis O B-ADR
is O O
a O O
very O O
rare O O
adverse O O
effect O O
associated O O
with O O
the O O
use O O
of O O
amiodarone B-DRUG B-DRUG
, O O
and O O
only O O
four O O
cases O O
of O O
amiodarone-induced O O
pancreatitis B-ADR B-ADR
have O O
been O O
reported O O
in O O
literature O O

acute B-ADR B-ADR
myopathy I-ADR I-ADR
with O O
selective O O
degeneration O B-ADR
of O I-ADR
myosin O I-ADR
filaments O I-ADR
following O O
status O B-ADR
asthmaticus O I-ADR
treated O O
with O O
methylprednisolone B-DRUG B-DRUG
and O O
vecuronium O B-DRUG

the O O
other O O
woman O O
had O O
rheumatoid O O
arthritis O O
and O O
developed O O
acute B-ADR B-ADR
tubular I-ADR I-ADR
necrosis I-ADR I-ADR
after O O
treatment O O
with O O
gentamicin O B-DRUG
and O O
cefoxitin B-DRUG B-DRUG

it O O
remains O O
to O O
be O O
seen O O
whether O O
the O O
hepatotoxicity B-ADR B-ADR
associated O O
with O O
troglitazone B-DRUG B-DRUG
is O O
a O O
drug-class O B-ADR
effect O I-ADR
or O O
specific O O
to O O
troglitazone B-DRUG B-DRUG

conclusions O O
: O O
this O O
observation O O
of O O
" O O
on-off O O
" O O
risperidone B-DRUG B-DRUG
treatment O O
suggests O O
that O O
risperidone B-DRUG B-DRUG
may O O
have O O
worsened O O
both O O
psychiatric B-ADR O
and I-ADR O
physical I-ADR O
manifestations I-ADR O
of O O
the O O
mitochondrial O B-ADR
disorder O I-ADR
in O O
this O O
adolescent O O

we O O
describe O O
in O O
detail O O
the O O
first O O
u.s. O O
case O O
report O O
, O O
of O O
a O O
4 O O
( O O
1 O O
/ O O
2 O O
)- O O
year-old O O
boy O O
who O O
experienced O O
angioedema B-ADR B-ADR
during O O
treatment O O
with O O
oxcarbazepine B-DRUG B-DRUG

physicians O O
treating O O
patients O O
with O O
methotrexate B-DRUG B-DRUG
for O O
juvenile O O
rheumatoid O O
arthritis O O
must O O
be O O
aware O O
of O O
this O O
extraarticular B-ADR B-ADR
side I-ADR I-ADR
effect I-ADR I-ADR

these O O
findings O O
support O O
previous O O
studies O O
that O O
showed O O
that O O
the O O
use O O
of O O
aspirin B-DRUG B-DRUG
during O O
the O O
antecedent O O
illness O O
may O O
be O O
a O O
risk O O
factor O O
for O O
the O O
development O O
of O O
rs B-ADR B-ADR

morphine B-DRUG B-DRUG
, O O
an O O
opium O O
alkaloid O O
, O O
frequently O O
causes O O
side O O
effects O O
such O O
as O O
hyperhidrosis O O
and O O
facial B-ADR O
flushing I-ADR O
, O O
but O O
serious O O
cutaneous O O
adverse O O
drug O O
reactions O O
are O O
seldom O O
observed O O

results O O
: O O
our O O
patient O O
developed O O
crohn O B-ADR
's O I-ADR
disease O I-ADR
while O O
on O O
copaxone B-DRUG B-DRUG
treatment O O
as O O
a O O
consequence O O
of O O
long-term B-ADR B-ADR
immunosuppression I-ADR I-ADR

we O O
postulate O O
that O O
gastritis B-ADR B-ADR
caused O O
by O O
dexamethasone B-DRUG B-DRUG
, O O
mucositis O O
caused O O
by O O
doxorubicin O B-DRUG
, O O
and O O
the O O
unique O O
anatomic O O
nature O O
of O O
a O O
meckel O B-ADR
diverticulum O I-ADR
may O O
have O O
contributed O O
to O O
this O O
extremely O O
unlikely O O
and O O
previously O O
unreported O O
event O O

transient B-ADR B-ADR
hemiparesis I-ADR I-ADR
caused O O
by O O
phenytoin B-DRUG B-DRUG
toxicity O O

we O O
experienced O O
a O O
male O O
patient O O
with O O
psoriasis O O
and O O
hypertension O O
whose O O
conditions O O
were O O
treated O O
with O O
tacalcitol O B-DRUG
ointment O O
and O O
thiazide B-DRUG B-DRUG
, O O
respectively O O
, O O
resulting O O
in O O
hypercalciuria B-ADR O
and O O
hypercalcemia O B-ADR

we O O
report O O
the O O
case O O
of O O
a O O
20-year-old O O
woman O O
originally O O
from O O
cameroon O O
who O O
was O O
infected O O
by O O
the O O
l. O O
loa O O
parasite O O
and O O
developed O O
severe B-ADR O
hepatitis I-ADR O
, O O
identified O O
1 O O
month O O
after O O
a O O
single O O
dose O O
of O O
ivermectin B-DRUG B-DRUG

zoledronic B-DRUG B-DRUG
acid-induced O O
severe B-ADR B-ADR
hypocalcaemia I-ADR I-ADR
in O O
a O O
prostate O O
cancer O O
patient O O
with O O
extensive O O
osteoblastic O O
bone O O
metastases O O

nephrotic B-ADR B-ADR
range I-ADR I-ADR
pseudoproteinuria I-ADR I-ADR
in O O
a O O
tolmetin-treated O O
patient O O

a O O
further O O
case O O
of O O
anaphylactoid B-ADR B-ADR
reaction I-ADR I-ADR
to O O
methylprednisolone B-DRUG B-DRUG
is O O
reported O O

hashimoto B-ADR B-ADR
's I-ADR I-ADR
disease I-ADR I-ADR
during O O
interferon-alpha B-DRUG B-DRUG
therapy O O
in O O
a O O
patient O O
with O O
pre-treatment O O
negative O O
anti-thyroid O O
autoantibodies O O
and O O
with O O
the O O
specific O O
genetic O O
susceptibility O O
to O O
the O O
thyroid O O
disease O O

successful O O
recovery O O
from O O
interstitial B-ADR B-ADR
pneumonitis I-ADR I-ADR
, O O
induced O O
by O O
bicalutamide O B-DRUG
and O O
leuprorelin B-DRUG B-DRUG
acetate I-DRUG I-DRUG
given O O
as O O
treatment O O
for O O
prostate O O
cancer O O

tamoxifen B-DRUG B-DRUG
retinopathy B-ADR B-ADR

our O O
patient O O
had O O
headache B-ADR O
, O O
mild O O
fever O O
, O O
nausea O O
, O O
vomiting O O
, O O
rash O O
, O O
and O O
eosinophilia O O
after O O
3 O O
weeks O O
of O O
disulfiram B-DRUG B-DRUG
therapy O O

amphotericin O B-DRUG
b O I-DRUG
( O O
amb B-DRUG O
) O O
is O O
effective O O
, O O
but O O
its O O
use O O
is O O
limited O O
by O O
toxicity O O
: O O
renal B-ADR O
impairment I-ADR O
, O O
anaemia O O
, O O
fever O O
, O O
malaise O O
, O O
and O O
hypokalaemia O O
are O O
common O O

this O O
article O O
describes O O
two O O
cases O O
of O O
aplastic B-ADR B-ADR
anemia I-ADR I-ADR
, O O
at O O
least O O
one O O
of O O
which O O
was O O
almost O O
certainly O O
induced O O
by O O
the O O
use O O
of O O
methazolamide B-DRUG B-DRUG
, O O
and O O
one O O
case O O
of O O
agranulocytosis O B-ADR
related O O
to O O
the O O
use O O
of O O
methazolamide B-DRUG B-DRUG

myoclonus O B-ADR
and O O
seizures B-ADR B-ADR
in O O
a O O
patient O O
with O O
parkinsonism O O
: O O
induction O O
by O O
levodopa B-DRUG B-DRUG
and O O
its O O
confirmation O O
on O O
seps O O

hypoxia B-ADR B-ADR
is O O
a O O
predisposing O O
factor O O
for O O
premature O O
ductal O B-ADR
closure O I-ADR
and O O
often O O
occurs O O
after O O
maternal O O
indomethacin B-DRUG B-DRUG
therapy O O

the O O
most O O
serious O O
dental O O
side O O
effect O O
of O O
bisphosphonate B-DRUG B-DRUG
treatment O O
( O O
particularly O O
when O O
it O O
is O O
administered O O
intravenously O O
) O O
is O O
, O O
paradoxically O O
, O O
osteonecrosis B-ADR O
of I-ADR O
the I-ADR O
mandible I-ADR O
or O O
the O O
maxilla O O
represented O O
by O O
exposed O O
nonhealing O O
bone O O

review O O
of O O
the O O
literature O O
relating O O
to O O
methicillin-induced O O
nephropathy B-ADR B-ADR
suggests O O
a O O
hypersensitivity O O
origin O O
for O O
this O O
disorder O O
, O O
but O O
immunologic O O
and O O
ultrastructural O O
investigation O O
to O O
date O O
has O O
failed O O
to O O
elucidate O O
pathogenesis O B-ADR

three O O
patients O O
, O O
in O O
whom O O
tumour O O
overkill O O
by O O
cytotoxic O O
treatment O O
, O O
including O O
high O O
dose O O
methotrexate B-DRUG B-DRUG
with O O
folinic O B-DRUG
acid O I-DRUG
rescue O O
, O O
resulted O O
in O O
the O O
' O O
phosphate O O
shower O O
syndrome O O
' O O
( O O
hyper-uricaemia O O
, O O
hyperkalaemia O O
and O O
hyperphosphataemia O O
with O O
hypocalcaemia O O
and O O
tetany O O
, O O
with O O
metabolic O O
acidosis O O
and O O
acute B-ADR O
renal I-ADR O
impairment I-ADR O
) O O
are O O
described O O

until O O
additional O O
data O O
are O O
available O O
, O O
if O O
intravenous O O
acyclovir B-DRUG B-DRUG
is O O
administered O O
concurrently O O
with O O
lithium O B-DRUG
, O O
we O O
recommend O O
closely O O
monitoring O O
patients O O
for O O
signs O O
of O O
lithium B-ADR B-DRUG
toxicity I-ADR O
and O O
measuring O O
serum O O
lithium O B-DRUG
levels O O
every O O
second O O
or O O
third O O
day O O

the O O
occurrence O O
of O O
neuromuscular B-ADR O
blockade I-ADR O
and O O
the O O
resulting O O
potentiation O O
of O O
muscle O O
relaxants O O
during O O
magnesium O B-DRUG
sulfate O I-DRUG
( O O
mgso4 B-DRUG B-DRUG
) O O
administration O O
is O O
well O O
known O O

case O O
summaries O O
: O O
while O O
conducting O O
a O O
protocol O O
evaluating O O
the O O
efficacy O O
of O O
intraperitoneal O O
cisplatin B-DRUG B-DRUG
and O O
hyperthermia O O
in O O
the O O
treatment O O
of O O
recurrent O O
ovarian O O
cancer O O
, O O
3 O O
patients O O
were O O
noted O O
to O O
exhibit O O
anaphylactoid B-ADR B-ADR
reactions I-ADR I-ADR

we O O
report O O
a O O
case O O
of O O
pancytopenia B-ADR B-ADR
in O O
a O O
23-year-old O O
man O O
with O O
crohn O O
's O O
disease O O
who O O
was O O
treated O O
with O O
5-aminosalicylic B-DRUG B-DRUG
acid I-DRUG I-DRUG
( O O
pentasa O O
; O O
nisshin O O
, O O
tokyo O O
, O O
japan O O
) O O
3.0 O O
g O O
/ O O
day O O

case O O
: O O
we O O
present O O
an O O
11-year O O
old O O
male O O
with O O
budd-chiari O O
syndrome O O
who O O
experienced O O
profound O O
worsening B-ADR O
of I-ADR O
chronic I-ADR B-ADR
aphthous I-ADR I-ADR
ulcers I-ADR I-ADR
after O O
immunosuppressive O O
therapy O O
was O O
changed O O
from O O
tacrolimus B-DRUG B-DRUG
to O O
sirolimus O B-DRUG

in O O
the O O
following O O
case O O
report O O
, O O
a O O
patient O O
developed O O
acute O B-ADR
interstitial O I-ADR
nephritis O I-ADR
with O O
renal O O
failure O O
and O O
exfoliative B-ADR B-ADR
dermatitis I-ADR I-ADR
following O O
ampicillin B-DRUG B-DRUG
therapy O O

we O O
now O O
report O O
the O O
first O O
known O O
cancer O O
patient O O
who O O
developed O O
life-threatening B-ADR B-ADR
complications I-ADR I-ADR
after O O
treatment O O
with O O
topical O O
5-fu B-DRUG B-DRUG
and O O
was O O
shown O O
subsequently O O
to O O
have O O
profound O B-ADR
dpd O I-ADR
deficiency O I-ADR

this O O
is O O
the O O
first O O
report O O
of O O
a O O
catatonic B-ADR B-ADR
syndrome I-ADR I-ADR
occurring O O
in O O
a O O
patient O O
receiving O O
disulfiram B-DRUG B-DRUG
treatment O O

the O O
clinical O O
symptoms O O
of O O
gastric B-ADR B-ADR
mucosa I-ADR I-ADR
foveolar I-ADR I-ADR
hyperplasia I-ADR I-ADR
due O O
to O O
long-term O O
pge1 B-DRUG B-DRUG
therapy O O
simulate O O
hypertrophic O B-ADR
pyloric O I-ADR
stenosis O I-ADR

a O O
wide O O
variety O O
of O O
adverse B-ADR O
central I-ADR B-ADR
nervous I-ADR I-ADR
system I-ADR I-ADR
effects I-ADR I-ADR
have O O
been O O
reported O O
in O O
association O O
with O O
propafenone B-DRUG B-DRUG
; O O
dizziness O O
is O O
the O O
most O O
common O O

the O O
relationship O O
between O O
infliximab B-DRUG B-DRUG
treatment O O
and O O
lymphoma B-ADR O
in O O
crohn O O
's O O
disease O O

introduction O O
: O O
we O O
describe O O
the O O
neurointensive O O
care O O
( O O
nic O O
) O O
management O O
of O O
a O O
patient O O
with O O
severe O O
cerebral O O
swelling O O
and O O
raised B-ADR O
intracranial I-ADR B-ADR
pressure I-ADR I-ADR
( O O
icp O O
) O O
after O O
severe O O
sodium B-DRUG B-DRUG
valproic I-DRUG I-DRUG
acid I-DRUG I-DRUG
( O O
vpa O O
) O O
intoxication O O

gangrene B-ADR B-ADR
of O I-ADR
the O I-ADR
fingertips O I-ADR
after O O
bleomycin O B-DRUG
and O O
methotrexate B-DRUG B-DRUG

we O O
experienced O O
a O O
male O O
patient O O
with O O
psoriasis O O
and O O
hypertension O O
whose O O
conditions O O
were O O
treated O O
with O O
tacalcitol B-DRUG B-DRUG
ointment O O
and O O
thiazide O B-DRUG
, O O
respectively O O
, O O
resulting O O
in O O
hypercalciuria O O
and O O
hypercalcemia B-ADR B-ADR

gynecomastia B-ADR B-ADR
in O O
epileptics O O
treated O O
with O O
phenobarbital O B-DRUG
, O O
phenytoin O O
and O O
fluoresone B-DRUG O
: O O
two O O
case O O
reports O O

the O O
reversal O O
of O O
heparin O B-DRUG
by O O
protamine B-DRUG B-DRUG
may O O
cause O O
severe B-ADR O
hemodynamic I-ADR O
deterioration I-ADR O
, O O
characterized O O
by O O
systemic O B-ADR
hypotension O I-ADR
, O O
pulmonary O O
hypertension O O
, O O
and O O
bronchoconstriction O B-ADR

acute B-ADR B-ADR
non-lymphocytic I-ADR I-ADR
leukemia I-ADR I-ADR
occurred O O
in O O
eight O O
women O O
following O O
long-term O O
treatment O O
with O O
treosulfan B-DRUG B-DRUG
(= O O
dihydroxybusulfan O B-DRUG
) O O
for O O
ovarian O O
carcinoma O O

marked O B-ADR
sinus B-ADR I-ADR
tachycardia I-ADR I-ADR
resulting O O
from O O
the O O
synergistic O O
effects O O
of O O
marijuana O O
and O O
nortriptyline B-DRUG B-DRUG

acute B-ADR B-ADR
delirium I-ADR I-ADR
resulting O O
from O O
levofloxacin B-DRUG B-DRUG
therapy O O
is O O
an O O
exceedingly O O
rare O O
complication O O
that O O
has O O
been O O
thought O O
to O O
occur O O
more O O
commonly O O
in O O
elderly O O
patients O O

we O O
hypothesize O O
that O O
decreased O O
renal O O
elimination O O
of O O
mtx B-DRUG B-DRUG
induced O O
by O O
the O O
cox-2 O O
inhibitor O O
resulted O O
in O O
enhanced O O
hematopoietic B-ADR O
toxicity I-ADR O
and O O
immunosuppression O O
causing O O
the O O
ebv-associated O O
lymphoproliferative O B-ADR
disease O I-ADR

a O O
patient O O
is O O
described O O
who O O
developed O O
a O O
rapid O O
onset O O
of O O
pulmonary B-ADR B-ADR
fibrosis I-ADR I-ADR
following O O
treatment O O
with O O
a O O
new O O
non-steroidal O O
anti-inflammatory O O
drug O O
, O O
nabumetone B-DRUG B-DRUG

two O O
patients O O
who O O
were O O
receiving O O
tolazoline B-DRUG B-DRUG
by O O
infusion O O
developed O O
duodenal B-ADR B-ADR
ulceration I-ADR I-ADR
and O O
subsequent O O
intestinal O B-ADR
perforation O I-ADR

a O O
variety O O
of O O
movement B-ADR O
disorders I-ADR O
are O O
known O O
to O O
occur O O
in O O
association O O
with O O
carbamazepine O B-DRUG
( O O
cbz B-DRUG B-DRUG
) O O
therapy O O
in O O
adults O O
and O O
children O O
, O O
but O O
development O O
of O O
tics O O
has O O
been O O
described O O
infrequently O O
and O O
only O O
in O O
patients O O
with O O
underlying O O
tourette O O
's O O
syndrome O O
or O O
other O O
movement B-ADR O
disorders I-ADR O

incomplete B-ADR O
posterior I-ADR B-ADR
hyaloid I-ADR I-ADR
detachment I-ADR I-ADR
after O O
intravitreal O O
pegaptanib B-DRUG B-DRUG
injection O O
in O O
diabetic O O
macular O O
edema O O

angioedema O B-ADR
and O O
dysphagia B-ADR B-ADR
caused O O
by O O
contact O O
allergy O O
to O O
inhaled O O
budesonide B-DRUG B-DRUG

he O O
had O O
been O O
taking O O
trimethoprim-sulfamethoxazole O B-DRUG
for O O
approximately O O
eight O O
days O O
when O O
he O O
revisited O O
his O O
family O O
physician O O
, O O
complaining O O
of O O
headaches O O
, O O
dizziness O O
, O O
difficulty O O
with O O
speech O O
, O O
weakness B-ADR O
, O O
and O O
itching O O
on O O
the O O
trunk O O
of O O
his O O
body O O
and O O
legs O O
, O O
where O O
a O O
maculopapular O B-ADR
rash O I-ADR
was O O
noted O O

physicians O O
who O O
use O O
sulfasalazine B-DRUG B-DRUG
to O O
treat O O
patients O O
with O O
inflammatory O O
bowel O O
disease O O
should O O
be O O
aware O O
of O O
the O O
signs O O
of O O
sulfasalazine-induced O O
lupus B-ADR B-ADR
syndrome I-ADR I-ADR

objective O O
: O O
to O O
report O O
on O O
the O O
possible O O
development O O
of O O
serotonin B-ADR B-ADR
syndrome I-ADR I-ADR
in O O
a O O
patient O O
receiving O O
clomipramine B-DRUG B-DRUG
after O O
clozapine O B-DRUG
was O O
withdrawn O O
from O O
the O O
treatment O O
regimen O O

the O O
site O O
of O O
thrombosis O O
and O O
the O O
chronological O O
relationship O O
with O O
the O O
iir O B-DRUG
implicates O O
a O O
hypersensitivity B-ADR O
to O O
infliximab B-DRUG B-DRUG
in O O
the O O
causation O O
of O O
the O O
venous O B-ADR
thrombosis O I-ADR
in O O
this O O
case O O

although O O
adverse O O
effects O O
are O O
usually O O
mild O O
, O O
the O O
author O O
reports O O
here O O
a O O
case O O
of O O
leucocytopenia O B-ADR
and O O
thrombocytopenia B-ADR O
with O O
quetiapine B-DRUG B-DRUG
treatment O O
that O O
required O O
its O O
discontinuation O O

on O O
the O O
fifth O O
day O O
of O O
tocolysis O O
with O O
magnesium O B-DRUG
sulfate O I-DRUG
, O O
nifedipine B-DRUG O
, O O
terbutaline O O
and O O
betamethasone O O
, O O
edema B-ADR B-ADR
developed O O
in O O
both O O
labia O O

objective O O
: O O
to O O
report O O
a O O
fatal O O
case O O
of O O
toxic B-ADR B-ADR
epidermal I-ADR I-ADR
necrolysis I-ADR I-ADR
in O O
a O O
man O O
who O O
was O O
treated O O
with O O
oral O O
ofloxacin B-DRUG B-DRUG
for O O
epididymitis O O

a O O
64 O O
year O O
old O O
man O O
with O O
recurrent O O
metastatic O O
squamous O O
cell O O
carcinoma O O
of O O
the O O
head O O
and O O
neck O O
developed O O
severe B-ADR B-ADR
skin I-ADR I-ADR
rash I-ADR I-ADR
and O O
bone O B-ADR
marrow O I-ADR
aplasia O I-ADR
4 O O
and O O
7 O O
days O O
, O O
respectively O O
, O O
following O O
a O O
single O O
dose O O
of O O
40 O O
mg O O
/ O O
m2 O O
methotrexate B-DRUG O
( O O
mtx O B-DRUG

experience O O
with O O
five O O
patients O O
in O O
whom O O
impaired B-ADR B-ADR
renal I-ADR I-ADR
function I-ADR I-ADR
developed O O
early O O
during O O
amphotericin B-DRUG B-DRUG
b I-DRUG I-DRUG
therapy O O
is O O
reported O O

isotretinoin B-DRUG B-DRUG
, O O
a O O
drug O O
used O O
for O O
the O O
treatment O O
of O O
acne O O
, O O
has O O
been O O
shown O O
to O O
have O O
teratogenic B-ADR B-ADR
effects I-ADR I-ADR

the O O
following O O
is O O
a O O
case O O
report O O
analysis O O
intended O O
to O O
draw O O
attention O O
to O O
the O O
need O O
for O O
better O O
care O O
coordination O O
by O O
describing O O
the O O
observed O O
relationship O O
of O O
olanzapine B-DRUG B-DRUG
to O O
metabolic O O
changes O O
manifested O O
as O O
uncontrolled B-ADR O
diabetes I-ADR O
mellitus I-ADR O
and O O
weight O B-ADR
gain O I-ADR

peripheral B-ADR B-ADR
nerve I-ADR I-ADR
dysfunction I-ADR I-ADR
is O O
a O O
potentially O O
serious O O
complication O O
of O O
high-dose O O
cytosine B-DRUG B-DRUG
arabinoside I-DRUG I-DRUG

camptocormia B-ADR B-ADR
, O O
a O O
new O O
side O O
effect O O
of O O
sodium B-DRUG B-DRUG
valproate I-DRUG I-DRUG

the O O
probability O O
of O O
developing O O
acute B-ADR B-ADR
leukemia I-ADR I-ADR
in O O
this O O
study O O
was O O
not O O
significantly O O
correlated O O
to O O
the O O
total O O
cumulative O O
dosage O O
of O O
treosulfan B-DRUG B-DRUG

basilar B-ADR O
invagination I-ADR O
and O O
mid-line O B-ADR
skeletal O I-ADR
abnormalities O I-ADR
due O O
to O O
in O O
utero O O
exposure O O
to O O
phenytoin B-DRUG B-DRUG

the O O
patient O O
experienced O O
hallucinations B-ADR O
, O O
agitation O O
, O O
vomiting O O
, O O
tachycardia O O
and O O
seizures O O
after O O
ingestion O O
of O O
1050 O O
( O O
48 O O
mg O O
/ O O
kg O O
) O O
of O O
extended-release O O
bupropion B-DRUG B-DRUG

we O O
report O O
a O O
case O O
of O O
reversible O B-ADR
encephalopathy B-ADR I-ADR
syndrome I-ADR I-ADR
in O O
a O O
16-year-old O O
girl O O
with O O
acute O O
myelogenous O O
leukemia O O
( O O
aml O O
) O O
, O O
who O O
is O O
undergoing O O
during O O
consolidation O O
chemotherapy O O
composed O O
of O O
bh-ac O B-DRUG
( O O
n4-behenoyl-1-beta-d-arabinofuranosyl O O
cytosine O O
) O O
and O O
idarubicin B-DRUG B-DRUG

discussion O O
: O O
anaphylactoid B-ADR B-ADR
reactions I-ADR I-ADR
have O O
been O O
described O O
previously O O
with O O
cisplatin B-DRUG B-DRUG
administration O O

he O O
had O O
been O O
taking O O
trimethoprim-sulfamethoxazole O B-DRUG
for O O
approximately O O
eight O O
days O O
when O O
he O O
revisited O O
his O O
family O O
physician O O
, O O
complaining O O
of O O
headaches B-ADR O
, O O
dizziness O O
, O O
difficulty O O
with O O
speech O O
, O O
weakness O O
, O O
and O O
itching O O
on O O
the O O
trunk O O
of O O
his O O
body O O
and O O
legs O O
, O O
where O O
a O O
maculopapular O B-ADR
rash O I-ADR
was O O
noted O O

salicylate O B-ADR
intoxication B-ADR I-ADR
was O O
excluded O O
, O O
and O O
theophylline B-DRUG B-DRUG
was O O
finally O O
incriminated O O

we O O
report O O
the O O
case O O
of O O
an O O
87-year-old O O
white O O
woman O O
with O O
myasthenia O O
gravis O O
who O O
presented O O
with O O
nausea O O
, O O
shortness O B-ADR
of O I-ADR
breath O I-ADR
, O O
azotemia B-ADR O
, O O
and O O
hyperkalemia O O
shortly O O
after O O
completing O O
a O O
course O O
of O O
intravenous O O
immunoglobulin B-DRUG B-DRUG
( O O
ivig O B-DRUG

discussion O O
: O O
electrolyte B-ADR B-ADR
disorders I-ADR I-ADR
associated O O
with O O
foscarnet B-DRUG B-DRUG
are O O
reviewed O O

gestational B-ADR B-ADR
diabetes I-ADR I-ADR
was O O
no O O
less O O
severe O O
( O O
degree O O
of O O
hyperglycaemia O O
, O O
need O O
for O O
insulin O O
therapy O O
) O O
when O O
associated O O
with O O
norethisterone B-DRUG B-DRUG

since O O
tamoxifen B-DRUG B-DRUG
therapy O O
can O O
induce O O
endometrial B-ADR B-ADR
disorders I-ADR I-ADR
, O O
surveillance O O
schemes O O
of O O
women O O
taking O O
tamoxifen B-DRUG B-DRUG
have O O
been O O
recommended O O

carbamazepine-induced O O
hyperammonemia B-ADR B-ADR

rta B-ADR B-ADR
is O O
one O O
type O O
of O O
nephrotoxicity O B-ADR
induced O O
by O O
fk506 B-DRUG B-DRUG
, O O
and O O
it O O
is O O
reversible O O
in O O
mild O O
cases O O
when O O
appropriately O O
treated O O

this O O
patient O O
rapidly O O
progressed O O
from O O
mild B-ADR O
neurotoxicity I-ADR O
to O O
fatal O B-ADR
encephalopathy O I-ADR
after O O
one O O
dose O O
of O O
intrathecal O O
methotrexate B-DRUG B-DRUG
during O O
his O O
third O O
cycle O O
of O O
chemotherapy O O

primary B-ADR B-ADR
cutaneous I-ADR I-ADR
coccidioidomycosis I-ADR I-ADR
and O O
subsequent O O
drug O B-ADR
eruption O I-ADR
to O O
itraconazole B-DRUG B-DRUG
in O O
a O O
dog O O

severe B-ADR B-ADR
symptomatic I-ADR I-ADR
hyponatremia I-ADR I-ADR
during O O
sibutramine B-DRUG B-DRUG
therapy O O
: O O
a O O
case O O
report O O

methods O O
: O O
a O O
55-year-old O O
woman O O
became O O
stuporous B-ADR B-ADR
after O O
overdose O O
with O O
lamotrigine O B-DRUG
( O O
ltg O O
) O O
and O O
valproic B-DRUG O
acid I-DRUG O
( O O
vpa O O
) O O
tablets O O

fever O O
, O O
lymphadenopathy O O
, O O
eosinophilia B-ADR O
, O O
lymphocytosis O O
, O O
hepatitis O O
, O O
and O O
dermatitis O O
: O O
a O O
severe O O
adverse O O
reaction O O
to O O
minocycline B-DRUG B-DRUG

objective O O
: O O
to O O
describe O O
a O O
patient O O
with O O
asymptomatic O O
bronchial O O
asthma O O
and O O
hypertension O O
who O O
developed O O
an O O
acute B-ADR B-ADR
asthma I-ADR I-ADR
attack O I-ADR
after O O
receiving O O
sustained-release O O
verapamil B-DRUG B-DRUG

rosaceiform B-ADR B-ADR
eruption I-ADR I-ADR
induced O O
by O O
erlotinib B-DRUG B-DRUG

lithium B-DRUG B-DRUG
is O O
known O O
to O O
cause O O
acute O O
renal O O
failure O O
and O O
tubulo-interstitial O O
disease O O
, O O
but O O
the O O
recently O O
described O O
association O O
with O O
proteinuria O O
or O O
nephrotic B-ADR B-ADR
syndrome I-ADR I-ADR
is O O
little O O
recognized O O

physicians O O
should O O
keep O O
in O O
mind O O
that O O
taxanes O O
such O O
as O O
paclitaxel B-DRUG B-DRUG
have O O
the O O
potential O O
to O O
cause O O
pneumonitis B-ADR O
and O O
lung O O
fibrosis O O

we O O
present O O
the O O
case O O
of O O
a O O
5-year-old O O
girl O O
who O O
developed O O
bilateral B-ADR B-ADR
vocal I-ADR I-ADR
cord I-ADR I-ADR
paralysis I-ADR I-ADR
following O O
preoperative O O
peritonsillar O B-DRUG
bupivacaine B-DRUG I-DRUG
infiltration O O

methotrexate B-DRUG B-DRUG
pneumonitis B-ADR B-ADR
in O O
nonsurgical O O
treatment O O
of O O
ectopic O O
pregnancy O O

cholestyramine B-DRUG B-DRUG
induced O O
hyperchloremic B-ADR B-ADR
metabolic I-ADR I-ADR
acidosis I-ADR I-ADR

after O O
receiving O O
3 O O
doses O O
of O O
ifosfamide O B-DRUG
/ O O
mesna B-DRUG O
, O O
she O O
was O O
found O O
to O O
be O O
unresponsive B-ADR O

bulbar B-ADR O
and O O
pseudobulbar O B-ADR
palsy O I-ADR
complicating O O
therapy O O
with O O
high-dose O O
cytosine B-DRUG B-DRUG
arabinoside I-DRUG I-DRUG
in O O
children O O
with O O
leukemia O O

intraventricular O O
nafcillin-induced O O
seizures B-ADR B-ADR
in O O
a O O
neonate O O

we O O
report O O
a O O
case O O
of O O
reversible O O
dka O B-ADR
and O O
new-onset O B-ADR
dm B-ADR I-ADR
that O O
developed O O
in O O
a O O
demented O O
patient O O
who O O
was O O
treated O O
with O O
quetiapine B-DRUG B-DRUG
for O O
14 O O
days O O

favorable O O
outcome O O
of O O
de O O
novo O O
hepatitis B-ADR B-ADR
b I-ADR I-ADR
infection I-ADR I-ADR
after O O
liver O O
transplantation O O
with O O
lamivudine B-DRUG B-DRUG
and O O
adefovir O B-DRUG
therapy O O

an O O
infant O O
girl O O
with O O
choanal B-ADR O
atresia I-ADR O
, O O
athelia O O
, O O
minor O O
anomalies O O
, O O
and O O
mild O O
to O O
moderate O O
mental O O
retardation O O
was O O
born O O
to O O
a O O
woman O O
treated O O
for O O
hyperthyroidism O O
throughout O O
pregnancy O O
with O O
methimazole B-DRUG B-DRUG
and O O
propranolol O B-DRUG

a O O
64 O O
year O O
old O O
woman O O
with O O
previous O O
history O O
of O O
coronary O B-ADR
stenting O I-ADR
five O O
days O O
before O O
was O O
admitted O O
in O O
our O O
institution O O
for O O
intracranial B-ADR B-ADR
bleeding I-ADR I-ADR
while O O
receiving O O
aspirin O B-DRUG
and O O
clopidogrel B-DRUG B-DRUG

during O O
and O O
after O O
ifn B-DRUG B-DRUG
therapy O O
we O O
should O O
consider O O
the O O
possibility O O
of O O
occurrence O O
of O O
iddm B-ADR B-ADR
as O O
well O O
as O O
other O O
autoimmune O O
diseases O O
and O O
observe O O
the O O
clinical O O
course O O
carefully O O

the O O
authors O O
describe O O
pericardial B-ADR B-ADR
hemorrhage I-ADR I-ADR
, O O
which O O
is O O
related O O
to O O
the O O
use O O
of O O
low-dose O O
acetylsalicylic B-DRUG B-DRUG
acid I-DRUG I-DRUG
in O O
a O O
patient O O
with O O
essential O O
thrombocythemia O O

we O O
present O O
an O O
aids O O
patient O O
with O O
severe O O
and O O
prolonged O O
lactic B-ADR B-ADR
acidosis I-ADR I-ADR
on O O
stavudine O B-DRUG
and O O
lamivudine B-DRUG B-DRUG

rapamycin O O
/ O O
sirolimus O O
( O O
sr O O
) O O
, O O
trade O O
named O O
rapammune B-DRUG O
( O O
wyeth-ayerst O O
, O O
sydney O O
, O O
australia O O
) O O
, O O
is O O
a O O
potent O O
immunosuppressive O O
drug O O
associated O O
with O O
myelosuppression O O
, O O
hypertension O O
, O O
hyperlipidemia O O
, O O
and O O
infection B-ADR O

a O O
patient O O
suffering O O
from O O
heparin-associated O O
thrombocytopenia B-ADR O
( O O
hat O O
) O O
, O O
recurrent O O
arteriothromboses O O
, O O
and O O
acute O B-ADR
renal O I-ADR
failure O I-ADR
after O O
treatment O O
with O O
standard O O
heparin B-DRUG B-DRUG
is O O
described O O

results O O
: O O
a O O
patient O O
developed O O
a O O
bilaterally B-ADR B-ADR
symmetric I-ADR I-ADR
bull's-eye I-ADR I-ADR
maculopathy I-ADR I-ADR
45 O O
years O O
after O O
taking O O
quinacrine B-DRUG B-DRUG
for O O
18 O O
months O O
as O O
prophylaxis O O
against O O
malaria O O

a O O
60-year-old O O
woman O O
with O O
diabetes O O
mellitus O O
( O O
type O O
2 O O
) O O
developed O O
an O O
acute B-ADR B-ADR
icteric I-ADR I-ADR
hepatitis-like I-ADR I-ADR
illness I-ADR I-ADR
6 O O
weeks O O
after O O
the O O
initiation O O
of O O
gliclazide B-DRUG B-DRUG
therapy O O

results O O
: O O
the O O
estimated O O
number O O
of O O
accutane B-DRUG B-DRUG
prescriptions O O
for O O
reproductive-aged O O
women O O
has O O
more O O
than O O
doubled O O
in O O
the O O
past O O
10 O O
years O O
; O O
it O O
is O O
the O O
most O O
widely O O
used O O
teratogenic B-ADR O
drug O O
in O O
the O O
united O O
states O O
, O O
with O O
approximately O O
2.5 O O
per O O
1,000 O O
reproductive-aged O O
women O O
exposed O O
to O O
accutane B-DRUG B-DRUG
in O O
1999 O O

treatment O O
of O O
elp B-ADR O
in O O
children O O
is O O
generally O O
supportive O O
, O O
with O O
the O O
symptoms O O
and O O
roentgenographic O B-ADR
abnormalities O I-ADR
resolving O O
within O O
months O O
after O O
stopping O O
the O O
use O O
of O O
mineral B-DRUG B-DRUG
oil I-DRUG I-DRUG

two O O
of O O
our O O
patients O O
developed O O
td B-ADR B-ADR
after O O
23 O O
months O O
and O O
34 O O
months O O
of O O
ziprasidone B-DRUG B-DRUG
monotherapy O O
, O O
respectively O O

the O O
more O O
common O O
grade O O
3 O O
or O O
4 O O
adverse O O
effects O O
of O O
sunitinib B-DRUG B-DRUG
include O O
hypertension O O
, O O
fatigue O O
, O O
hand-foot O O
syndrome O O
, O O
elevated B-ADR O
lipase I-ADR O
and O O
lymphopenia O O

in O O
a O O
female O O
with O O
acute O O
lymphoblastic O O
leukemia O O
, O O
inadvertent O O
doxorubicin B-DRUG B-DRUG
administration O O
intrathecally O O
caused O O
severe O O
, O O
life-threatening O O
, O O
acute O O
encephalopathy O O
with O O
high-pressure B-ADR B-ADR
hydrocephalus I-ADR I-ADR

however O O
, O O
continued O O
low-dose O O
mtx B-DRUG B-DRUG
led O O
, O O
in O O
spite O O
of O O
normal O O
liver O O
tests O O
, O O
8 O O
years O O
after O O
the O O
last O O
biopsy O O
to O O
liver O O
failure O O
and O O
death B-ADR O
in O O
1 O O
of O O
our O O
patients O O

objective O O
: O O
to O O
report O O
teicoplanin-related O O
neutropenia B-ADR B-ADR
that O O
developed O O
after O O
an O O
episode O O
of O O
neutropenia B-ADR B-ADR
induced O O
by O O
vancomycin B-DRUG B-DRUG
therapy O O

after O O
having O O
received O O
gemcitabine B-DRUG B-DRUG
on O O
day O O
1 O O
of O O
the O O
second O O
course O O
, O O
the O O
patient O O
developed O O
dry B-ADR O
cough I-ADR O
, O O
subfebrile O O
temperatures O O
and O O
dyspnea O O
within O O
48 O O
h O O

this O O
concerns O O
2 O O
male O O
patients O O
who O O
experienced O O
incontinence B-ADR B-ADR
while O O
taking O O
venlafaxine B-DRUG B-DRUG

muscle O O
biopsy O O
revealed O O
variation O O
in O O
muscle O O
fiber O O
size O O
and O O
few O O
vacuolated B-ADR O
fibers I-ADR O
which O O
were O O
features O O
of O O
colchicine-induced O O
myopathy O B-ADR

several O O
possible O O
explanations O O
of O O
the O O
mechanism O O
of O O
renal B-ADR B-ADR
failure I-ADR I-ADR
associated O O
with O O
the O O
use O O
of O O
dextran-40 B-DRUG B-DRUG
are O O
discussed O O

discussion O O
: O O
the O O
main O O
adverse O O
effects O O
of O O
leflunomide B-DRUG B-DRUG
consist O O
of O O
diarrhea O O
, O O
nausea O O
, O O
liver B-ADR O
enzyme I-ADR O
elevation I-ADR O
, O O
hypertension O O
, O O
alopecia O O
, O O
and O O
allergic O B-ADR
skin O I-ADR
reactions O I-ADR

this O O
case O O
demonstrates O O
the O O
association O O
of O O
selective O O
iga B-ADR B-ADR
deficiency I-ADR I-ADR
with O O
remission O O
in O O
rheumatoid O O
arthritis O O
induced O O
by O O
fenclofenac O B-DRUG
as O O
well O O
as O O
aurothiomalate B-DRUG O
and O O
sulphasalazine O B-DRUG

after O O
1 O O
week O O
of O O
nefazodone B-DRUG B-DRUG
therapy O O
the O O
patient O O
experienced O O
headache O O
, O O
confusion B-ADR O
, O O
and O O
" O O
gray O O
areas O O
" O O
in O O
her O O
vision O O
, O O
without O O
abnormal O O
ophthalmologic O O
findings O O

based O O
on O O
our O O
experience O O
and O O
on O O
previously O O
published O O
data O O
, O O
serum O O
ammonia O O
levels O O
appear O O
to O O
be O O
indicated O O
in O O
all O O
ed O O
patients O O
on O O
valproic B-DRUG B-DRUG
acid I-DRUG I-DRUG
therapy O O
who O O
present O O
with O O
altered B-ADR O
mental I-ADR B-ADR
status I-ADR I-ADR

we O O
report O O
two O O
cases O O
of O O
tenofovir B-DRUG B-DRUG
( O O
tdf O O
)- O O
associated O O
nephrotoxicity B-ADR B-ADR
in O O
perinatally O O
hiv-infected O O
adolescents O O

conclusion O O
: O O
fixed O B-ADR
drug O I-ADR
eruption B-ADR I-ADR
is O O
associated O O
with O O
many O O
drugs O O
but O O
this O O
is O O
the O O
first O O
such O O
report O O
with O O
omeprazole B-DRUG B-DRUG

conclusion O O
: O O
the O O
new O O
quinolone O O
derivatives O O
( O O
levofloxacin O O
, O O
sparfloxacin O O
, O O
grepafloxacin O O
, O O
trovafloxacin O O
, O O
gatifloxacin B-DRUG O
and O O
moxifloxacin O O
) O O
, O O
also O O
called O O
gyrase O O
inhibitors O O
, O O
are O O
known O O
for O O
their O O
potential O O
to O O
cause O O
central O O
nervous O O
system-related O O
adverse O O
effects O O
, O O
including O O
headache O O
, O O
dizziness B-ADR O
and O O
insomnia O O

a O O
case O O
of O O
pyridoxine-dependent O O
seizures B-ADR B-ADR
is O O
reported O O

the O O
authors O O
also O O
determined O O
that O O
their O O
case O O
of O O
myositis B-ADR B-ADR
developing O O
in O O
the O O
rectus O O
abdominus O O
muscle O O
of O O
a O O
patient O O
with O O
pancreatic O O
adenocarcinoma O O
was O O
the O O
manifestation O O
of O O
radiation O B-ADR
recall O I-ADR
, O O
thereby O O
bringing O O
the O O
number O O
of O O
patients O O
who O O
developed O O
radiation O B-ADR
recall O I-ADR
to O O
gemcitabine B-DRUG B-DRUG
and O O
were O O
discussed O O
in O O
the O O
current O O
study O O
to O O
13 O O

case O O
summary O O
: O O
a O O
25-year-old O O
postpartum O O
white O O
woman O O
developed O O
multiple B-ADR B-ADR
watery I-ADR I-ADR
stools I-ADR I-ADR
and O O
abdominal O B-ADR
cramping O I-ADR
on O O
day O O
6 O O
of O O
therapy O O
with O O
clindamycin B-DRUG B-DRUG
vaginal O O
cream O O
for O O
bacterial O O
vaginosis O O

we O O
present O O
a O O
case O O
of O O
an O O
elderly O O
woman O O
with O O
a O O
pre-existing O O
history O O
of O O
ischaemic O O
heart O O
disease O O
, O O
who O O
was O O
treated O O
with O O
venlafaxine B-DRUG B-DRUG
, O O
and O O
developed O O
acute B-ADR B-ADR
myocardial I-ADR I-ADR
ischaemia I-ADR I-ADR
within O O
the O O
first O O
week O O
of O O
treatment O O

pneumocystis B-ADR B-ADR
pneumonia I-ADR I-ADR
should O O
be O O
considered O O
in O O
asthmatic O O
patients O O
taking O O
methotrexate B-DRUG B-DRUG
who O O
present O O
with O O
fever O O
, O O
pulmonary O O
infiltrates O O
, O O
and O O
hypoxia O O

the O O
clinical O O
course O O
suggests O O
that O O
caffeine B-DRUG B-DRUG
, O O
which O O
is O O
present O O
in O O
oolong O O
tea O O
, O O
was O O
mainly O O
responsible O O
for O O
the O O
rhabdomyolysis B-ADR B-ADR
as O O
well O O
as O O
the O O
delirium O O
, O O
although O O
severe O O
hyponatremia O O
has O O
been O O
reported O O
to O O
cause O O
rhabdomyolysis B-ADR B-ADR
on O O
rare O O
occasions O O

the O O
first O O
patient O O
developed O O
mild B-ADR O
nitritoid I-ADR B-ADR
symptoms I-ADR I-ADR
and O O
pain O O
in O O
a O O
band-like O O
distribution O O
, O O
corresponding O O
to O O
t10-t12 O O
dermatomes O O
, O O
shortly O O
after O O
gold B-DRUG B-DRUG
sodium I-DRUG I-DRUG
thiomalate I-DRUG I-DRUG
( O O
gstm O B-DRUG
) O O
injection O O

ticlopidine-induced O O
aplastic O B-ADR
anemia O I-ADR
( O O
tiaa B-ADR B-ADR
) O O
is O O
considered O O
very O O
uncommon O O

vancomycin B-DRUG B-DRUG
is O O
widely O O
used O O
against O O
methicillin-resistant O O
staphylococcus O O
aureus O O
infections O O
, O O
but O O
it O O
is O O
associated O O
with O O
many O O
adverse O O
effects O O
such O O
as O O
nephrotoxicity B-ADR O
, O O
ototoxicity O O
, O O
gastrointestinal O O
disturbances O O
, O O
blood O O
disorders O O
, O O
and O O
two O O
types O O
of O O
hypersensitivity O O
reactions O O
- O O
an O O
anaphylactoid O O
reaction O O
known O O
as O O
" O O
red O O
man O O
syndrome O O
" O O
and O O
anaphylaxis O O

this O O
report O O
describes O O
two O O
patients O O
who O O
developed O O
acute B-ADR B-ADR
myelocytic I-ADR I-ADR
leukemia I-ADR I-ADR
only O O
after O O
exposure O O
to O O
cyclophosphamide O B-DRUG
, O O
methotrexate O O
, O O
and O O
5-fluorouracil B-DRUG B-DRUG
adjuvant O O
therapy O O

we O O
report O O
a O O
case O O
of O O
biopsy O O
proven O O
myositis B-ADR B-ADR
whose O I-ADR
symptoms O I-ADR
began O O
within O O
10 O O
days O O
of O O
receiving O O
leuprolide B-DRUG B-DRUG
acetate I-DRUG I-DRUG
therapy O O
for O O
prostate O O
cancer O O

background O O
: O O
to O O
describe O O
the O O
occurrence O O
of O O
ocular B-ADR B-ADR
hypertension I-ADR I-ADR
in O O
four O O
patients O O
following O O
injection O O
of O O
ranibizumab B-DRUG B-DRUG
intravitreally O O

an O O
objective O O
causality O O
assessment O O
suggests O O
that O O
the O O
jhr B-ADR B-ADR
in O O
our O O
patient O O
was O O
probably O O
related O O
to O O
penicillin B-DRUG B-DRUG

we O O
report O O
a O O
43-year-old O O
woman O O
who O O
developed O O
sore B-ADR O
throat I-ADR O
, O O
swelling O B-ADR
of O I-ADR
the O I-ADR
lips O I-ADR
and O O
oral O O
cavity O O
and O O
dysphagia O O
, O O
2 O O
weeks O O
after O O
the O O
use O O
of O O
budesonide O B-DRUG
spray O O
( O O
budefat B-DRUG O
) O O
for O O
treatment O O
of O O
bronchial O O
asthma O O

the O O
possibility O O
of O O
phenytoin B-DRUG B-DRUG
hypersensitivity O O
reactions O O
should O O
be O O
considered O O
when O O
patients O O
receiving O O
phenytoin B-DRUG B-DRUG
have O O
unusual O O
symptoms O O
, O O
particularly O O
fever O O
, O O
rash B-ADR O
, O O
and O O
lymphadenopathy O O

optic B-ADR B-ADR
neuropathy I-ADR I-ADR
developed O O
in O O
a O O
patient O O
with O O
rheumatoid O O
arthritis O O
who O O
had O O
been O O
receiving O O
d-penicillamine B-DRUG B-DRUG
for O O
about O O
1 O O
year O O

pulmonary O B-ADR
eosinophilia O I-ADR
or O O
granulomas B-ADR O
, O O
classically O O
seen O O
in O O
previously O O
reported O O
cases O O
of O O
methotrexate B-DRUG B-DRUG
pneumonitis O O
, O O
were O O
not O O
observed O O

we O O
report O O
on O O
a O O
14-year-old O O
boy O O
with O O
severe O O
haemophilia O O
a O O
who O O
developed O O
a O O
portal B-ADR B-ADR
vein I-ADR I-ADR
thrombosis I-ADR I-ADR
during O O
continuous O O
infusion O O
of O O
f B-DRUG B-DRUG
viii I-DRUG I-DRUG

ards B-ADR B-ADR
is O O
rarely O O
associated O O
with O O
rituximab B-DRUG B-DRUG
infusion O O
for O O
lympho-proliferative O O
disorders O O
, O O
but O O
it O O
should O O
be O O
considered O O
by O O
those O O
administering O O
rituximab B-DRUG B-DRUG
, O O
especially O O
when O O
a O O
patient O O
develops O O
severe O O
pulmonary O B-ADR
symptoms O I-ADR
soon O O
after O O
infusion O O

retinal O O
abnormalities O O
, O O
including O O
retinal B-ADR O
hemorrhage I-ADR O
and O O
" O O
cotton-wool O O
" O O
spots O O
, O O
often O O
occur O O
within O O
the O O
first O O
8 O O
weeks O O
in O O
the O O
course O O
of O O
interferon B-DRUG B-DRUG
therapy O O
in O O
patients O O
with O O
chronic O O
hepatitis O O
c O O

this O O
case O O
suggests O O
that O O
acyclovir B-DRUG B-DRUG
when O O
given O O
intravenously O O
in O O
doses O O
of O O
10 O O
mg O O
/ O O
kg O O
may O O
result O O
in O O
increased B-ADR O
serum I-ADR O
lithium I-ADR B-DRUG
concentrations O O

a O O
case O O
is O O
reported O O
in O O
which O O
severe O B-ADR
hypocalcemia O I-ADR
, O O
with O O
a O O
low B-ADR O
plasma I-ADR O
parathyroid I-ADR O
hormone I-ADR O
( O O
pth O O
) O O
concentration O O
, O O
resulted O O
from O O
the O O
therapeutic O O
use O O
of O O
magnesium B-DRUG B-DRUG
sulfate I-DRUG I-DRUG
for O O
toxemia O O
of O O
pregnancy O O

we O O
conclude O O
that O O
the O O
presence O O
of O O
this O O
metabolic O B-ADR
defect O I-ADR
combined O O
with O O
topical O O
5-fu B-DRUG B-DRUG
( O O
a O O
drug O O
demonstrating O O
a O O
narrow O O
therapeutic O O
index O O
) O O
results O O
in O O
the O O
unusual O O
presentation O O
of O O
life-threatening B-ADR B-ADR
toxicity I-ADR I-ADR
after O O
treatment O O
with O O
a O O
topical O O
drug O O

infliximab-induced O O
lupus B-ADR B-ADR
in O O
crohn O O
's O O
disease O O
: O O
a O O
case O O
report O O

a O O
21-year-old O O
patient O O
developed O O
rhabdomyolysis B-ADR B-ADR
during O O
his O O
nineteenth O O
week O O
of O O
treatment O O
with O O
clozapine B-DRUG B-DRUG
for O O
drug-resistant O O
schizophrenia O O

this O O
case O O
report O O
describes O O
a O O
38-year-old O O
male O O
in O O
whom O O
siadh B-ADR B-ADR
was O O
strongly O O
suspected O O
secondary O O
to O O
tegretol B-DRUG B-DRUG
therapy O O
to O O
control O O
a O O
seizure O B-ADR
disorder O I-ADR

olanzapine-associated O O
neuroleptic B-ADR B-ADR
malignant I-ADR I-ADR
syndrome I-ADR I-ADR

acute B-ADR O
bilateral I-ADR B-ADR
phrenic I-ADR I-ADR
neuropathy I-ADR I-ADR
following O O
treatment O O
with O O
adalimumab B-DRUG B-DRUG

conclusions O O
: O O
this O O
case O O
describes O O
the O O
clinically O O
significant O O
increase B-ADR B-ADR
of I-ADR I-ADR
inr I-ADR I-ADR
in O O
an O O
elderly O O
patient O O
after O O
adding O O
a O O
chemotherapy O O
regimen O O
of O O
levamisole B-DRUG B-DRUG
and O O
5-fu O B-DRUG
to O O
a O O
previous O O
regimen O O
of O O
warfarin O B-DRUG
alone O O

during O O
clarithromycin O B-DRUG
coadministration O O
, O O
four O O
out O O
of O O
the O O
seven O O
patients O O
developed O O
moderate-to-severe O O
toxic O O
symptoms O O
of O O
carbamazepine B-DRUG B-DRUG
, O O
such O O
as O O
drowsiness O O
, O O
dizziness B-ADR O
, O O
and O O
ataxia O O
, O O
which O O
resolved O O
within O O
5 O O
days O O
after O O
clarithromycin O B-DRUG
discontinuation O O

oxygen B-DRUG O
potentiation O O
of O O
bleomycin-induced O O
pulmonary B-ADR B-ADR
toxicity I-ADR I-ADR
is O O
discussed O O

reversible O O
valproic B-DRUG B-DRUG
acid-induced O O
dementia B-ADR B-ADR
was O O
documented O O
in O O
a O O
21-year-old O O
man O O
with O O
epilepsy O O
who O O
had O O
a O O
3-year O O
history O O
of O O
insidious O O
progressive O O
decline O O
in O O
global O O
cognitive O O
abilities O O
documented O O
by O O
serial O O
neuropsychological O O
studies O O

methods O O
: O O
we O O
report O O
a O O
patient O O
who O O
had O O
an O O
anaphylactic B-ADR B-ADR
reaction I-ADR I-ADR
during O O
the O O
intravenous O O
infusion O O
of O O
cyclosporine B-DRUG B-DRUG

a O O
second O O
patient O O
with O O
a O O
similar O O
glucose O O
tolerance O O
test O O
result O O
showed O O
postprandial B-ADR B-ADR
hyperglycemia I-ADR I-ADR
when O O
treated O O
similarly O O
with O O
betamethasone B-DRUG B-DRUG
valerate I-DRUG I-DRUG
cream O O
0.1 O O

interstitial B-ADR B-ADR
pneumonitis I-ADR I-ADR
and O O
alveolar O B-ADR
hemorrhage O I-ADR
complicating O O
use O O
of O O
rituximab B-DRUG B-DRUG
: O O
case O O
report O O
and O O
review O O
of O O
the O O
literature O O

a O O
combination O O
of O O
behavioural O O
and O O
cognitive O O
adverse O O
effects O O
is O O
illustrated O O
in O O
this O O
case O O
report O O
of O O
a O O
recurrent O O
triazolam-induced O O
eating B-ADR B-ADR
disorder I-ADR I-ADR

objective O O
: O O
to O O
report O O
a O O
case O O
of O O
severe B-ADR O
chloroquine I-ADR B-DRUG
toxicity I-ADR O
in O O
the O O
presence O O
of O O
high-grade O O
chloroquine-resistant O O
plasmodium O O
vivax O O

rapid O O
identification O O
of O O
speech B-ADR B-ADR
loss I-ADR I-ADR
linked O O
to O O
fk506 B-DRUG B-DRUG
may O O
be O O
important O O
because O O
reduction O O
or O O
cessation O O
of O O
the O O
drug O O
may O O
be O O
associated O O
with O O
reverse O B-ADR
of O I-ADR
speech B-ADR I-ADR
loss I-ADR I-ADR

we O O
report O O
a O O
case O O
of O O
rta B-ADR B-ADR
secondary O O
to O O
fk506 B-DRUG B-DRUG
administration O O
in O O
liver O O
transplantation O O

results O O
: O O
a O O
previously O O
healthy O O
42-year-old O O
woman O O
presented O O
with O O
acute-onset B-ADR B-ADR
delirium I-ADR I-ADR
with I-ADR O
psychotic I-ADR B-ADR
features I-ADR I-ADR
as O O
a O O
consequence O O
of O O
levofloxacin B-DRUG B-DRUG
therapy O O

severe B-ADR B-ADR
osteomalacia I-ADR I-ADR
was O O
present O O
in O O
two O O
epileptic O O
patients O O
who O O
were O O
under O O
long-term O O
treatment O O
with O O
congeners O O
of O O
phenytoin B-DRUG B-DRUG
, O O
phenobarbital O O
, O O
and O O
acetazolamide O B-DRUG

rapamycin B-DRUG O
/ O O
sirolimus O O
( O O
sr O O
) O O
, O O
trade O O
named O O
rapammune O O
( O O
wyeth-ayerst O O
, O O
sydney O O
, O O
australia O O
) O O
, O O
is O O
a O O
potent O O
immunosuppressive O O
drug O O
associated O O
with O O
myelosuppression O O
, O O
hypertension O O
, O O
hyperlipidemia O O
, O O
and O O
infection B-ADR O

dyspnea O O
, O O
hypoxemia O O
, O O
and O O
pleuritic B-ADR B-ADR
chest I-ADR I-ADR
pain I-ADR I-ADR
occurred O O
within O O
24 O O
hours O O
of O O
rituximab B-DRUG B-DRUG
administration O O
, O O
and O O
there O O
was O O
no O O
other O O
apparent O O
explanation O O

a O O
51-year-old O O
man O O
developed O O
type B-ADR B-ADR
1 I-ADR I-ADR
diabetes I-ADR I-ADR
mellitus I-ADR I-ADR
following O O
24 O O
weeks O O
of O O
treatment O O
with O O
recombinant O B-DRUG
alpha-2b O I-DRUG
peginterferon O O
plus O O
ribavirin B-DRUG B-DRUG
for O O
chronic O O
hepatitis O O
c O O

proconvulsive B-ADR B-ADR
tendency O I-ADR
of O O
imipenem O B-DRUG
/ O O
cilastatin B-DRUG B-DRUG
is O O
one O O
of O O
its O O
well-known O O
side O O
effects O O

naproxen B-DRUG B-DRUG
is O O
a O O
commonly O O
used O O
nonsteroidal O O
anti-inflammatory O O
drug O O
( O O
nsaid O O
) O O
whose O O
side O O
effects O O
include O O
tinnitus B-ADR O
and O O
transient O B-ADR
hearing O I-ADR
loss O I-ADR

nevertheless O O
, O O
the O O
coagulopathy B-ADR B-ADR
seemed O O
to O O
be O O
most O O
closely O O
associated O O
with O O
the O O
administration O O
of O O
the O O
cephalosporin B-DRUG B-DRUG

sensory O B-ADR
neuropathy O I-ADR
revealing O O
necrotizing B-ADR B-ADR
vasculitis I-ADR I-ADR
during O O
infliximab B-DRUG B-DRUG
therapy O O
for O O
rheumatoid O O
arthritis O O

thus O O
, O O
the O O
possible O O
in O O
vivo O O
effects O O
of O O
insulin B-DRUG O
on O O
adipocytes O O
were O O
clearly O O
observed O O
in O O
this O O
case O O
of O O
insulin-induced O O
lipohypertrophy B-ADR B-ADR

gold B-DRUG B-ADR
nephropathy B-ADR I-ADR
: O O
tissue O O
analysis O O
by O O
x-ray O O
fluorescent O O
spectroscopy O O

we O O
report O O
on O O
three O O
cases O O
wherein O O
treatment O O
of O O
dexmedetomidine-induced O O
bradycardia O B-ADR
with O O
i.v. O O
glycopyrrolate B-DRUG B-DRUG
( O O
5.0 O O
microg O O
/ O O
kg O O
) O O
not O O
only O O
resulting O O
in O O
resolution O O
of O O
bradycardia O B-ADR
but O O
also O O
resulting O O
in O O
an O O
exaggerated B-ADR O
increase I-ADR O
of I-ADR O
arterial I-ADR B-ADR
blood I-ADR I-ADR
pressure I-ADR I-ADR

the O O
newborn O O
manifested O O
a O O
four O O
day O O
course O O
of O O
lethargy B-ADR B-ADR
with O O
unexplained O O
high O O
lithium B-DRUG B-DRUG
levels O O
in O O
the O O
adult O O
toxic O O
range O O

his O O
fever O B-ADR
resolved O O
, O O
but O O
he O O
developed O O
symptoms O O
consistent O O
with O O
those O O
of O O
chloroquine B-ADR B-DRUG
toxicity I-ADR O

sudden B-ADR B-ADR
death I-ADR I-ADR
in O O
an O O
infant O O
from O O
methemoglobinemia O B-ADR
after O O
administration O O
of O O
" O O
sweet B-DRUG O
spirits I-DRUG O
of I-DRUG O
nitre I-DRUG B-DRUG

the O O
reported O O
cases O O
of O O
in O O
utero O O
exposure O O
to O O
cyclosposphamide B-DRUG B-DRUG
shared O O
the O O
following O O
manifestations O O
with O O
our O O
patient O O
: O O
growth O O
deficiency O O
, O O
developmental O O
delay O O
, O O
craniosynostosis B-ADR O
, O O
blepharophimosis O O
, O O
flat O O
nasal O O
bridge O O
, O O
abnormal O O
ears O O
, O O
and O O
distal O O
limb O O
defects O O
including O O
hypoplastic O O
thumbs O O
and O O
oligodactyly O O

acute O B-ADR
esmolol B-ADR I-ADR
toxicity I-ADR I-ADR
may O O
be O O
self-limiting O O
because O O
of O O
its O O
extremely O O
short O O
half-life O O

this O O
case O O
and O O
a O O
review O O
of O O
the O O
literature O O
show O O
the O O
severe O O
and O O
unpredictable O O
nature O O
of O O
ethambutol B-DRUG B-DRUG
toxicity O O
and O O
its O O
potential O O
for O O
irreversible O B-ADR
vision B-ADR I-ADR
loss I-ADR I-ADR
despite O O
careful O O
ophthalmologic O O
monitoring O O

we O O
present O O
a O O
case O O
in O O
which O O
dipyridamole B-DRUG B-DRUG
induced O O
high-grade O O
atrioventricular O O
( O O
av O O
) O O
block O O
that O O
responded O O
promptly O O
to O O
intravenous O O
aminophylline O B-DRUG
but O O
not O O
to O O
atropine O B-DRUG

no O O
explanation O O
for O O
this O O
delay O O
was O O
found O O
, O O
other O O
than O O
the O O
possibility O O
that O O
magnesium B-DRUG B-DRUG
sulfate I-DRUG I-DRUG
treatment O O
impeded B-ADR O
lactogenesis I-ADR B-ADR

rapamycin O O
/ O O
sirolimus O O
( O O
sr B-DRUG O
) O O
, O O
trade O O
named O O
rapammune O O
( O O
wyeth-ayerst O O
, O O
sydney O O
, O O
australia O O
) O O
, O O
is O O
a O O
potent O O
immunosuppressive O O
drug O O
associated O O
with O O
myelosuppression O O
, O O
hypertension B-ADR O
, O O
hyperlipidemia O O
, O O
and O O
infection O O

we O O
present O O
a O O
case O O
of O O
acute O O
epinephrine B-DRUG B-DRUG
toxicity O O
resulting O O
in O O
acute B-ADR B-ADR
myocardial I-ADR I-ADR
ischemia I-ADR I-ADR
in O O
a O O
young O O
boy O O
with O O
combined O O
variable O O
immunodeficiency O O
syndrome O O
who O O
developed O O
severe O O
allergic O B-ADR
reaction O I-ADR
to O O
intravenous O O
immunoglobulin O O
, O O
and O O
was O O
subsequently O O
given O O
epinephrine B-DRUG B-DRUG
by O O
mistake O O
intravenously O O
rather O O
than O O
subcutaneously O O

a O O
58-year-old O O
man O O
with O O
advanced O O
renal O O
cell O O
carcinoma O O
developed O O
grade O O
3 O O
proteinuria B-ADR O
( O O
8.5 O O
g O O
/ O O
24 O O
h O O
) O O
without O O
microscopic O O
hematuria O O
or O O
renal O B-ADR
insufficiency O I-ADR
five O O
days O O
after O O
temsirolimus B-DRUG B-DRUG
infusion O O

we O O
describe O O
2 O O
children O O
with O O
cerebral O O
palsy O O
who O O
suffered O O
significant O O
morbidity B-ADR O
immediately O O
after O O
treatment O O
with O O
hyperbaric B-DRUG O
oxygen I-DRUG O

5-fluorouracil O O
( O O
5-fu B-DRUG B-DRUG
)- O O
associated O O
peripheral B-ADR B-ADR
neuropathy I-ADR I-ADR
is O O
an O O
uncommon O O
event O O

after O O
therapy O O
with O O
parenteral O O
amiodarone B-DRUG B-DRUG
( O O
2300 O O
mg O O
in O O
3 O O
days O O
) O O
and O O
other O O
measures O O
, O O
signs O O
of O O
congestive O O
heart O O
failure O O
disappeared O O
; O O
subsequently O O
the O O
patient O O
developed O O
jaundice B-ADR O
, O O
marked O O
increase O O
in O O
serum O O
transaminase O O
levels O O
and O O
fall O O
in O O
prothrombin O O
time O O
, O O
and O O
histologic O O
changes O O
of O O
severe O B-ADR
centrilobular O I-ADR
necrosis O I-ADR
were O O
observed O O
in O O
hepatic O O
biopsy O O

methamphetamine B-DRUG B-DRUG
's O O
extensive O O
physiologic O O
effects O O
, O O
inconsistent O O
street O O
purity O O
, O O
and O O
multiple O O
routes O O
of O O
administration O O
offer O O
many O O
possibilities O O
for O O
injury B-ADR O
to I-ADR O
the I-ADR O
cornea I-ADR O

a O O
patient O O
receiving O O
vancomycin B-DRUG B-DRUG
for O O
a O O
serious O O
staphylococcal O O
infection O O
had O O
a O O
lupus-like O O
syndrome O O
characterized O O
by O O
a O O
malar O B-ADR
rash O I-ADR
, O O
pain B-ADR O
and O O
erythema O O
of O O
the O O
cartilage O O
of O O
both O O
ears O O
, O O
and O O
tender O O
erythematous O O
and O O
hemorrhagic O B-ADR
lesions O I-ADR
of O I-ADR
the O I-ADR
finger O I-ADR
tips O I-ADR

purpose O O
: O O
to O O
present O O
a O O
case O O
of O O
respiratory B-ADR B-ADR
depression I-ADR I-ADR
following O O
the O O
administration O O
of O O
nebulised O O
morphine B-DRUG B-DRUG

a O O
patient O O
is O O
described O O
with O O
the O O
characteristic O O
features O O
of O O
phenytoin B-DRUG B-DRUG
hypersensitivity O O
syndrome O O
( O O
phs O O
) O O
including O O
fever O O
, O O
erythroderma O O
, O O
tibial O O
and O O
facial O O
oedema O O
, O O
pinhead-sized O O
facial O O
pustules O O
and O O
abnormal B-ADR O
liver I-ADR O
function I-ADR O
tests I-ADR O

objective O O
: O O
to O O
report O O
a O O
case O O
of O O
fatal B-ADR B-ADR
hyperkalemia I-ADR I-ADR
owing O O
to O O
succinylcholine B-DRUG B-DRUG
administration O O
in O O
a O O
patient O O
with O O
mucositis O O
secondary O O
to O O
chemotherapy O O

after O O
taking O O
cholestyramine B-DRUG B-DRUG
ii I-DRUG I-DRUG
sachets O O
twice O O
daily O O
for O O
two O O
months O O
she O O
presented O O
with O O
lethargy O O
, O O
confusion O O
and O O
drowsiness B-ADR B-ADR

we O O
report O O
a O O
case O O
of O O
seizure B-ADR B-ADR
associated O O
with O O
l-asparaginase B-DRUG B-DRUG
therapy O O
but O O
no O O
evidence O O
of O O
hemorrhagic O O
or O O
thrombotic O B-ADR
cerebrovascular O I-ADR
events O I-ADR

piloerection B-ADR B-ADR
induced O O
by O O
replacing O O
fluvoxamine B-DRUG B-DRUG
with O O
milnacipran O B-DRUG

we O O
present O O
the O O
first O O
case O O
( O O
to O O
our O O
knowledge O O
) O O
of O O
a O O
potentially O O
serious O O
drug-drug B-ADR B-ADR
interaction I-ADR I-ADR
between O O
zafirlukast O B-DRUG
and O O
theophylline B-DRUG B-DRUG

we O O
describe O O
the O O
infectious O B-ADR
toxicities O I-ADR
experienced O O
by O O
the O O
first O O
two O O
patients O O
in O O
our O O
institution O O
treated O O
with O O
dexamethasone B-DRUG B-DRUG
( O O
10 O O
mg O O
/ O O
m O O
( O O
2 O O
)/ O O
day O O
for O O
4 O O
weeks O O
with O O
gradual O O
tapering O O
) O O
during O O
induction O O
according O O
to O O
the O O
dexamethasone B-DRUG O
arm O O
of O O
bfm O O
2000 O O
and O O
review O O
the O O
relevant O O
literature O O
that O O
suggests O O
an O O
increased O O
risk O O
of O O
infectious B-ADR O
complications I-ADR O
with O O
dexamethasone B-DRUG B-DRUG

rapid O O
resolution O O
of O O
topiramate-induced O O
angle-closure B-ADR B-ADR
glaucoma I-ADR I-ADR
with O O
methylprednisolone O B-DRUG
and O O
mannitol B-DRUG B-DRUG

warfarin-associated O O
thoracic B-ADR B-ADR
aortic I-ADR I-ADR
dissection I-ADR I-ADR
in O O
an O O
elderly O O
woman O O

in O O
rare O O
cases O O
mitomycin B-DRUG O
c I-DRUG O
( O O
mmc O B-DRUG
) O O
may O O
induce O O
cancer-associated O O
hemolytic O B-ADR
uremic O I-ADR
syndrome O I-ADR
, O O
which O O
is O O
characterized O O
by O O
hemolytic O O
anemia O O
, O O
thrombocytopenia O O
and O O
progressive B-ADR B-ADR
renal I-ADR I-ADR
failure I-ADR I-ADR

in O O
a O O
patient O O
suffering O O
from O O
rheumatoid O O
arthritis O O
, O O
we O O
report O O
the O O
first O O
simultaneous O O
occurrence O O
of O O
two O O
side O O
effects O O
of O O
low-dose O O
methotrexate B-DRUG B-DRUG
: O O
an O O
acute O B-ADR
megaloblastic O I-ADR
anaemia O I-ADR
and O O
a O O
pneumonitis B-ADR O

the O O
responsibility O O
of O O
ccnu B-DRUG B-DRUG
in O O
the O O
pathogenesis O O
of O O
pulmonary B-ADR B-ADR
fibrosis I-ADR I-ADR
seems O O
very O O
likely O O

accelerated B-ADR B-ADR
nodulosis I-ADR I-ADR
during O O
methotrexate B-DRUG B-DRUG
therapy O O
for O O
juvenile O O
rheumatoid O O
arthritis O O

two O O
patients O O
treated O O
with O O
5-fluorouracil B-DRUG B-DRUG
( O O
5-fu O B-DRUG
) O O
for O O
disseminated O O
adenocarcinoma O O
of O O
the O O
colon O O
developed O O
cerebellar O B-ADR
dysfunction O I-ADR
typical O O
of O O
5-fu O B-DRUG
neurotoxicity B-ADR B-ADR

two O O
of O O
the O O
five O O
patients O O
who O O
worsened B-ADR O
motorically I-ADR O
also O O
developed O O
encephalopathy O B-ADR
during O O
risperidone B-DRUG B-DRUG
treatment O O
; O O
the O O
encephalopathy O B-ADR
resolved O O
when O O
the O O
patients O O
were O O
switched O O
to O O
clozapine O B-DRUG
treatment O O

temozolomide B-DRUG B-DRUG
was O O
restarted O O
2 O O
months O O
later O O
; O O
the O O
patient O O
again O O
developed O O
a O O
fever B-ADR B-ADR

when O O
the O O
acute O O
manic O O
state O O
is O O
characterized O O
by O O
marked O O
psychotic O O
symptoms O O
and O O
intense B-ADR O
anxiety I-ADR O
, O O
it O O
may O O
be O O
associated O O
with O O
increased O O
vulnerability O O
to O O
the O O
development O O
of O O
severe O O
lithium B-DRUG B-DRUG
neurotoxicity O B-ADR

she O O
was O O
thus O O
diagnosed O O
as O O
having O O
az B-ADR B-ADR
intoxication I-ADR I-ADR

conclusion O O
: O O
long-term O O
treatment O O
with O O
rifabutin B-DRUG B-DRUG
may O O
have O O
a O O
reversible O O
and O O
previously O O
undescribed O O
side-effect B-ADR O
on I-ADR O
retinal I-ADR O
function I-ADR O

pulmonary B-ADR B-ADR
edema I-ADR I-ADR
occurred O O
24 O O
hours O O
after O O
intravenous O O
ritodrine O B-DRUG
therapy O O
and O O
10 O O
hours O O
after O O
subcutaneous O O
terbutaline B-DRUG B-DRUG
therapy O O

we O O
report O O
an O O
hiv-infected O O
woman O O
who O O
developed O O
mild O O
leukopenia O O
as O O
the O O
first O O
sign O O
of O O
a O O
nevirapine-related O O
adverse O O
event O O
, O O
which O O
was O O
followed O O
by O O
skin B-ADR O
and I-ADR O
hepatic I-ADR O
toxicity I-ADR O
associated O O
with O O
a O O
more O O
severe O B-ADR
leukopenia O I-ADR

asthenozoospermia B-ADR B-ADR
: O O
possible O O
association O O
with O O
long-term O O
exposure O O
to O O
an O O
anti-epileptic O O
drug O O
of O O
carbamazepine B-DRUG B-DRUG

cutaneous B-ADR B-ADR
mycobacterial I-ADR I-ADR
infection I-ADR I-ADR
post O O
intravesical O O
bcg B-DRUG B-DRUG
installation O O

data O O
have O O
been O O
published O O
regarding O O
the O O
possibility O O
that O O
tamoxifen B-DRUG B-DRUG
may O O
be O O
responsible O O
for O O
the O O
subsequent O O
development O O
of O O
carcinoma B-ADR B-ADR
of I-ADR I-ADR
the I-ADR I-ADR
corpus I-ADR I-ADR
uteri I-ADR I-ADR
in O O
these O O
patients O O

this O O
progressed O O
to O O
tracheal B-ADR O
compression I-ADR O
with O O
stridor O O
after O O
he O O
had O O
taken O O
some O O
aspirin B-DRUG B-DRUG
for O O
relief O O
of O O
the O O
neck O B-ADR
pain O I-ADR

only O O
a O O
few O O
reports O O
of O O
overt O B-ADR
jaundice B-ADR I-ADR
are O O
associated O O
with O O
streptokinase B-DRUG B-DRUG

discussion O O
: O O
patients O O
with O O
5-fu-induced O O
ectropion O B-ADR
experience O O
tender B-ADR O
, I-ADR O
red I-ADR O
, I-ADR O
scaled I-ADR O
lids I-ADR O
, O O
making O O
contact O O
lens O O
wear O O
difficult O O

laryngeal B-ADR B-ADR
dyspnea I-ADR I-ADR
in O O
relation O O
to O O
an O O
interaction O O
between O O
acenocoumarol B-DRUG B-DRUG
and O O
topical O O
econazole O B-DRUG
lotion O O

there O O
is O O
a O O
putative O O
role O O
of O O
liothyronine B-DRUG B-DRUG
administration O O
in O O
precipitating O O
or O O
activating O O
hyperthyroidism B-ADR B-ADR

she O O
was O O
placed O O
on O O
adjuvant O O
adriamycin B-DRUG B-DRUG
( O O
doxorubicin O O
) O O
chemotherapy O O
, O O
but O O
6 O O
months O O
later O O
died B-ADR O
of O O
adriamycin B-DRUG B-ADR
toxicity O I-ADR

a O O
22-year-old O O
black O O
man O O
developed O O
fever O O
, O O
chills B-ADR O
, O O
fatigue O O
, O O
night O O
sweats O O
, O O
tender O O
lymphadenopathy O O
, O O
and O O
a O O
generalized O O
, O O
pruritic O O
, O O
macular O B-ADR
eruption O I-ADR
3 O O
weeks O O
after O O
starting O O
minocycline B-DRUG B-DRUG
therapy O O
for O O
acne O O

after O O
discontinuing O O
captopril B-DRUG B-DRUG
and O O
starting O O
systemic O O
steroids O O
, O O
her O O
symptomatology O O
rapidly O O
improved O O
, O O
and O O
her O O
eosinophilia O O
and O O
radiographic B-ADR B-ADR
abnormalities I-ADR I-ADR
both O O
resolved O O

treatment O O
/ O O
outcome O O
: O O
standard O O
anti-tuberculosis O O
therapy O O
was O O
administered O O
but O O
was O O
complicated O O
by O O
interaction O O
with O O
cyclosporine B-DRUG B-DRUG
and O O
drug-induced O O
cholestasis B-ADR B-ADR

gemcitabine B-DRUG B-DRUG
therapy O O
has O O
been O O
associated O O
with O O
radiation B-ADR B-ADR
recall I-ADR I-ADR
reactions I-ADR I-ADR
when O O
used O O
in O O
the O O
treatment O O
of O O
carcinoma O O

cough B-ADR B-ADR
induced O O
by O O
quinapril B-DRUG B-DRUG
with O O
resolution O O
after O O
changing O O
to O O
fosinopril O B-DRUG

the O O
literature O O
search O O
revealed O O
22 O O
cases O O
of O O
hypersensitivity B-ADR B-ADR
reaction I-ADR I-ADR
to O O
cyclosporine B-DRUG B-DRUG

after O O
approximately O O
two O O
weeks O O
of O O
sertraline B-DRUG B-DRUG
treatment O O
he O O
noted O O
an O O
intense B-ADR O
itching I-ADR B-ADR
sensation I-ADR I-ADR
in O O
his O O
scalp O O
after O O
eating O O
a O O
piece O O
of O O
chocolate O B-DRUG
cake O I-DRUG

acute O B-ADR
renal B-ADR I-ADR
failure I-ADR I-ADR
should O O
be O O
recognized O O
as O O
a O O
potential O O
complication O O
of O O
suramin B-DRUG B-DRUG
treatment O O

this O O
case O O
of O O
linezolid-associated O O
acute B-ADR B-ADR
interstitial I-ADR I-ADR
nephritis I-ADR I-ADR
within O O
the O O
context O O
of O O
a O O
drug O O
rash O O
with O O
eosinophilia O O
and O O
systemic O O
symptoms O O
( O O
dress O O
) O O
syndrome O O
in O O
a O O
patient O O
treated O O
with O O
linezolid B-DRUG B-DRUG
raises O O
concerns O O
about O O
the O O
presumed O O
renal O O
safety O O
of O O
this O O
drug O O

divalproex B-DRUG B-DRUG
sodium-induced O O
eosinophilic B-ADR B-ADR
pleural I-ADR I-ADR
effusion I-ADR I-ADR

a O O
case O O
is O O
presented O O
of O O
a O O
patient O O
who O O
experienced O O
benzodiazepine B-ADR B-ADR
withdrawal I-ADR I-ADR
symptoms I-ADR I-ADR
on O O
discontinuation O O
of O O
nefazodone B-DRUG B-DRUG
, O O
an O O
antidepressant O O
that O O
inhibits O O
the O O
cytochrome O O
p450 O O
3a4 O O
isoenzyme O O

these O O
results O O
indicate O O
that O O
lithium B-DRUG B-DRUG
may O O
cause O O
biochemical B-ADR B-ADR
hyperparathyroidism I-ADR I-ADR

the O O
evidence O O
of O O
high O O
plasmatic O O
levels O O
of O O
cbz B-DRUG B-DRUG
and O O
the O O
absence O O
of O O
other O O
aetiologic O O
factors O O
lead O O
the O O
authors O O
to O O
conclude O O
that O O
the O O
overdose O O
of O O
cbz B-DRUG B-DRUG
could O O
have O O
represented O O
the O O
precipitating O O
of O O
the O O
episode O O
of O O
acute B-ADR B-ADR
pancreatitis I-ADR I-ADR

the O O
authors O O
report O O
the O O
first O O
case O O
of O O
bucillamine-induced O O
giant B-ADR B-ADR
mammary I-ADR I-ADR
hyperplasia I-ADR I-ADR

heparin-induced O O
thrombocytopenia B-ADR B-ADR
complicated O O
with O O
massive O O
thrombosis O B-ADR
of O I-ADR
the O I-ADR
inferior O I-ADR
vena O I-ADR
cava O I-ADR
after O O
filter O O
placement O O

while O O
both O O
amiodarone O B-DRUG
and O O
digoxin B-DRUG B-DRUG
can O O
cause O O
permanent O O
visual B-ADR O
changes I-ADR O
, O O
the O O
ocular O B-ADR
effects O I-ADR
are O O
often O O
reversible O O

we O O
report O O
an O O
unusual O O
case O O
of O O
simultaneous O O
transitional O O
cell O O
carcinoma O O
of O O
the O O
renal O O
pelvis O O
and O O
distal B-ADR O
ureter I-ADR O
without I-ADR O
transitional I-ADR O
cell I-ADR O
carcinoma I-ADR O
of I-ADR O
the I-ADR O
bladder I-ADR O
occurring O O
after O O
chronic O O
cyclophosphamide B-DRUG B-DRUG
therapy O O
for O O
nonhodgkin O O
's O O
lymphoma O O

aseptic O B-ADR
meningitis O I-ADR
, O O
hemolytic O O
anemia O O
, O O
hepatitis B-ADR O
, O O
and O O
orthostatic O B-ADR
hypotension O I-ADR
in O O
a O O
patient O O
treated O O
with O O
trimethoprim-sulfamethoxazole O B-DRUG

we O O
report O O
a O O
patient O O
with O O
pulmonary O O
adenocarcinoma O O
complicated O O
by O O
the O O
syndrome B-ADR O
of I-ADR O
inappropriate I-ADR O
secretion I-ADR O
of I-ADR O
antidiuretic I-ADR O
hormone I-ADR O
( O O
siadh O B-ADR
) O O
following O O
systemic O O
chemotherapy O O
with O O
cisplatin O O
( O O
cddp O O
) O O
and O O
vindesine B-DRUG O
( O O
vds O O

seizures B-ADR B-ADR
and O O
transient O B-ADR
blindness O I-ADR
following O O
intravenous O O
pulse O O
methylprednisolone B-DRUG B-DRUG
in O O
children O O
with O O
primary O O
glomerulonephritis O O

conclusion O O
: O O
all O O
doctors O O
need O O
to O O
be O O
aware O O
of O O
the O O
need O O
to O O
review O O
the O O
indications O O
for O O
gabapentin B-DRUG B-DRUG
use O O
during O O
periods O O
of O O
acute O O
illness O O
, O O
especially O O
with O O
regard O O
to O O
renal B-ADR B-ADR
impairment I-ADR I-ADR

mitomycin-c B-DRUG B-DRUG
induced O O
hemolytic B-ADR B-ADR
uremic I-ADR I-ADR
syndrome I-ADR I-ADR
: O O
a O O
case O O
report O O

a O O
patient O O
developed O O
optic B-ADR B-ADR
neuropathy I-ADR I-ADR
while O O
being O O
treated O O
with O O
isoniazid O B-DRUG
and O O
ethambutol B-DRUG B-DRUG

we O O
present O O
the O O
management O O
of O O
agranulocytosis O B-ADR
and O O
neutropenic B-ADR B-ADR
sepsis I-ADR I-ADR
secondary O O
to O O
carbimazole B-DRUG B-DRUG
with O O
recombinant O O
human O O
granulocyte O O
colony O O
stimulating O O
factor O O
( O O
g-csf O O

the O O
potential O O
role O O
of O O
propranolol B-DRUG B-DRUG
in O O
inducing O O
central B-ADR B-ADR
nervous I-ADR I-ADR
system I-ADR I-ADR
disturbances I-ADR I-ADR
is O O
emphasized O O
, O O
and O O
the O O
literature O O
on O O
the O O
subject O O
is O O
reviewed O O

sustained B-ADR O
monomorphic I-ADR B-ADR
ventricular I-ADR I-ADR
tachycardia I-ADR I-ADR
after O O
adenosine B-DRUG B-DRUG
infusion O O

we O O
report O O
two O O
cases O O
of O O
fulminant B-ADR B-ADR
hepatic I-ADR I-ADR
failure I-ADR I-ADR
in O O
hiv-1-infected O O
patients O O
treated O O
with O O
didanosine O B-DRUG
( O O
ddi B-DRUG B-DRUG

two O O
children O O
with O O
rheumatic O O
fever O O
developed O O
anicteric B-ADR B-ADR
hepatitis I-ADR I-ADR
while O O
on O O
high-dose O O
aspirin B-DRUG B-DRUG
therapy O O

long O O
lasting O O
respiratory B-ADR B-ADR
depression I-ADR I-ADR
induced O O
by O O
morphine-6-glucuronide B-DRUG B-DRUG

a O O
case O O
of O O
tuberculosis B-ADR B-ADR
in O O
a O O
patient O O
on O O
efalizumab B-DRUG B-DRUG
and O O
etanercept O B-DRUG
for O O
treatment O O
of O O
refractory O O
palmopustular O O
psoriasis O O
and O O
psoriatic O O
arthritis O O

pvt B-ADR O
during O O
chemotherapy O O
in O O
children O O
is O O
a O O
rare O O
event O O
and O O
appears O O
to O O
be O O
closely O O
related O O
to O O
intensive O O
chemotherapy O O
containing O O
busulfan B-DRUG B-DRUG
and O O
to O O
be O O
associated O O
with O O
hvod O B-DRUG

we O O
report O O
a O O
case O O
of O O
contact B-ADR B-ADR
dermatitis I-ADR I-ADR
due O O
to O O
sodium B-DRUG B-DRUG
bisulfite I-DRUG I-DRUG
in O O
tathion O O
eye O O
drops O O

dyspnea B-ADR O
, O O
hypoxemia O O
, O O
and O O
pleuritic O B-ADR
chest O I-ADR
pain O I-ADR
occurred O O
within O O
24 O O
hours O O
of O O
rituximab B-DRUG B-DRUG
administration O O
, O O
and O O
there O O
was O O
no O O
other O O
apparent O O
explanation O O

we O O
report O O
a O O
case O O
of O O
amiodarone-induced O O
thyrotoxicosis B-ADR B-ADR
of O O
protracted O O
duration O O
, O O
unresponsive O O
to O O
conventional O O
thionamide O B-DRUG
therapy O O
, O O
with O O
therapy O O
limited O O
by O O
severe O O
adverse O O
drug O O
reactions O O

evidence O O
obtained O O
indicated O O
that O O
the O O
reye-like O B-ADR
syndrome O I-ADR
might O O
be O O
caused O O
by O O
calcium B-DRUG B-DRUG
hopantenate I-DRUG I-DRUG
possibly O O
due O O
to O O
the O O
induction O O
of O O
pantothenic B-ADR B-DRUG
acid I-ADR I-DRUG
deficiency I-ADR O

we O O
report O O
an O O
unusual O O
case O O
of O O
simultaneous O O
transitional B-ADR O
cell I-ADR O
carcinoma I-ADR O
of I-ADR O
the I-ADR O
renal I-ADR O
pelvis I-ADR O
and O O
distal O O
ureter O O
without O O
transitional O O
cell O O
carcinoma O O
of O O
the O O
bladder O O
occurring O O
after O O
chronic O O
cyclophosphamide B-DRUG B-DRUG
therapy O O
for O O
nonhodgkin O O
's O O
lymphoma O O

lymphoma B-ADR B-ADR
developing O O
in O O
a O O
patient O O
with O O
rheumatoid O O
arthritis O O
taking O O
methotrexate B-DRUG B-DRUG

children O O
receiving O O
zonisamide B-DRUG B-DRUG
should O O
be O O
monitored O O
for O O
oligohidrosis B-ADR O
and O O
the O O
development O O
of O O
neurological O B-ADR
symptoms O I-ADR
associated O O
with O O
an O O
elevation O B-ADR
of O I-ADR
body O I-ADR
temperature O I-ADR

acute B-ADR B-ADR
acoustic I-ADR I-ADR
nerve I-ADR I-ADR
palsy I-ADR I-ADR
associated O O
with O O
vincristine B-DRUG B-DRUG
therapy O O

we O O
report O O
a O O
case O O
of O O
a O O
previously O O
healthy O O
, O O
postmenopausal O O
woman O O
who O O
developed O O
anticonvulsant B-ADR B-ADR
hypersensitivity I-ADR I-ADR
syndrome I-ADR I-ADR
while O O
taking O O
bellamine O O
s O O
( O O
belladonna O O
alkaloids O O
; O O
ergotamine O O
; O O
phenobarbital B-DRUG O
) O O
for O O
hot O O
flashes O O

transient B-ADR B-ADR
acute I-ADR I-ADR
myopia I-ADR I-ADR
resulting O O
from O O
isotretinoin B-DRUG B-DRUG
( O O
accutane O B-DRUG
) O O
therapy O O

introduction O O
: O O
although O O
gefitinib B-DRUG B-DRUG
used O O
for O O
the O O
treatment O O
of O O
non-small-cell O O
lung O O
cancer O O
is O O
a O O
well-known O O
cause O O
of O O
interstitial B-ADR O
lung I-ADR O
disease I-ADR O
( O O
ild O B-ADR
) O O
, O O
few O O
case O O
reports O O
on O O
erlotinib-induced O O
ild O B-ADR
have O O
been O O
issued O O

focal B-ADR B-ADR
glomerulonephritis I-ADR I-ADR
and O O
interstitial O B-ADR
nephritis O I-ADR
in O O
methicillin-treated O O
, O O
heroin-related O O
infective O B-ADR
endocarditis O I-ADR

this O O
report O O
presents O O
a O O
case O O
of O O
colon B-ADR B-ADR
perforation I-ADR I-ADR
which O O
occurred O O
4 O O
months O O
after O O
treatment O O
with O O
intraperitoneal O O
chromic B-DRUG B-DRUG
phosphate I-DRUG I-DRUG
for O O
stage O O
ib O O
ovarian O O
papillary O O
serous O O
cystadenocarcinoma O O

abrupt O O
, O O
accidental O O
withdrawal O O
of O O
trihexyphenidyl B-DRUG B-DRUG
triggered O O
severe O O
exacerbation O O
of O O
the O O
cranial B-ADR O
dystonia I-ADR O
associated O O
with O O
inspiratory O O
stridor O O
and O O
acute O O
respiratory O O
difficulties O O
, O O
prompting O O
emergency O O
admission O O

objective O O
: O O
to O O
study O O
therapy O O
with O O
indapamide B-DRUG B-DRUG
impairing O O
carbohydrate O O
metabolism O O
in O O
essential O O
hypertension O O
patients O O
and O O
achieve O O
earlier O O
prevention O O
, O O
diagnoses O O
and O O
treatment O O
of O O
diabetes B-ADR B-ADR
induced O O
by O O
indapamide B-DRUG B-DRUG

the O O
international O O
literature O O
regarding O O
opportunistic B-ADR B-ADR
infections I-ADR I-ADR
after O O
immunosuppressive O O
therapy O O
with O O
alemtuzumab B-DRUG B-DRUG
with O O
particular O O
attention O O
on O O
fungal O O
infections O O
has O O
also O O
been O O
reviewed O O

gemcitabine-induced O O
rectus B-ADR B-ADR
abdominus I-ADR I-ADR
radiation I-ADR I-ADR
recall I-ADR I-ADR

methylphenidate O O
( O O
ritalin B-DRUG O
)- O O
associated O O
cataract O O
and O O
glaucoma B-ADR O

treatment O O
with O O
infliximab B-DRUG B-DRUG
is O O
known O O
to O O
produce O O
an O O
increase B-ADR O
of I-ADR O
autoantibodies I-ADR O
( O O
antinuclear O O
antibodies O O
, O O
anti-double-stranded O O
dna O O
) O O
, O O
but O O
not O O
clinical O O
disease O O

we O O
observed O O
3 O O
diabetic O O
patients O O
with O O
intolerable O O
dizziness O O
followed O O
by O O
nausea O O
and O O
vomiting B-ADR O
immediately O O
after O O
an O O
initial O O
administration O O
of O O
the O O
alpha-glucosidase O O
inhibitor O O
, O O
voglibose B-DRUG B-DRUG

after O O
infliximab B-DRUG B-DRUG
treatment O O
, O O
additional O O
sleep O O
studies O O
revealed O O
an O O
increase B-ADR O
in I-ADR O
the I-ADR O
number I-ADR O
of I-ADR O
apneic I-ADR O
events I-ADR O
and O O
sao2 O O
dips O O
suggesting O O
that O O
tnfalpha O B-DRUG
plays O O
an O O
important O O
role O O
in O O
the O O
pathophysiology O O
of O O
sleep O B-ADR
apnea O I-ADR

overdose O O
of O O
magnesium B-DRUG B-DRUG
sulfate I-DRUG I-DRUG
in O O
combination O O
with O O
renal O O
insufficiency O O
, O O
hypocalcemia O O
, O O
or O O
compromise O O
of O O
intestinal O O
integrity O O
may O O
predispose O O
horses O O
to O O
magnesium B-ADR B-ADR
toxicosis I-ADR I-ADR

conclusion O O
: O O
zidovudine B-DRUG B-DRUG
is O O
well O O
a O O
known O O
cause O O
of O O
anaemia B-ADR O
and O O
thus O O
should O O
be O O
used O O
with O O
caution O O
in O O
the O O
initiation O O
of O O
antiretroviral O O
therapy O O

serious B-ADR O
adverse I-ADR O
events I-ADR O
experienced O O
by O O
patients O O
with O O
chronic O O
heart O O
failure O O
taking O O
spironolactone B-DRUG B-DRUG

cardiac B-ADR B-ADR
arrest I-ADR I-ADR
after O O
esmolol B-DRUG B-DRUG
administration O O
: O O
a O O
review O O
of O O
acute O B-ADR
beta-blocker O I-ADR
toxicity O I-ADR

thrombo-embolic B-ADR B-ADR
complication I-ADR I-ADR
after O O
streptokinase B-DRUG B-DRUG
therapy O O
of O O
pulmonary O O
emboli O O

the O O
association O O
of O O
central O O
diabetes O O
insipidus O O
( O O
cdi B-ADR O
) O O
with O O
lithium B-DRUG B-DRUG
use O O
is O O
rare O O

the O O
more O O
common O O
grade O O
3 O O
or O O
4 O O
adverse O O
effects O O
of O O
sunitinib B-DRUG B-DRUG
include O O
hypertension O O
, O O
fatigue O O
, O O
hand-foot O O
syndrome O O
, O O
elevated O O
lipase O O
and O O
lymphopenia B-ADR O

it O O
is O O
suggested O O
that O O
the O O
patient O O
had O O
sulfasalazine-induced O O
lupus O B-ADR
, O O
which O O
manifested O O
with O O
serositis O O
and O O
pulmonary B-ADR B-ADR
parenchymal I-ADR I-ADR
involvement I-ADR I-ADR
in O O
the O O
absence O O
of O O
joint O O
symptoms O O

herein O O
, O O
we O O
describe O O
a O O
patient O O
with O O
aids O O
who O O
presented O O
to O O
medical O O
attention O O
with O O
pancytopenia B-ADR B-ADR
48 O O
months O O
postchemotherapy O O
with O O
etoposide B-DRUG B-DRUG
, O O
prednisone O O
, O O
vincristine O O
, O O
cyclophosphamide O O
, O O
doxorubicin O O
, O O
and O O
rituximab O O
( O O
r-epoch O O
) O O
for O O
diffuse O O
large O O
b-cell O O
lymphoma O O

background O O
: O O
methotrexate B-DRUG B-DRUG
( O O
mtx O B-DRUG
) O O
may O O
induce O O
liver B-ADR O
damage I-ADR O
, O O
which O O
in O O
some O O
psoriatics O O
will O O
lead O O
to O O
fibrosis O O
or O O
cirrhosis O O

an O O
83-year-old O O
man O O
receiving O O
glipizide O O
10 O O
mg O O
bid O O
developed O O
symptomatic B-ADR B-ADR
hypoglycemia I-ADR I-ADR
within O O
three O O
days O O
of O O
adding O O
trimethoprim O O
/ O O
sulfamethoxazole O O
( O O
tmp O O
/ O O
smx B-DRUG O
) O O
to O O
his O O
regimen O O

the O O
literature O O
search O O
found O O
12 O O
cases O O
of O O
radiation B-ADR B-ADR
recall I-ADR I-ADR
caused O O
by O O
gemcitabine B-DRUG B-DRUG

six O O
patients O O
with O O
rheumatoid O O
arthritis O O
developed O O
a O O
syndrome O O
resembling O O
lupus B-ADR B-ADR
erythematosus I-ADR I-ADR
while O O
being O O
treated O O
with O O
penicillamine B-DRUG B-DRUG

we O O
report O O
a O O
case O O
of O O
chronic O O
use O O
of O O
hcq B-DRUG B-DRUG
associated O O
with O O
torsade B-ADR B-ADR
de I-ADR I-ADR
pointes I-ADR I-ADR

this O O
report O O
describes O O
a O O
probable O O
case O O
of O O
infliximab-induced O O
membranous B-ADR B-ADR
nephropathy I-ADR I-ADR

idiosyncratic O O
factors O O
involving O O
vasopressin B-DRUG O
receptor O O
affinity O O
and O O
distribution O O
, O O
vasopressin-associated O O
vasodilation O O
in O O
some O O
vascular O O
beds O O
, O O
and O O
the O O
effect O O
of O O
vasopressin B-DRUG B-DRUG
on O O
the O O
renin-angiotensin O O
system O O
may O O
further O O
contribute O O
to O O
impaired B-ADR B-ADR
tissue I-ADR I-ADR
perfusion I-ADR I-ADR

the O O
current O O
report O O
describes O O
a O O
man O O
who O O
was O O
prescribed O O
zonisamide B-DRUG B-DRUG
for O O
epilepsy O O
and O O
subsequently O O
developed O O
widespread O O
skin O O
rash O O
, O O
acute O O
kidney O O
injury O O
, O O
high-grade O O
fever O O
, O O
eosinophilia O O
, O O
liver B-ADR O
dysfunction I-ADR O
, O O
lymphadenopathy O O
and O O
an O O
increase O O
in O O
antihuman O O
herpesvirus-6 O O
immunoglobulin O O
g O O
titer O O

the O O
case O O
demonstrates O O
that O O
hypersensitivity B-ADR B-ADR
reaction I-ADR I-ADR
to O O
pranlukast B-DRUG B-DRUG
and O O
resultant O O
atin O O
is O O
possible O O
, O O
and O O
that O O
periodic O O
urine O O
testing O O
in O O
patients O O
receiving O O
pranlukast B-DRUG B-DRUG
should O O
be O O
considered O O

evaluation O O
revealed O O
elevated B-ADR B-ADR
serum I-ADR I-ADR
ltg I-ADR I-ADR
levels I-ADR I-ADR
and O O
no O O
other O O
etiology O O
for O O
encephalopathy O O

some O O
patients O O
develop O O
hypersensitivity B-ADR B-ADR
rash I-ADR I-ADR
in O O
response O O
to O O
hcq B-DRUG B-DRUG

no O O
cases O O
of O O
renal O B-ADR
acidosis O I-ADR
, O O
and O O
only O O
one O O
case O O
of O O
nephrogenic B-ADR B-ADR
diabetes I-ADR I-ADR
insipidus I-ADR I-ADR
, O O
has O O
been O O
previously O O
reported O O
as O O
a O O
complication O O
of O O
foscarnet B-DRUG B-DRUG
treatment O O

the O O
most O O
common O O
side O O
effects O O
associated O O
with O O
amifostine B-DRUG B-DRUG
are O O
nausea O O
, O O
vomiting O O
, O O
hypotension B-ADR O
, O O
hypocalcemia O O
and O O
allergic O B-ADR
reactions O I-ADR

conclusions O O
: O O
the O O
fundus O B-ADR
picture O I-ADR
shown O O
in O O
these O O
cases O O
may O O
be O O
typical O O
of O O
asppc B-ADR B-ADR
after O O
ivta B-DRUG B-DRUG
injection O O

a O O
case O O
of O O
propranolol B-DRUG B-DRUG
overdose O O
complicated O O
by O O
esophageal B-ADR O
spasm I-ADR O
preventing O O
extrication O O
of O O
an O O
orogastric O B-ADR
lavage O I-ADR
tube O I-ADR
and O O
relieved O O
by O O
intravenous O O
glucagon O B-DRUG
is O O
presented O O

purpose O O
: O O
to O O
describe O O
the O O
clinical O O
and O O
electrophysiological O O
findings O O
in O O
a O O
young O O
boy O O
with O O
decreased O B-ADR
vision O I-ADR
possibly O O
due O O
to O O
retinal B-ADR B-ADR
damage I-ADR I-ADR
by O O
rifabutin B-DRUG B-DRUG

recurrent O B-ADR
palmar-plantar B-ADR I-ADR
erythrodysaesthesia I-ADR I-ADR
following O O
high-dose O O
cytarabine B-DRUG B-DRUG
treatment O O
for O O
acute O O
lymphoblastic O O
leukemia O O

dyspnea B-ADR B-ADR
possibly O O
associated O O
with O O
controlled-release O O
morphine B-DRUG O
sulfate I-DRUG O
tablets O O

we O O
believe O O
that O O
these O O
skin B-ADR O
eruptions I-ADR O
belong O O
to O O
a O O
spectrum O O
of O O
neutrophilic O B-ADR
dermatoses O I-ADR
that O O
can O O
be O O
induced O O
or O O
aggravated O O
by O O
g-csf B-DRUG B-DRUG
therapy O O

gold-induced O O
pneumonitis B-ADR B-ADR
is O O
a O O
rare O O
complication O O
of O O
gold O B-DRUG
salt O O
therapy O O

clozapine-induced O O
eosinophilia B-ADR B-ADR
and O O
switch O O
to O O
quetiapine O B-DRUG
in O O
a O O
patient O O
with O O
chronic O O
schizophrenia O O
with O O
suicidal O O
tendencies O O

materials O O
and O O
methods O O
: O O
we O O
present O O
two O O
cases O O
of O O
significant O O
morbidity O O
related O O
to O O
primary B-ADR O
and I-ADR O
secondary I-ADR O
perforation I-ADR B-ADR
of I-ADR I-ADR
the I-ADR I-ADR
bladder I-ADR I-ADR
following O O
two O O
instillations O O
of O O
epirubicin B-DRUG B-DRUG

a O O
new O O
type O O
of O O
minocycline-induced O O
cutaneous B-ADR B-ADR
hyperpigmentation I-ADR I-ADR

prominent B-ADR O
eye I-ADR O
movements I-ADR O
during I-ADR O
nrem I-ADR O
sleep I-ADR O
and O O
rem O B-ADR
sleep O I-ADR
behavior O I-ADR
disorder O I-ADR
associated O O
with O O
fluoxetine B-DRUG B-DRUG
treatment O O
of O O
depression O O
and O O
obsessive-compulsive O O
disorder O O

we O O
suggest O O
that O O
nicotinic B-DRUG B-DRUG
acid I-DRUG I-DRUG
was O O
the O O
cause O O
of O O
his O O
liver O O
disease O O
, O O
that O O
this O O
case O O
is O O
of O O
particular O O
note O O
because O O
of O O
the O O
rather O O
short O O
period O O
of O O
therapy O O
before O O
the O O
onset O O
of O O
liver O O
injury O O
and O O
the O O
severity O O
of O O
the O O
hepatic O B-ADR
failure O I-ADR
, O O
and O O
that O O
the O O
probable O O
increased O O
use O O
of O O
nicotinic B-DRUG B-DRUG
acid I-DRUG I-DRUG
for O O
serum O O
cholesterol O O
control O O
makes O O
it O O
especially O O
important O O
for O O
physicians O O
and O O
their O O
patients O O
to O O
be O O
alert O O
to O O
the O O
signs O O
of O O
hepatotoxicity B-ADR B-ADR

acute B-ADR B-ADR
pancreatitis I-ADR I-ADR
in O O
a O O
child O O
with O O
idiopathic O O
ulcerative O O
colitis O O
on O O
long-term O O
5-aminosalicylic B-DRUG B-DRUG
acid I-DRUG I-DRUG
therapy O O

in O O
this O O
report O O
we O O
described O O
a O O
case O O
of O O
juvenile O O
idiopathic O O
arthritis O O
patient O O
who O O
developed O O
thymic B-ADR O
enlargement I-ADR O
( O O
true O O
thymic O O
hyperplasia O O
) O O
, O O
mediastinal O B-ADR
lymphadenopathy O I-ADR
and O O
pleurisy O O
associated O O
with O O
systemic O B-ADR
symptoms O I-ADR
under O O
etanercept B-DRUG B-DRUG
treatment O O

method O O
: O O
case O O
analysis O O
of O O
a O O
poly-drug O O
overdose O O
( O O
venlafaxine O O
, O O
topiramate O O
, O O
divalproex B-DRUG O
sodium I-DRUG O
, O O
risperidone O O
, O O
and O O
carbamazepine O O
) O O
presenting O O
with O O
mixed O O
ss B-ADR B-ADR
/ O O
nms O B-ADR
features O O
and O O
whose O O
clinical O O
management O O
suggests O O
a O O
practical O O
algorithm O O
for O O
treatment O O
of O O
undifferentiated O O
ss B-ADR B-ADR
/ O O
nms O B-ADR
in O O
critical O O
care O O
settings O O

multiple O B-ADR
myeloma O I-ADR
complicated O O
by O O
congestive B-ADR B-ADR
heart I-ADR I-ADR
failure I-ADR I-ADR
following O O
first O O
administration O O
of O O
recombinant B-DRUG B-DRUG
alpha-interferon I-DRUG I-DRUG

polymyoclonus B-ADR B-ADR
seizure I-ADR I-ADR
resulting O O
from O O
accidental O O
injection O O
of O O
tranexamic B-DRUG B-DRUG
acid I-DRUG I-DRUG
in O O
spinal O O
anesthesia O O

para-aminosalicylic B-DRUG O
acid-induced O O
hypoglycaemia B-ADR B-ADR
in O O
a O O
patient O O
with O O
diabetic O O
nephropathy O O

in O O
both O O
patients O O
the O O
rippling B-ADR B-ADR
phenomena I-ADR I-ADR
worsened I-ADR O
with O O
pyridostigmine B-DRUG B-DRUG
treatment O O
but O O
markedly O O
improved O O
after O O
immunosuppression O O
with O O
azathioprine O B-DRUG

after O O
therapy O O
with O O
parenteral O O
amiodarone B-DRUG B-DRUG
( O O
2300 O O
mg O O
in O O
3 O O
days O O
) O O
and O O
other O O
measures O O
, O O
signs O O
of O O
congestive O O
heart O O
failure O O
disappeared O O
; O O
subsequently O O
the O O
patient O O
developed O O
jaundice O O
, O O
marked B-ADR O
increase I-ADR O
in I-ADR O
serum I-ADR O
transaminase I-ADR O
levels I-ADR O
and O O
fall O O
in O O
prothrombin O O
time O O
, O O
and O O
histologic O O
changes O O
of O O
severe O B-ADR
centrilobular O I-ADR
necrosis O I-ADR
were O O
observed O O
in O O
hepatic O O
biopsy O O

when O O
sasp O B-DRUG
was O O
changed O O
to O O
5-aminosalicylic B-DRUG B-DRUG
acid I-DRUG I-DRUG
( O O
5-asa O O
) O O
, O O
his O O
skin O O
eruptions O O
were O O
resolved O O
, O O
however O O
, O O
he O O
developed O O
weakness O O
and O O
atrophy O O
in O O
his O O
right O O
arm O O
as O O
well O O
as O O
progressive O O
worsening O O
of O O
the O O
dysesthesia O O
in O O
his O O
legs O O
and O O
gait B-ADR O
disturbance I-ADR O

reye B-ADR B-ADR
syndrome I-ADR I-ADR
( O O
rs O B-ADR
) O O
is O O
believed O O
to O O
occur O O
infrequently O O
among O O
children O O
receiving O O
long-term O O
aspirin B-DRUG B-DRUG
therapy O O

purpose O O
: O O
to O O
report O O
patients O O
who O O
presented O O
to O O
the O O
oculoplastics O O
department O O
for O O
repair O O
of O O
cicatrical B-ADR B-ADR
entropion I-ADR I-ADR
after O O
topical O O
use O O
of O O
dipivefrin B-DRUG B-DRUG

in O O
this O O
case O O
senna B-DRUG B-DRUG
was O O
likely O O
the O O
cause O O
of O O
a O O
subacute B-ADR B-ADR
cholestatic I-ADR I-ADR
hepatitis I-ADR I-ADR
exemplifying O O
again O O
the O O
potential O O
role O O
of O O
herbal O O
related O O
liver O O
injury O O

the O O
patient O O
was O O
initially O O
treated O O
with O O
hydration O O
and O O
furosemide B-DRUG B-DRUG
but O O
developed O O
congestive B-ADR B-ADR
heart I-ADR I-ADR
failure I-ADR I-ADR

goiter O O
and O O
hypothyroidism O O
during O O
re-treatment O O
with O O
amiodarone B-DRUG B-DRUG
in O O
a O O
patient O O
who O O
previously O O
experienced O O
amiodarone-induced O O
thyrotoxicosis B-ADR B-ADR

uveitis B-ADR B-ADR
during O O
treatment O O
of O O
disseminated O O
mycobacterium O O
avium-intracellulare O O
complex O O
infection O O
with O O
the O O
combination O O
of O O
rifabutin O B-DRUG
, O O
clarithromycin B-DRUG O
and O O
ethambutol O B-DRUG

interstitial O B-ADR
pneumonitis O I-ADR
and O O
alveolar B-ADR B-ADR
hemorrhage I-ADR I-ADR
complicating O O
use O O
of O O
rituximab B-DRUG B-DRUG
: O O
case O O
report O O
and O O
review O O
of O O
the O O
literature O O

aluminum B-ADR B-ADR
intoxication I-ADR I-ADR
, O O
along O O
with O O
other O O
factors O O
, O O
was O O
considered O O
to O O
be O O
the O O
cause O O
of O O
tc O B-ADR
development O O

however O O
, O O
one O O
patient O O
exhibited O O
severe O O
hypersensitivity O O
reactions O O
including O O
cardiac O B-ADR
arrest O I-ADR
and O O
apnea O O
, O O
and O O
another O O
four O O
patients O O
developed O O
eruptions B-ADR O
, O O
hypotension O O
, O O
and O O
tachycardia O O
soon O O
after O O
administration O O
of O O
cbdca B-DRUG B-DRUG

disopyramide B-DRUG B-DRUG
( O O
norpace O B-DRUG
)- O O
induced O O
hypoglycemia B-ADR B-ADR

hypersensitivity O B-ADR
to O O
carboplatin B-DRUG B-DRUG
is O O
a O O
rare O O
but O O
real O O
complication O O
of O O
therapy O O
and O O
should O O
be O O
considered O O
in O O
patients O O
presenting O O
with O O
hyperacute B-ADR B-ADR
changes I-ADR I-ADR
on I-ADR O
ecg I-ADR O
whilst O O
receiving O O
carboplatin B-DRUG B-DRUG
therapy O O

ophthalmologic B-ADR B-ADR
and I-ADR I-ADR
neurologic I-ADR I-ADR
findings I-ADR I-ADR
in O O
two O O
children O O
exposed O O
to O O
vigabatrin B-DRUG B-DRUG
in O O
utero O O

eye B-ADR B-ADR
movement I-ADR I-ADR
disorders I-ADR I-ADR
in O O
bone O O
marrow O O
transplant O O
patients O O
on O O
cyclosporin O O
and O O
ganciclovir B-DRUG B-DRUG

conclusions O O
: O O
itraconazole-induced O O
liver O O
injury O O
presents O O
with O O
a O O
cholestatic B-ADR O
pattern I-ADR O
of I-ADR O
injury I-ADR O
with O O
damage O O
to O O
the O O
interlobular O O
bile O O
ducts O O
, O O
possibly O O
leading O O
to O O
ductopenia O B-ADR

three O O
years O O
later O O
, O O
treatment O O
with O O
ampicillin B-DRUG B-DRUG
caused O O
another O O
episode O O
of O O
cholestatic O B-ADR
hepatitis O I-ADR
with O O
cholestasis O O
and O O
duct B-ADR O
paucity I-ADR O
on O O
rebiopsy O O

lethal B-ADR B-ADR
anuria I-ADR I-ADR
complicating O O
high O O
dose O O
ifosfamide B-DRUG B-DRUG
chemotherapy O O
in O O
a O O
breast O O
cancer O O
patient O O
with O O
an O O
impaired O O
renal O O
function O O

we O O
introduce O O
a O O
case O O
of O O
a O O
sixty O O
years O O
old O O
woman O O
with O O
several O O
previous O O
episodes O O
of O O
rhinitis O O
, O O
conjunctivitis O O
and O O
perspiration B-ADR O
immediately O O
after O O
the O O
administration O O
of O O
salmon O B-DRUG
calcitonin O I-DRUG
with O O
nasal O O
spray O O
or O O
intramuscular O O
administration O O
( O O
calsynar B-DRUG B-DRUG

methods O O
: O O
two O O
patients O O
with O O
exudative O O
age-related B-ADR O
macular I-ADR O
degeneration I-ADR O
were O O
treated O O
sequentially O O
with O O
an O O
intravitreal O O
injection O O
of O O
bevacizumab B-DRUG B-DRUG
and O O
developed O O
signs O O
of O O
severe O O
but O O
painless O O
infectious O B-ADR
endophthalmitis O I-ADR
2 O O
days O O
later O O

hypoxemia O B-ADR
improved O O
during O O
continuous O O
tolazoline B-DRUG B-DRUG
infusion O O
, O O
but O O
gastrointestinal B-ADR B-ADR
bleeding I-ADR I-ADR
occurred O O

prolonged O O
responses O O
were O O
achieved O O
with O O
low O O
doses O O
of O O
hu B-DRUG B-DRUG
( O O
3-10 O O
mg O O
/ O O
kg O O
/ O O
day O O
) O O
and O O
higher O O
doses O O
were O O
associated O O
with O O
mild O O
reversible O O
hematologic O O
or O O
hepatic B-ADR B-ADR
toxicity I-ADR I-ADR
and O O
no O O
further O O
increases O O
in O O
hb O O

desipramine-associated O O
siadh B-ADR B-ADR
in O O
an O O
elderly O O
woman O O
: O O
case O O
report O O

the O O
clinical O O
course O O
suggested O O
that O O
recombinant B-DRUG O
alpha-2b I-DRUG O
peginterferon I-DRUG O
plus O O
ribavirin O B-DRUG
provoked O O
type B-ADR O
1 I-ADR O
diabetes I-ADR O
mellitus I-ADR O
, O O
therefore O O
, O O
in O O
patients O O
who O O
are O O
candidates O O
for O O
interferon O B-DRUG
therapy O O
the O O
presence O O
of O O
pancreatic O O
autoantibodies O O
and O O
the O O
fasting O O
plasma O O
glucose O O
level O O
should O O
be O O
investigated O O
before O O
and O O
during O O
treatment O O

a O O
case O O
of O O
siadh B-ADR B-ADR
associated O O
with O O
desipramine B-DRUG B-DRUG
treatment O O
in O O
an O O
elderly O O
depressed O O
woman O O
is O O
described O O

a O O
27-year-old O O
man O O
who O O
had O O
a O O
history O O
of O O
bronchial O O
asthma O O
, O O
eosinophilic O O
enteritis O O
, O O
and O O
eosinophilic O O
pneumonia O O
presented O O
with O O
fever O O
, O O
skin O O
eruptions O O
, O O
cervical O O
lymphadenopathy O O
, O O
hepatosplenomegaly B-ADR O
, O O
atypical O O
lymphocytosis O O
, O O
and O O
eosinophilia O O
two O O
weeks O O
after O O
receiving O O
trimethoprim O O
( O O
tmp B-DRUG O
)- O O
sulfamethoxazole O O
( O O
smx O O
) O O
treatment O O

this O O
report O O
describes O O
a O O
case O O
of O O
acute O O
compromise O O
of O O
renal O B-ADR
function O I-ADR
associated O O
with O O
hypotension B-ADR O
in O O
a O O
7-year-old O O
boy O O
treated O O
with O O
the O O
ace O O
inhibitor O O
lisinopril O B-DRUG
and O O
the O O
arb O O
losartan B-DRUG B-DRUG

thrombolytic O O
therapy O O
with O O
tissue B-DRUG B-DRUG
plasminogen I-DRUG I-DRUG
activator I-DRUG I-DRUG
( O O
tpa O B-DRUG
) O O
for O O
acute O O
myocardial O O
infarction O O
may O O
result O O
in O O
major O O
bleeding O O
complications O O
such O O
as O O
gastrointestinal B-ADR O
or I-ADR O
intracranial I-ADR B-ADR
bleeding I-ADR I-ADR

the O O
pulmonary O O
toxicity O O
of O O
gold B-DRUG B-DRUG
salts O O
is O O
an O O
uncommon O O
cause O O
of O O
life-threatening O O
respiratory B-ADR B-ADR
failure I-ADR I-ADR

a O O
27-year-old O O
man O O
who O O
had O O
a O O
history O O
of O O
bronchial O O
asthma O O
, O O
eosinophilic O O
enteritis O O
, O O
and O O
eosinophilic O O
pneumonia O O
presented O O
with O O
fever B-ADR O
, O O
skin O O
eruptions O O
, O O
cervical O O
lymphadenopathy O O
, O O
hepatosplenomegaly O O
, O O
atypical O O
lymphocytosis O O
, O O
and O O
eosinophilia O O
two O O
weeks O O
after O O
receiving O O
trimethoprim B-DRUG O
( O O
tmp O O
)- O O
sulfamethoxazole O O
( O O
smx O O
) O O
treatment O O

acute B-ADR B-ADR
vision I-ADR I-ADR
loss I-ADR I-ADR
after O O
intravitreal O O
injection O O
of O O
bevacizumab O B-DRUG
( O O
avastin B-DRUG B-DRUG
) O O
associated O O
with O O
ocular O B-ADR
ischemic O I-ADR
syndrome O I-ADR

pulmonary B-ADR B-ADR
hemorrhage I-ADR I-ADR
is O O
an O O
uncommon O O
feature O O
in O O
the O O
hus O O
, O O
and O O
seems O O
to O O
appear O O
especially O O
in O O
the O O
hus O B-ADR
associated O O
with O O
mmc B-DRUG B-DRUG
therapy O O

the O O
sulfonamides B-DRUG O
are O O
the O O
best O O
verified O O
drug-trigger O O
for O O
erythema B-ADR O
multiforme I-ADR O
and O O
stevens-johnson O B-ADR
syndrome O I-ADR

case O O
summaries O O
: O O
in O O
each O O
case O O
, O O
the O O
patients O O
were O O
treated O O
over O O
5 O O
years O O
with O O
lovastatin B-DRUG B-DRUG
and O O
developed O O
rhabdomyolysis B-ADR B-ADR
that O O
coincided O O
with O O
the O O
completion O O
of O O
a O O
prescribed O O
regimen O O
of O O
a O O
newer O O
macrolide O O
antibiotic O O

amphotericin O B-DRUG
b O I-DRUG
( O O
amb B-DRUG O
) O O
is O O
effective O O
, O O
but O O
its O O
use O O
is O O
limited O O
by O O
toxicity O O
: O O
renal O O
impairment O O
, O O
anaemia O O
, O O
fever O O
, O O
malaise O O
, O O
and O O
hypokalaemia B-ADR O
are O O
common O O

linear B-ADR O
immunoglobulin I-ADR B-DRUG
a I-ADR O
bullous I-ADR B-ADR
dermatosis I-ADR I-ADR
induced O O
by O O
gemcitabine B-DRUG B-DRUG

a O O
35-year-old O O
woman O O
presented O O
with O O
neurotoxicity B-ADR B-ADR
correlated O O
to O O
an O O
i.v. O O
regimen O O
of O O
5-fluorouracil B-DRUG B-DRUG
as O O
episodes O O
of O O
acute O O
confusional O O
state O O
and O O
abnormalities O O
of O O
symmetrically O O
restricted O O
diffusion O O
in O O
the O O
periventricular O O
white O O
matter O O
and O O
corpus O O
callosum O O

in O O
a O O
61-year-old O O
man O O
receiving O O
chronic O O
low-dosage O O
amiodarone B-DRUG B-DRUG
an O O
interstitial B-ADR B-ADR
pneumopathy I-ADR I-ADR
was O O
observed O O

heparin-associated O O
thrombocytopenia B-ADR B-ADR
: O O
successful O O
therapy O O
with O O
the O O
heparinoid O O
org O O
10172 O O
in O O
a O O
patient O O
showing O O
cross-reaction O O
to O O
lmw O B-ADR
heparins O I-ADR

the O O
day O O
after O O
methotrexate B-DRUG B-DRUG
administration O O
, O O
the O O
patient O O
complained O O
of O O
severe B-ADR B-ADR
back I-ADR I-ADR
pain I-ADR I-ADR
and O O
urinary O B-ADR
retention O I-ADR

radiation B-ADR B-ADR
recall I-ADR I-ADR
from O O
gemcitabine B-DRUG B-DRUG
is O O
rare O O
, O O
but O O
can O O
potentially O O
arise O O
in O O
any O O
site O O
that O O
has O O
been O O
previously O O
irradiated O O

after O O
therapy O O
for O O
diabetic O O
coma O O
with O O
insulin O O
( O O
containing O O
the O O
preservative O O
cresol B-DRUG O
) O O
and O O
electrolyte O O
solutions O O
was O O
started O O
, O O
the O O
patient O O
complained O O
of O O
increasing O O
myalgia O O
, O O
developed O O
a O O
high O O
fever O O
and O O
respiratory O O
and O O
metabolic O B-ADR
acidosis O I-ADR
and O O
lost B-ADR O
consciousness I-ADR O

a O O
dapsone B-DRUG B-DRUG
hypersensitivity O O
syndrome O O
, O O
consisting O O
of O O
fever B-ADR O
, O O
headache O O
, O O
nausea O O
, O O
vomiting O O
, O O
lymphadenopathy O O
, O O
hepatitis O O
, O O
hemolysis O O
, O O
leukopenia O O
, O O
and O O
mononucleosis O O
, O O
has O O
been O O
described O O
in O O
patients O O
treated O O
with O O
the O O
drug O O
for O O
leprosy O O

the O O
case O O
history O O
confirms O O
that O O
gold B-DRUG B-DRUG
treatment O O
, O O
even O O
in O O
the O O
same O O
patient O O
, O O
can O O
give O O
rise O O
to O O
a O O
wide O O
range O O
of O O
skin B-ADR B-ADR
disturbances I-ADR I-ADR
, O O
which O O
in O O
many O O
cases O O
do O O
not O O
break O O
out O O
until O O
long O O
after O O
the O O
drug O O
has O O
been O O
withdrawn O O

ischaemia B-ADR B-ADR
following O O
selfadministered O O
intra-arterial O O
injection O O
of O O
methylphenidate B-DRUG B-DRUG
and O O
diamorphine O B-DRUG

the O O
majority O O
of O O
radiation B-ADR B-ADR
recall I-ADR I-ADR
reactions I-ADR I-ADR
attributed O O
to O O
gemcitabine B-DRUG B-DRUG
are O O
reported O O
to O O
affect O O
internal O O
tissue O O
or O O
organs O O

objective O O
: O O
to O O
describe O O
onset O O
of O O
syndrome O O
of O O
inappropriate O O
antidiuretic O O
hormone O O
( O O
siadh B-ADR B-ADR
) O O
associated O O
with O O
vinorelbine B-DRUG B-DRUG
therapy O O
for O O
advanced O O
breast O O
cancer O O

painful O O
neutrophilic B-ADR B-ADR
skin I-ADR I-ADR
lesions I-ADR I-ADR
were O O
observed O O
in O O
two O O
children O O
receiving O O
granulocyte B-DRUG B-DRUG
colony-stimulating I-DRUG I-DRUG
factor I-DRUG I-DRUG
( O O
g-csf O O
) O O
for O O
treatment O O
of O O
idiopathic O O
neutropenia O O

transient B-ADR B-ADR
asymptomatic I-ADR I-ADR
bradycardia I-ADR I-ADR
in O O
patients O O
on O O
infusional O O
5-fluorouracil B-DRUG B-DRUG

hemodynamic B-ADR B-ADR
collapse I-ADR I-ADR
following O O
labetalol B-DRUG B-DRUG
administration O O
in O O
preeclampsia O O

we O O
report O O
the O O
case O O
of O O
a O O
patient O O
who O O
developed O O
polyserositis O O
( O O
pericardial O O
effusion O O
, O O
pleural B-ADR B-ADR
effusion I-ADR I-ADR
, O O
and O O
pericarditis O O
) O O
after O O
being O O
started O O
on O O
clozapine B-DRUG B-DRUG
, O O
and O O
whose O O
symptoms O O
remitted O O
upon O O
discontinuation O O
of O O
clozapine B-DRUG B-DRUG

we O O
report O O
a O O
patient O O
with O O
advanced O O
colonic O O
carcinoma O O
who O O
was O O
treated O O
with O O
concomitant O O
chemoirradiation O O
with O O
oxaliplatin B-DRUG B-DRUG
and O O
developed O O
a O O
peculiar O B-ADR
dermnatitis B-ADR I-ADR
in O O
the O O
irradiated O O
field O O
after O O
being O O
exposed O O
to O O
subsequent O O
chemotherapy O O
with O O
oxaliplatin B-DRUG B-DRUG

we O O
speculate O O
that O O
platelet O B-ADR
activation O I-ADR
induced O O
by O O
pfviii B-DRUG B-DRUG
may O O
have O O
contributed O O
to O O
thrombosis B-ADR O
and O O
suggest O O
that O O
pfviii B-DRUG B-DRUG
be O O
used O O
with O O
caution O O
in O O
elderly O O
patients O O
with O O
pre-existing O O
cardiovascular O O
risk O O
factors O O

we O O
report O O
a O O
cae O O
of O O
paranoid O B-ADR
psychosis O I-ADR
following O O
use O O
of O O
a O O
decongestant O O
containing O O
ppa B-DRUG B-DRUG
and O O
summarize O O
the O O
case O O
report O O
literature O O
of O O
psychiatric B-ADR B-ADR
adverse I-ADR I-ADR
effects I-ADR I-ADR
to O O
ppa B-DRUG B-DRUG
in O O
which O O
doses O O
were O O
known O O
and O O
stated O O
to O O
be O O
within O O
recommended O O
guidelines O O

findings O O
on O O
discontinuation O O
and O O
rechallenge O O
supported O O
the O O
assumption O O
that O O
the O O
hair B-ADR B-ADR
loss I-ADR I-ADR
was O O
a O O
side O O
effect O O
of O O
the O O
paroxetine B-DRUG B-DRUG

early O O
ritonavir-induced O O
maculopapular B-ADR B-ADR
eruption I-ADR I-ADR

two O O
cases O O
of O O
mequitazine-induced O O
photosensitivity B-ADR B-ADR
reactions I-ADR I-ADR

two O O
children O O
, O O
1 O O
with O O
idiopathic O O
nephrotic O O
syndrome O O
and O O
1 O O
with O O
endo-extracapillary O O
glomerulonephritis O O
, O O
presented O O
an O O
episode O O
of O O
seizures B-ADR O
and O O
transient O B-ADR
blindness O I-ADR
at O O
different O O
times O O
after O O
i.v. O O
pulse O O
methylprednisolone B-DRUG B-DRUG
( O O
ivpmp O B-DRUG
) O O
treatment O O

a O O
40-year-old O O
man O O
with O O
advanced O O
hiv O O
infection O O
and O O
mycobacterium O O
avium O O
complex O O
infection O O
experienced O O
rapid B-ADR O
cognitive I-ADR B-ADR
decline I-ADR I-ADR
after O O
commencement O O
of O O
ethambutol B-DRUG B-DRUG
, O O
and O O
symptoms O O
fully O O
resolved O O
with O O
cessation O O

subacute B-ADR B-ADR
cholestatic I-ADR I-ADR
hepatitis I-ADR I-ADR
likely O O
related O O
to O O
the O O
use O O
of O O
senna B-DRUG B-DRUG
for O O
chronic O O
constipation O O

this O O
case O O
demonstrates O O
an O O
occupational O O
activity O O
( O O
construction O O
) O O
that O O
has O O
now O O
become O O
the O O
dominant O O
source O O
of O O
lead B-DRUG O
exposure O O
for O O
u.s. O O
adults O O
, O O
the O O
importance O O
of O O
a O O
good O O
occupational O O
history O O
to O O
suspecting O O
and O O
making O O
a O O
diagnosis O O
, O O
the O O
possible O O
outcomes O O
of O O
chronic O B-ADR
lead B-ADR I-ADR
toxicity I-ADR I-ADR
, O O
and O O
the O O
importance O O
of O O
preventing O O
further O O
exposure O O
and O O
using O O
proper O O
methods O O
to O O
treat O O
acute O B-ADR
toxicity O I-ADR

our O O
patient O O
had O O
headache O O
, O O
mild O O
fever O O
, O O
nausea O O
, O O
vomiting O O
, O O
rash B-ADR O
, O O
and O O
eosinophilia O O
after O O
3 O O
weeks O O
of O O
disulfiram B-DRUG B-DRUG
therapy O O

we O O
report O O
a O O
case O O
of O O
hypoglycaemia B-ADR B-ADR
after O O
mefloquine B-DRUG B-DRUG
therapy O O
( O O
1,500 O O
mg O O
over O O
two O O
days O O
) O O
for O O
severe O B-ADR
gastrointestinal O I-ADR
cryptosporidiasis O I-ADR
in O O
a O O
cachectic O O
aids O O
patient O O
with O O
protracted O O
diarrhoea O O

in O O
addition O O
, O O
a O O
31-year-old O O
man O O
with O O
obsessive-compulsive O O
disorder O O
developed O O
rbd B-ADR B-ADR
soon O O
after O O
starting O O
fluoxetine B-DRUG B-DRUG
therapy O O
, O O
which O O
persisted O O
at O O
psg O O
study O O
19 O O
months O O
after O O
fluoxetine B-DRUG B-DRUG
discontinuation O O

ptosis B-ADR B-ADR
occurring O O
24 O O
h O O
after O O
chloroquine B-DRUG B-DRUG
therapy O O
, O O
with O O
full O O
recovery O O
48 O O
h O O
after O O
cessation O O
of O O
chloroquine B-DRUG B-DRUG
, O O
has O O
not O O
been O O
described O O
previously O O

we O O
describe O O
two O O
dark-skinned O O
patients O O
who O O
developed O O
hyperpigmented B-ADR O
skin I-ADR O
and O O
tongue O B-ADR
lesions O I-ADR
during O O
combination O O
therapy O O
with O O
ifn B-DRUG B-DRUG
and O O
ribavirin O B-DRUG

propoxyphene-induced O O
wide B-ADR O
complex I-ADR O
dysrhythmia I-ADR O
responsive O O
to O O
sodium O B-DRUG
bicarbonate O I-DRUG
therapy O O
has O O
not O O
been O O
previously O O
reported O O
in O O
the O O
literature O O

protease O O
inhibitors O O
( O O
ritonavir O O
and O O
saquinavir O B-DRUG
) O O
were O O
added O O
to O O
the O O
treatment O O
and O O
the O O
patient O O
developed O O
progressive B-ADR B-ADR
ataxia I-ADR I-ADR
related O O
to O O
carbamazepine B-DRUG B-ADR
toxicity O I-ADR

conclusions O O
: O O
clinicians O O
treating O O
elderly O O
patients O O
with O O
olanzapine B-DRUG B-DRUG
should O O
be O O
aware O O
of O O
the O O
potential O O
for O O
rapidly O O
developing O O
hyperglycemia B-ADR O
and O O
monitor O O
such O O
patients O O
accordingly O O

since O O
amiodarone B-DRUG B-DRUG
was O O
first O O
marketed O O
in O O
1992 O O
in O O
japan O O
, O O
the O O
incidence O O
of O O
amiodarone-induced O O
thyrotoxicosis B-ADR B-ADR
( O O
ait O B-ADR
) O O
has O O
been O O
increasing O O

herein O O
is O O
reported O O
an O O
unusual O O
case O O
of O O
coexistent O O
warfarin-induced O O
skin O B-ADR
necrosis O I-ADR
and O O
heparin-induced O O
thrombocytopenia B-ADR B-ADR
following O O
mitral O O
valve O O
replacement O O
for O O
thromboembolic O O
phenomena O O
associated O O
with O O
marantic O O
endocarditis O O
and O O
bronchial O B-ADR
adenocarcinoma O I-ADR

less O O
common O O
adverse O O
events O O
to O O
dapsone B-DRUG B-DRUG
include O O
the O O
idiosyncratic O O
reactions O O
of O O
leukopenia O O
and O O
agranulocytosis O O
, O O
cutaneous O O
eruptions O O
, O O
peripheral O O
neuropathy O O
, O O
psychosis O O
, O O
toxic O O
hepatitis O O
, O O
cholestatic O O
jaundice O O
, O O
nephrotic B-ADR O
syndrome I-ADR O
, O O
renal O O
papillary O O
necrosis O O
, O O
severe O O
hypoalbuminemia O O
without O O
proteinuria O O
, O O
an O O
infectious O O
mononucleosis-like O O
syndrome O O
, O O
and O O
minor O O
neurological O O
and O O
gastrointestinal O O
complaints O O

zolpidem B-DRUG B-DRUG
tissue O B-ADR
concentrations O I-ADR
in O O
a O O
multiple O O
drug O O
related O O
death B-ADR B-ADR
involving O O
ambien O B-DRUG

development O O
of O O
crohn B-ADR B-ADR
's I-ADR I-ADR
disease I-ADR I-ADR
in O O
a O O
patient O O
with O O
multiple O O
sclerosis O O
treated O O
with O O
copaxone B-DRUG B-DRUG

muscle O O
biopsy O O
revealed O O
variation O O
in O O
muscle O O
fiber O O
size O O
and O O
few O O
vacuolated O O
fibers O O
which O O
were O O
features O O
of O O
colchicine-induced O O
myopathy B-ADR B-ADR

hyponatremia B-ADR B-ADR
in O O
patients O O
treated O O
with O O
lorcainide B-DRUG B-DRUG
, O O
a O O
new O O
antiarrhythmic O O
drug O O

the O O
risk O O
of O O
cardiac B-ADR B-ADR
decompensation I-ADR I-ADR
in O O
infants O O
with O O
supraventricular O O
tachycardia O O
and O O
congestive O B-ADR
cardiac O I-ADR
failure O I-ADR
should O O
be O O
kept O O
in O O
mind O O
prior O O
to O O
administration O O
of O O
verapamil B-DRUG B-DRUG

acute B-ADR O
pulmonary I-ADR O
reactions I-ADR O
to O O
nitrofurantoin B-DRUG B-DRUG
are O O
an O O
uncommon O O
side O O
effect O O
of O O
therapy O O
and O O
can O O
cause O O
minor O O
or O O
life-threatening O O
pulmonary O B-ADR
dysfunction O I-ADR

presently O O
, O O
treatment O O
of O O
acute O O
ibuprofen B-ADR B-DRUG
intoxication I-ADR O
with O O
complications O O
requires O O
supportive O O
therapy O O
until O O
the O O
symptoms O O
resolve O O
over O O
24 O O
to O O
48 O O
hours O O

objective O O
: O O
to O O
report O O
two O O
cases O O
of O O
fixed B-ADR B-ADR
drug I-ADR I-ADR
eruption I-ADR I-ADR
induced O O
by O O
methylphenidate B-DRUG B-DRUG

intravitreal O O
triamcinolone B-DRUG B-DRUG
may O O
have O O
had O O
an O O
influence O O
on O O
the O O
exacerbation B-ADR O
of I-ADR O
retinochoroiditis I-ADR B-ADR
in O O
the O O
posterior O O
pole O O
of O O
the O O
patient O O

ticlopidine-induced O O
aplastic B-ADR B-ADR
anemia I-ADR I-ADR
( O O
tiaa O B-ADR
) O O
is O O
considered O O
very O O
uncommon O O

erythromycin O B-DRUG
is O O
a O O
macrolide O O
antibiotic O O
that O O
may O O
increase O O
the O O
risk O O
of O O
lovastatin-induced O O
rhabdomyolysis B-ADR B-ADR

in O O
patients O O
with O O
a O O
known O O
access O O
to O O
inh B-DRUG B-DRUG
, O O
seizures B-ADR B-ADR
should O O
be O O
considered O O
to O O
be O O
caused O O
by O O
inh B-DRUG B-DRUG
toxicity O O
unless O O
proved O O
otherwise O O

anaphylaxis B-ADR B-ADR
from O O
isoniazid B-DRUG B-DRUG
is O O
a O O
possible O O
side O O
effect O O
to O O
this O O
commonly O O
prescribed O O
antibiotic O O

case O O
3 O O
: O O
a O O
29-year-old O O
female O O
alcoholic O O
complained O O
of O O
general O O
fatigue B-ADR O
and O O
a O O
slight O B-ADR
fever O I-ADR
after O O
1.5 O O
years O O
of O O
abstinence O O
with O O
cyanamide B-DRUG B-DRUG
treatment O O

the O O
diagnosis O O
was O O
based O O
on O O
the O O
rapid O O
onset O O
of O O
renal B-ADR O
failure I-ADR O
, O O
presence O O
of O O
eosinophilia O O
, O O
skin O O
rash O O
, O O
and O O
characteristic O O
renal O O
biopsy O O
finding O O
, O O
following O O
the O O
administration O O
of O O
ampicillin B-DRUG B-DRUG

these O O
findings O O
are O O
consistent O O
with O O
an O O
immune-complex O O
form O O
of O O
glomerulopathy O B-ADR
in O O
which O O
gold B-DRUG B-DRUG
is O O
neither O O
the O O
antigen O O
nor O O
a O O
hapten O O
in O O
the O O
glomerular O O
deposits O O
, O O
and O O
they O O
suggest O O
the O O
hypothesis O O
that O O
antibodies O O
to O O
tubular O O
epithelial O O
antigens O O
induced O O
by O O
gold B-DRUG B-DRUG
therapy O O
may O O
be O O
a O O
causative O O
factor O O
in O O
the O O
renal B-ADR B-ADR
disease I-ADR I-ADR
associated O O
with O O
gold B-DRUG B-DRUG
therapy O O
in O O
rheumatoid O O
arthritis O O

this O O
case O O
illustrates O O
the O O
potential O O
decoupling B-ADR B-ADR
of I-ADR I-ADR
psa I-ADR I-ADR
response I-ADR I-ADR
from O O
disease O B-ADR
status O I-ADR
in O O
flutamide B-DRUG B-DRUG
withdrawal O O

gemcitabine-related O O
radiation B-ADR B-ADR
recall I-ADR I-ADR
in O O
a O O
patient O O
with O O
pancreatic O O
cancer O O

however O O
, O O
one O O
patient O O
exhibited O O
severe B-ADR O
hypersensitivity I-ADR O
reactions I-ADR O
including O O
cardiac O B-ADR
arrest O I-ADR
and O O
apnea O O
, O O
and O O
another O O
four O O
patients O O
developed O O
eruptions O O
, O O
hypotension O O
, O O
and O O
tachycardia O O
soon O O
after O O
administration O O
of O O
cbdca B-DRUG B-DRUG

conclusions O O
: O O
topiramate B-DRUG B-DRUG
may O O
be O O
associated O O
with O O
ciliochoroidal O B-ADR
effusion O I-ADR
with O O
forward O O
displacement B-ADR O
of I-ADR O
the I-ADR O
lens-iris I-ADR O
diaphragm I-ADR O
and O O
anterior O O
chamber O O
shallowing O O
, O O
resulting O O
in O O
acute O O
myopia O O
and O O
angle-closure O B-ADR
glaucoma O I-ADR

to O O
our O O
knowledge O O
, O O
our O O
report O O
is O O
one O O
of O O
the O O
first O O
on O O
shock B-ADR O
and O O
angio-oedema O B-ADR
from O O
irbesartan B-DRUG B-DRUG

conclusions O O
: O O
priapism B-ADR B-ADR
is O O
an O O
uncommon O O
but O O
potentially O O
serious O O
adverse O O
effect O O
of O O
zuclopenthixol B-DRUG B-DRUG
that O O
practitioners O O
, O O
as O O
with O O
many O O
other O O
antipsychotics O O
, O O
should O O
be O O
aware O O
of O O

this O O
case O O
of O O
linezolid-associated O O
acute O B-ADR
interstitial O I-ADR
nephritis O I-ADR
within O O
the O O
context O O
of O O
a O O
drug O O
rash O O
with O O
eosinophilia O O
and O O
systemic O O
symptoms O O
( O O
dress B-ADR O
) O O
syndrome O O
in O O
a O O
patient O O
treated O O
with O O
linezolid B-DRUG B-DRUG
raises O O
concerns O O
about O O
the O O
presumed O O
renal O O
safety O O
of O O
this O O
drug O O

our O O
findings O O
suggest O O
that O O
hyperkalemia B-ADR B-ADR
can O O
develop O O
with O O
the O O
use O O
of O O
low-dose O O
heparin B-DRUG B-DRUG
, O O
within O O
seven O O
days O O
of O O
initiating O O
heparin B-DRUG B-DRUG
therapy O O
, O O
and O O
that O O
patients O O
with O O
diabetes O O
mellitus O O
or O O
chronic O O
renal O O
insufficiency O O
are O O
especially O O
predisposed O O
to O O
this O O
complication O O

because O O
of O O
a O O
hypersensitivity B-ADR B-ADR
reaction I-ADR I-ADR
, O O
initial O O
therapy O O
with O O
penicillin O O
g O O
and O O
gentamicin B-DRUG B-DRUG
was O O
stopped O O
and O O
substituted O O
with O O
cefazolin O B-DRUG

such O O
a O O
case O O
induced O O
by O O
hypothyroidism B-ADR B-ADR
complicating O O
long-term O O
therapy O O
with O O
amiodarone B-DRUG B-DRUG
in O O
a O O
45 O O
year O O
old O O
woman O O
with O O
pre-excitation O O
is O O
presented O O

idiosyncratic B-ADR O
pulmonary I-ADR O
reactions I-ADR O
to O O
nitrofurantoin B-DRUG B-DRUG
are O O
not O O
unusual O O
, O O
often O O
presenting O O
as O O
eosinophilic O B-ADR
pneumonia O I-ADR

two O O
65-year-old O O
white O O
men O O
with O O
coronary O O
heart O O
disease O O
, O O
given O O
niacin B-DRUG B-DRUG
therapy O O
for O O
dyslipidemia O O
for O O
5 O O
months O O
, O O
developed O O
intense B-ADR O
dental I-ADR O
and I-ADR O
gingival I-ADR B-ADR
pain I-ADR I-ADR
that O O
was O O
associated O O
with O O
increases O O
in O O
dose O O
and O O
that O O
was O O
relieved O O
with O O
discontinuance O O
of O O
niacin B-DRUG B-DRUG
treatment O O

magnesium B-ADR B-ADR
toxicosis I-ADR I-ADR
in O O
two O O
horses O O

hypokalemia B-ADR B-ADR
after O O
normal O O
doses O O
of O O
neubulized O O
albuterol B-DRUG O
( O O
salbutamol O B-DRUG

in O O
this O O
report O O
we O O
present O O
four O O
patients O O
treated O O
with O O
a O O
combination O O
of O O
different O O
psychotropic O O
drugs O O
, O O
in O O
whom O O
asterixis B-ADR B-ADR
was O O
triggered O O
either O O
by O O
adding O O
carbamazepine O B-DRUG
( O O
cbz B-DRUG B-DRUG
) O O
to O O
a O O
treatment O O
regimen O O
, O O
or O O
by O O
increasing O O
its O O
dosage O O

the O O
toxic O O
effects O O
of O O
methotrexate B-DRUG B-DRUG
included O O
elevated O O
liver O O
transaminases O O
( O O
3 O O
/ O O
4 O O
) O O
, O O
nausea O O
( O O
2 O O
/ O O
4 O O
) O O
, O O
abdominal B-ADR O
pain I-ADR O
( O O
2 O O
/ O O
4 O O
) O O
, O O
bone O O
pain O O
( O O
2 O O
/ O O
4 O O
) O O
, O O
mild O O
neutropenia O O
( O O
1 O O
/ O O
4 O O
) O O
, O O
and O O
mild O O
pruritus O O
( O O
1 O O
/ O O
4 O O

purpose O O
: O O
to O O
report O O
a O O
case O O
of O O
severe O O
corticosteroid-induced O O
glaucoma B-ADR B-ADR
after O O
intravitreal O O
injection O O
of O O
triamcinolone O B-DRUG
acetate O I-DRUG
in O O
a O O
34-year-old O O
man O O
without O O
a O O
history O O
of O O
glaucoma B-ADR O

severe O O
sulfadiazine B-DRUG B-DRUG
hypersensitivity B-ADR O
in O O
a O O
child O O
with O O
reactivated O O
congenital O B-ADR
toxoplasmic O I-ADR
chorioretinitis O I-ADR

glomerulonephritis B-ADR B-ADR
in O O
procainamide B-DRUG B-DRUG
induced O O
lupus O B-ADR
erythematosus O I-ADR
: O O
report O O
of O O
a O O
case O O
and O O
review O O
of O O
the O O
literature O O

to O O
our O O
knowledge O O
, O O
drug-induced O O
fever B-ADR B-ADR
has O O
not O O
been O O
reported O O
with O O
the O O
use O O
of O O
diltiazem B-DRUG B-DRUG
hydrochloride I-DRUG I-DRUG
, O O
a O O
commonly O O
prescribed O O
calcium O O
channel O O
blocker O O

a O O
review O O
of O O
the O O
literature O O
found O O
11 O O
children O O
and O O
2 O O
adults O O
in O O
whom O O
intranasal O O
desmopressin B-DRUG B-DRUG
was O O
associated O O
with O O
hyponatremia O O
, O O
all O O
of O O
whom O O
experienced O O
seizures B-ADR O
or O O
altered O O
mental O B-ADR
status O I-ADR

initial O O
treatment O O
with O O
heparin B-DRUG B-DRUG
was O O
substituted O O
with O O
thrombolysis O O
, O O
which O O
resulted O O
in O O
clinical O O
improvement O O
and O O
dissolution O O
of O O
right O B-ADR
heart O I-ADR
thrombus O I-ADR
but O O
was O O
followed O O
by O O
fatal B-ADR O
intracerebral I-ADR O
haemorrhage I-ADR O

the O O
case O O
history O O
and O O
toxicological O O
findings O O
of O O
an O O
infant O O
fatality B-ADR O
involving O O
pseudoephedrine O O
, O O
brompheniramine B-DRUG O
, O O
and O O
dextromethorphan O B-DRUG
are O O
presented O O

the O O
toxic O O
effects O O
of O O
methotrexate B-DRUG B-DRUG
included O O
elevated O O
liver O O
transaminases O O
( O O
3 O O
/ O O
4 O O
) O O
, O O
nausea O O
( O O
2 O O
/ O O
4 O O
) O O
, O O
abdominal O O
pain O O
( O O
2 O O
/ O O
4 O O
) O O
, O O
bone O O
pain O O
( O O
2 O O
/ O O
4 O O
) O O
, O O
mild O O
neutropenia O O
( O O
1 O O
/ O O
4 O O
) O O
, O O
and O O
mild B-ADR O
pruritus I-ADR O
( O O
1 O O
/ O O
4 O O

the O O
authors O O
describe O O
a O O
case O O
of O O
combined O O
lithium O B-DRUG
and O O
haloperidol B-DRUG B-DRUG
toxicity O O
characterized O O
by O O
hyperpyrexia O O
, O O
severe B-ADR O
rigidity I-ADR O
, O O
mutism O O
, O O
and O O
development O O
of O O
irreversible O B-ADR
tardive O I-ADR
dyskinesia O I-ADR

case O O
description O O
: O O
a O O
59-year-old O O
man O O
with O O
known O O
neurocysticercosis O O
developed O O
a O O
large B-ADR O
cerebral I-ADR B-ADR
infarction I-ADR I-ADR
during O O
praziquantel B-DRUG B-DRUG
therapy O O

the O O
electrocardiogram O O
( O O
ecg O O
) O O
, O O
which O O
was O O
read O O
as O O
normal O O
prior O O
to O O
ritodrine B-DRUG B-DRUG
infusion O O
, O O
demonstrated O O
a O O
type B-ADR B-ADR
i I-ADR I-ADR
second-degree I-ADR I-ADR
av I-ADR I-ADR
block I-ADR I-ADR
which O O
disappeared O O
upon O O
discontinuation O O
of O O
ritodrine B-DRUG B-DRUG
therapy O O

mefloquine-associated O O
hypoglycaemia B-ADR B-ADR
in O O
a O O
cachectic O O
aids O O
patient O O

arterial B-ADR B-ADR
hypertension I-ADR I-ADR
associated O O
with O O
topical O O
ocular O O
use O O
of O O
phenylephrine B-DRUG B-DRUG
in O O
dogs O O

thrombocytosis B-ADR B-ADR
under O O
ciprofloxacin O O
and O O
tazobactam B-DRUG O
/ O O
piperacillin O B-DRUG

gabapentin-induced O O
mood B-ADR B-ADR
changes I-ADR I-ADR
with O O
hypomanic O B-ADR
features O I-ADR
in O O
adults O O

we O O
report O O
the O O
case O O
histories O O
of O O
identical O O
twin O O
brothers O O
who O O
developed O O
concordant O O
acute O B-ADR
lymphoblastic O I-ADR
leukemia O I-ADR
at O O
the O O
age O O
of O O
4 O O
years O O
and O O
who O O
later O O
developed O O
leukoencephalopathy O O
and O O
hydrocephalus B-ADR O
related O O
to O O
central O O
nervous O O
system O O
prophylaxis O O
by O O
, O O
in O O
the O O
first O O
case O O
intrathecally O O
administered O O
methotrexate B-DRUG B-DRUG
and O O
, O O
in O O
the O O
second O O
by O O
intrathecally O O
administered O O
methotrexate B-DRUG B-DRUG
and O O
cranial O O
irradiation O O

we O O
describe O O
a O O
case O O
of O O
poisoning B-ADR O
with O O
3,4-methylenedioxymet-amphetamine B-DRUG B-DRUG
ecstasy I-DRUG I-DRUG
that O O
presented O O
with O O
all O O
the O O
features O O
suggestive O O
of O O
a O O
fatal O O
outcome O O
, O O
including O O
a O O
creatinine O O
phosphokinase O O
level O O
markedly O O
higher O O
than O O
any O O
previously O O
reported O O

we O O
report O O
a O O
case O O
of O O
stevens-johnson O O
syndrome O O
/ O O
toxic B-ADR O
epidermal I-ADR O
necrolysis I-ADR O
( O O
sjs O O
/ O O
ten O O
) O O
secondary O O
to O O
trimethoprim-sulfamethoxazole B-DRUG O
( O O
tmp-sx O B-DRUG
) O O
therapy O O
for O O
presumed O O
community-associated O O
methicillin-resistant O O
staphylococcus O O
aureus O O
( O O
ca-mrsa O O
) O O
infection O O

in O O
this O O
healthy O O
population O O
, O O
the O O
relative O O
risk O O
of O O
developing O O
endometrial B-ADR B-ADR
carcinoma I-ADR I-ADR
in O O
the O O
tamoxifen B-DRUG B-DRUG
arm O O
was O O
2.54 O O
, O O
although O O
when O O
stratified O O
by O O
age O O
, O O
in O O
women O O
over O O
50 O O
, O O
the O O
risk O O
grew O O
to O O
4.01 O O

he O O
had O O
been O O
taking O O
trimethoprim-sulfamethoxazole O B-DRUG
for O O
approximately O O
eight O O
days O O
when O O
he O O
revisited O O
his O O
family O O
physician O O
, O O
complaining O O
of O O
headaches O O
, O O
dizziness B-ADR O
, O O
difficulty O O
with O O
speech O O
, O O
weakness O O
, O O
and O O
itching O O
on O O
the O O
trunk O O
of O O
his O O
body O O
and O O
legs O O
, O O
where O O
a O O
maculopapular O B-ADR
rash O I-ADR
was O O
noted O O

easily O O
reversible O O
hypoxemia B-ADR O
and O O
hypotension O O
induced O O
by O O
nimodipine B-DRUG B-DRUG

she O O
was O O
administered O O
metoclopramide B-DRUG B-DRUG
because O O
of O O
nausea O O
and O O
, O O
within O O
2 O O
hours O O
, O O
developed O O
agitation O O
, O O
dysarthria O O
, O O
diaphoresis O O
, O O
and O O
a O O
movement B-ADR O
disorder I-ADR O

the O O
psychotic B-ADR B-ADR
behavior I-ADR I-ADR
resolved O O
completely O O
soon O O
after O O
the O O
discontinuation O O
of O O
levetiracetam B-DRUG B-DRUG

soon O O
after O O
introduction O O
of O O
insulin B-DRUG B-DRUG
therapy O O
, O O
she O O
developed O O
severe O O
anasarca O B-DRUG
, O O
including O O
marked O O
peripheral O O
oedema O O
, O O
ascites B-ADR O
and O O
pleural O B-ADR
effusion O I-ADR

a O O
child O O
in O O
whom O O
a O O
phenobarbital B-DRUG B-DRUG
hypersensitivity O O
drug O O
reaction O O
developed O O
which O O
consisted O O
of O O
fever O O
, O O
a O O
pruritic O B-ADR
desquamating O I-ADR
erythrodermic O I-ADR
rash O I-ADR
, O O
alopecia B-ADR O
, O O
icterus O O
, O O
protein-losing O O
enteropathy O O
, O O
myositis O O
, O O
and O O
nephritis O O
, O O
is O O
described O O

zolpidem B-DRUG O
( O O
ambien O B-DRUG
) O O
, O O
a O O
relatively O O
new O O
nonbenzodiazepine O O
sedative-hypnotic O O
, O O
was O O
involved O O
in O O
the O O
death B-ADR O
of O O
a O O
39-year-old O O
obese O O
male O O
who O O
was O O
being O O
treated O O
for O O
depression O O
and O O
insomnia O O

an O O
encephalopathy B-ADR O
and O O
cardiomyopathy O O
developed O O
in O O
a O O
seventeen-year-old O O
girl O O
with O O
chemotherapy-induced O O
renal O B-ADR
failure O I-ADR
while O O
receiving O O
an O O
intravesical O O
aluminum B-DRUG B-DRUG
infusion O O
for O O
hemorrhagic O O
cystitis O O

hypoxia O B-ADR
is O O
a O O
predisposing O O
factor O O
for O O
premature B-ADR O
ductal I-ADR B-ADR
closure I-ADR I-ADR
and O O
often O O
occurs O O
after O O
maternal O O
indomethacin B-DRUG B-DRUG
therapy O O

physicians O O
should O O
be O O
aware O O
of O O
the O O
potential O O
for O O
developing O O
a O O
gemcitabine-induced O O
radiation B-ADR B-ADR
recall I-ADR I-ADR
reaction I-ADR I-ADR
resulting O O
in O O
hemodynamically O O
significant O O
pericardial O B-ADR
effusion O I-ADR

objective O O
: O O
to O O
report O O
2 O O
cases O O
of O O
serotonin O B-ADR
syndrome O I-ADR
with O O
serious O O
extrapyramidal B-ADR B-ADR
movement I-ADR I-ADR
disorders I-ADR I-ADR
occurring O O
when O O
metoclopramide B-DRUG B-DRUG
was O O
coadministered O O
with O O
sertraline O B-DRUG
or O O
venlafaxine O B-DRUG

in O O
both O O
cases O O
, O O
high B-ADR O
fever I-ADR O
, O O
skin O B-ADR
rash O I-ADR
, O O
liver O O
dysfunction O O
and O O
atypical O B-ADR
lymphocytosis O I-ADR
developed O O
3 O O
weeks O O
after O O
initiating O O
treatment O O
with O O
sasp B-DRUG B-DRUG

we O O
report O O
4 O O
patients O O
, O O
2 O O
on O O
methylphenidate B-DRUG B-DRUG
and O O
2 O O
on O O
dextroamphetamine O B-DRUG
who O O
presented O O
with O O
acral O B-ADR
cyanosis O I-ADR
, O O
livedo O B-ADR
reticularis O I-ADR
, O O
or O O
raynaud B-ADR B-ADR
phenomenon I-ADR I-ADR

contrary O O
to O O
previous O O
recommendations O O
, O O
our O O
experience O O
cautions O O
against O O
the O O
further O O
use O O
of O O
high-dose O O
cytarabine B-DRUG B-DRUG
in O O
patients O O
who O O
develop O O
ppe B-ADR B-ADR
, O O
and O O
is O O
a O O
timely O O
reminder O O
of O O
the O O
potential O O
toxicity O O
of O O
this O O
agent O O
, O O
which O O
is O O
now O O
increasingly O O
being O O
used O O
as O O
first-line O O
treatment O O
in O O
the O O
management O O
of O O
haematologic O B-ADR
malignancies O I-ADR

the O O
autopsy O O
findings O O
and O O
a O O
detailed O O
medical O O
history O O
supported O O
the O O
conclusion O O
that O O
clozapine-induced O O
hypersensitivity B-ADR B-ADR
myocarditis I-ADR I-ADR
was O O
the O O
most O O
likely O O
cause O O
of O O
death O O

enalaprilat B-DRUG B-DRUG
induced O O
acute B-ADR B-ADR
parotitis I-ADR I-ADR

bradycardia O B-ADR
and O O
congestive B-ADR B-ADR
heart I-ADR I-ADR
failure I-ADR I-ADR
associated O O
with O O
ocular O O
timolol B-DRUG B-DRUG
maleate I-DRUG I-DRUG

visual B-ADR B-ADR
loss I-ADR I-ADR
after O O
a O O
single O O
small O O
dose O O
of O O
vincristine B-DRUG B-DRUG
has O O
never O O
been O O
reported O O

three O O
cases O O
of O O
acute B-ADR B-ADR
renal I-ADR I-ADR
toxicity I-ADR I-ADR
in O O
patients O O
receiving O O
long-term O O
therapy O O
with O O
mitomycin O B-DRUG
c O I-DRUG
and O O
5-fluorouracil B-DRUG B-DRUG
are O O
reported O O

the O O
authors O O
describe O O
a O O
case O O
of O O
interstitial B-ADR B-ADR
granulomatous I-ADR I-ADR
dermatitis I-ADR I-ADR
associated O O
with O O
darifenacin B-DRUG B-DRUG

although O O
fluoxetine-induced O O
headache B-ADR B-ADR
occurred O O
in O O
one O O
patient O O
, O O
the O O
other O O
five O O
reported O O
no O O
side O O
effects O O
at O O
the O O
doses O O
used O O

symptomatic B-ADR B-ADR
hypoglycemia I-ADR I-ADR
secondary O O
to O O
a O O
glipizide-trimethoprim O O
/ O O
sulfamethoxazole O O
drug O O
interaction O O

a O O
rare O O
case O O
of O O
advanced O O
ovarian O O
carcinoma O O
who O O
developed O O
difficulty B-ADR B-ADR
walking I-ADR I-ADR
25 O O
days O O
after O O
treatment O O
with O O
weekly O O
paclitaxel B-DRUG B-DRUG

to O O
date O O
, O O
only O O
three O O
cases O O
of O O
seizures B-ADR B-ADR
associated O O
with O O
amphotericin B-DRUG B-DRUG
b I-DRUG I-DRUG
have O O
been O O
reported O O
in O O
the O O
literature O O
, O O
but O O
healthcare O O
providers O O
should O O
be O O
aware O O
of O O
the O O
potential O O
for O O
this O O
rare O O
adverse O O
effect O O

results O O
: O O
ethambutol O B-DRUG
, O O
and O O
to O O
a O O
lesser O O
extent O O
isoniazid B-DRUG B-DRUG
, O O
are O O
both O O
implicated O O
in O O
the O O
development B-ADR O
of I-ADR O
visually I-ADR O
related I-ADR O
side I-ADR O
effects I-ADR O

putaminal O B-ADR
infarct O I-ADR
in O O
methanol B-ADR B-DRUG
intoxication I-ADR O
: O O
case O O
report O O
and O O
role O O
of O O
brain O O
imaging O O
studies O O

two O O
cases O O
of O O
lepromatous O O
leprosy O O
with O O
erythema O O
nodosum O O
leprosum O O
who O O
were O O
on O O
high O O
doses O O
of O O
clofazimine B-DRUG B-DRUG
, O O
showed O O
discoloration B-ADR O
of I-ADR O
nail I-ADR O
plate I-ADR O
, O O
subungual O O
hyperkeratosis O O
and O O
onycholysis O B-ADR

objective O O
: O O
to O O
describe O O
a O O
case O O
of O O
cefazolin-induced O O
leukopenia B-ADR B-ADR
in O O
a O O
critically O O
ill O O
patient O O
who O O
developed O O
this O O
adverse O O
reaction O O
upon O O
rechallenge O O
with O O
cefoxitin O B-DRUG

we O O
report O O
a O O
patient O O
with O O
inoperable O O
pancreatic O O
cancer O O
who O O
developed O O
gastrointestinal O B-ADR
bleeding O I-ADR
secondary O O
to O O
radiation-recall B-ADR O
related O O
to O O
gemcitabine B-DRUG B-DRUG
and O O
review O O
literature O O

marked B-ADR O
qt I-ADR O
prolongation I-ADR O
and O O
torsades O B-ADR
de O I-ADR
pointes O I-ADR
secondary O O
to O O
acute O B-ADR
ischemia O I-ADR
in O O
an O O
elderly O O
man O O
taking O O
dofetilide B-DRUG B-DRUG
for O O
atrial O O
fibrillation O O
: O O
a O O
cautionary O O
tale O O

a O O
fatal B-ADR B-ADR
pancytopenia I-ADR I-ADR
occurred O O
in O O
a O O
patient O O
with O O
an O O
history O O
of O O
depression O O
with O O
hypomanic O O
rebounds O O
, O O
admitted O O
for O O
a O O
manic O O
episode O O
and O O
treated O O
with O O
levomepromazine O B-DRUG
, O O
diazepam B-DRUG O
and O O
lithium O B-DRUG
carbonate O I-DRUG

the O O
temporal O O
relationship O O
suggests O O
that O O
the O O
spinal B-ADR B-ADR
cord I-ADR I-ADR
infarction I-ADR I-ADR
may O O
be O O
related O O
to O O
the O O
use O O
of O O
zolmitriptan B-DRUG B-DRUG

based O O
on O O
these O O
findings O O
, O O
the O O
patient O O
was O O
diagnosed O O
with O O
diabetes B-ADR O
insipidus I-ADR O
secondary O O
to O O
lithium B-DRUG B-DRUG
therapy O O
and O O
was O O
treated O O
successfully O O
with O O
amiloride O B-DRUG

conclusions O O
: O O
this O O
report O O
indicates O O
clindamycin B-DRUG B-DRUG
phosphate O I-DRUG
vaginal O O
cream O O
as O O
the O O
most O O
probable O O
cause O O
of O O
cdic O O
due O O
to O O
the O O
temporal O O
relationship O O
between O O
the O O
occurrence O O
of O O
diarrhea O O
and O O
clindamycin B-DRUG B-DRUG
administration O O
, O O
lack O O
of O O
concomitant O O
medications O O
, O O
and O O
documentation O O
of O O
c. B-ADR O
difficile I-ADR O
toxin I-ADR O

we O O
report O O
the O O
case O O
of O O
a O O
17-year-old O O
male O O
who O O
developed O O
chest B-ADR O
pain I-ADR O
, O O
elevated O O
cardiac O O
biomarkers O O
, O O
and O O
acute O B-ADR
left O I-ADR
ventricular O I-ADR
dysfunction O I-ADR
following O O
a O O
single O O
dose O O
of O O
methylphenidate B-DRUG B-DRUG

discussion O O
: O O
rhabdomyolysis O B-ADR
is O O
a O O
clinical O O
syndrome O O
resulting O O
from O O
the O O
destruction O O
of O O
skeletal O O
muscle O O
that O O
may O O
progress O O
to O O
renal O O
failure O O
several O O
drugs O O
have O O
been O O
associated O O
with O O
rhabdomyolysis B-ADR B-ADR
, O O
including O O
lovastatin B-DRUG B-DRUG
, O O
a O O
hydroxymethylglutaryl-coenzyme O O
a O O
reductase O O
inhibitor O O

we O O
report O O
aza-induced O O
drug B-ADR B-ADR
eruption I-ADR I-ADR
that O O
developed O O
in O O
two O O
cases O O
of O O
systemic O O
scleroderma O O
with O O
polymyositis O O

two O O
patients O O
with O O
ovarian O O
cancer O O
who O O
had O O
received O O
multiple O O
courses O O
of O O
cisplatin B-DRUG B-DRUG
without O O
complications O O
experienced O O
hypersensitivity O O
reactions O O
to O O
cisplatin B-DRUG B-DRUG
: O O
one O O
, O O
involving O O
intrahepatic O O
artery O O
infusion O O
, O O
manifested O O
general O O
erythema O O
, O O
dyspnea O O
, O O
and O O
hypotension O O
; O O
the O O
other O O
, O O
involving O O
intravenous O O
infusion O O
, O O
manifested O O
abdominal B-ADR O
pain I-ADR O
, O O
general O O
erythema O O
, O O
and O O
fever O O

mechanism O O
of O O
topiramate-induced O O
acute-onset O B-ADR
myopia O I-ADR
and O O
angle B-ADR B-ADR
closure I-ADR I-ADR
glaucoma I-ADR I-ADR

the O O
time O O
course O O
of O O
events O O
suggested O O
that O O
amphotericin B-DRUG B-DRUG
b I-DRUG I-DRUG
was O O
the O O
cause O O
of O O
the O O
seizures B-ADR B-ADR
in O O
this O O
aids O O
patient O O

conclusions O O
: O O
low O O
dosages O O
of O O
quinacrine O B-DRUG
used O O
for O O
malaria O O
prophylaxis O O
can O O
be O O
associated O O
with O O
a O O
delayed O O
, O O
severe O O
maculopathy B-ADR O
indistinguishable O O
from O O
chloroquine B-DRUG B-DRUG
maculopathy B-ADR O
in O O
certain O O
patients O O

results O O
: O O
a O O
34-year-old O O
man O O
acquired O O
visual B-ADR O
field I-ADR O
defects I-ADR O
and O O
severe O B-ADR
vision O I-ADR
loss O I-ADR
in O O
both O O
eyes O O
after O O
intravitreal O O
injection O O
of O O
triamcinolone B-DRUG B-DRUG
for O O
diabetic O O
macular O O
edema O O

therefore O O
, O O
we O O
diagnosed O O
her O O
eruption O O
as O O
contact B-ADR B-ADR
dermatitis I-ADR I-ADR
due O O
to O O
sodium B-DRUG B-DRUG
bisulfite I-DRUG I-DRUG

one O O
case O O
of O O
tacrolimus-induced O O
hepatic B-ADR B-ADR
vod I-ADR I-ADR
developing O O
after O O
lung O O
transplantation O O
( O O
lt O O
) O O
has O O
been O O
recently O O
reported O O

introduction-the O O
aim O O
of O O
this O O
case O O
report O O
is O O
to O O
present O O
a O O
15-year O O
follow-up O O
of O O
a O O
patient O O
with O O
phenytoin O B-DRUG
( O O
pht B-DRUG O
) O O
intoxication O O
with O O
unilateral B-ADR O
gingival I-ADR O
hyperplasia I-ADR O
( O O
gh O O

a O O
7-year-old O O
with O O
congenital O O
toxoplasmosis O O
who O O
took O O
pyrimethamine O B-DRUG
and O O
sulfadiazine B-DRUG B-DRUG
for O O
reactivated O O
chorioretinitis O O
developed O O
fever O O
, O O
severe B-ADR O
cutaneous I-ADR O
involvement I-ADR O
, O O
swelling O O
, O O
abdominal O O
pain O O
and O O
transaminitis O O
, O O
persisting O O
weeks O O
after O O
withholding O O
medicines O O

we O O
report O O
a O O
case O O
of O O
a O O
patient O O
with O O
pulmonary O O
hypertension O O
and O O
undifferentiated O O
connective O O
tissue O O
disease O O
who O O
, O O
after O O
2 O O
months O O
of O O
treatment O O
with O O
epoprostenol B-DRUG B-DRUG
, O O
presented O O
with O O
rapidly O O
progressive O O
erythema O O
, O O
scaling B-ADR O
, O O
nausea O O
and O O
vomiting O O
, O O
and O O
fever O O

conclusion O O
: O O
lipoid B-ADR B-ADR
pneumonia I-ADR I-ADR
as O O
a O O
result O O
of O O
mineral B-DRUG B-DRUG
oil I-DRUG I-DRUG
aspiration O O
still O O
occurs O O
in O O
the O O
pediatric O O
population O O

one O O
patient O O
suffered O O
coronary B-ADR B-ADR
artery I-ADR I-ADR
vasospasm I-ADR I-ADR
, O O
attributed O O
to O O
the O O
use O O
of O O
topical O O
1:1000 O O
epinephrine B-DRUG B-DRUG
during O O
surgery O O

we O O
report O O
on O O
three O O
cases O O
wherein O O
treatment O O
of O O
dexmedetomidine-induced O O
bradycardia B-ADR B-ADR
with O O
i.v. O O
glycopyrrolate O B-DRUG
( O O
5.0 O O
microg O O
/ O O
kg O O
) O O
not O O
only O O
resulting O O
in O O
resolution O O
of O O
bradycardia B-ADR B-ADR
but O O
also O O
resulting O O
in O O
an O O
exaggerated O O
increase O O
of O O
arterial O B-ADR
blood O I-ADR
pressure O I-ADR

the O O
development O O
of O O
systemic O O
lupus O O
erythematosus O O
( O O
sle B-ADR O
) O O
after O O
38 O O
months O O
of O O
therapy O O
with O O
recombinant B-DRUG O
human I-DRUG O
interferon I-DRUG O
gamma I-DRUG O
( O O
rifn-gamma O O
) O O
was O O
observed O O
in O O
a O O
patient O O
with O O
rheumatoid O O
arthritis O O

refractory B-ADR B-ADR
hypoglycemia I-ADR I-ADR
from O O
ciprofloxacin O O
and O O
glyburide B-DRUG B-ADR
interaction O I-ADR

flecainide-associated O O
pneumonitis B-ADR B-ADR
with O O
acute O B-ADR
respiratory O I-ADR
failure O I-ADR
in O O
a O O
patient O O
with O O
the O O
leopard O O
syndrome O O

major O O
points O O
illustrated O O
are O O
, O O
( O O
1 O O
) O O
occurrence O O
of O O
hit B-ADR O
with O O
any O O
dose O O
or O O
form O O
of O O
heparin B-DRUG B-DRUG
; O O
( O O
2 O O
) O O
misperceptions O O
on O O
the O O
diagnostic O O
criteria O O
; O O
( O O
3 O O
) O O
correct O O
( O O
thrombin O O
inhibitors O O
) O O
and O O
incorrect O O
( O O
platelet O O
transfusions O O
and O O
warfarin O O
) O O
management O O
; O O
( O O
4 O O
) O O
influence O O
of O O
management O O
strategy O O
on O O
clinical O O
outcomes O O
; O O
( O O
5 O O
) O O
severity O O
of O O
the O O
syndrome O O
; O O
and O O
( O O
6 O O
) O O
potential O O
for O O
both O O
anamnestic O O
response O O
to O O
heparin B-DRUG B-DRUG
and O O
disappearance O O
of O O
hit B-ADR O
antibodies O O
over O O
time O O

gold B-ADR B-ADR
nephropathy I-ADR I-ADR
due O O
to O O
auranofin O B-DRUG
obscured O O
by O O
tolmetin B-DRUG B-DRUG
pseudoproteinuria O O

he O O
had O O
been O O
taking O O
trimethoprim-sulfamethoxazole O B-DRUG
for O O
approximately O O
eight O O
days O O
when O O
he O O
revisited O O
his O O
family O O
physician O O
, O O
complaining O O
of O O
headaches O O
, O O
dizziness B-ADR O
, O O
difficulty O O
with O O
speech O O
, O O
weakness O O
, O O
and O O
itching O O
on O O
the O O
trunk O O
of O O
his O O
body O O
and O O
legs O O
, O O
where O O
a O O
maculopapular O B-ADR
rash O I-ADR
was O O
noted O O

patients O O
treated O O
with O O
captopril B-DRUG B-DRUG
who O O
develop O O
" O O
atypical B-ADR B-ADR
cholangitis I-ADR I-ADR
" O O
should O O
be O O
suspected O O
of O O
having O O
captopril-associated O O
liver O B-ADR
damage O I-ADR

well-known O O
signs O O
of O O
methotrexate B-DRUG B-DRUG
toxicity O O
include O O
bone O O
marrow O O
suppression O O
and O O
oral B-ADR O
and I-ADR O
gastrointestinal I-ADR O
ulceration I-ADR O

after O O
a O O
second O O
dose O O
of O O
metoclopramide B-DRUG B-DRUG
, O O
these O O
symptoms O O
recurred O O
and O O
were O O
associated O O
with O O
confusion O O
, O O
agitation O O
, O O
fever B-ADR O
, O O
diaphoresis O O
, O O
tachypnea O O
, O O
tachycardia O O
, O O
and O O
hypertension O O

we O O
suggest O O
that O O
nicotinic B-DRUG B-DRUG
acid I-DRUG I-DRUG
was O O
the O O
cause O O
of O O
his O O
liver B-ADR O
disease I-ADR O
, O O
that O O
this O O
case O O
is O O
of O O
particular O O
note O O
because O O
of O O
the O O
rather O O
short O O
period O O
of O O
therapy O O
before O O
the O O
onset O O
of O O
liver O O
injury O O
and O O
the O O
severity O O
of O O
the O O
hepatic O B-ADR
failure O I-ADR
, O O
and O O
that O O
the O O
probable O O
increased O O
use O O
of O O
nicotinic B-DRUG B-DRUG
acid I-DRUG I-DRUG
for O O
serum O O
cholesterol O O
control O O
makes O O
it O O
especially O O
important O O
for O O
physicians O O
and O O
their O O
patients O O
to O O
be O O
alert O O
to O O
the O O
signs O O
of O O
hepatotoxicity O B-ADR

the O O
uncomplicated O O
long-term O O
use O O
of O O
adequately-dosed O O
aza B-DRUG B-DRUG
and O O
stable O O
non-toxic O O
metabolite O O
levels O O
could O O
not O O
acknowledge O O
tpmt O B-ADR
deficiency O I-ADR
as O O
a O O
primary O O
cause O O
of O O
the O O
leukopenia B-ADR B-ADR

she O O
was O O
administered O O
metoclopramide B-DRUG B-DRUG
because O O
of O O
nausea O O
and O O
, O O
within O O
2 O O
hours O O
, O O
developed O O
agitation B-ADR O
, O O
dysarthria O O
, O O
diaphoresis O O
, O O
and O O
a O O
movement O O
disorder O O

a O O
10-year-old O O
boy O O
with O O
osteosarcoma O O
and O O
normal O O
renal O O
function O O
manifested O O
laboratory O O
evidence O O
of O O
impending O O
renal O O
toxicity O O
and O O
extreme O O
elevation O O
of O O
aspartate O O
aminotrasferase O O
and O O
alanine O O
aminotransferase O O
within O O
2 O O
hours O O
after O O
the O O
completion O O
of O O
a O O
4-hour O O
infusion O O
of O O
high-dose O O
methotrexate B-DRUG B-DRUG
( O O
mtx O B-DRUG
) O O
( O O
12 O O
g O O
/ O O
m2 O O
) O O
, O O
and O O
went O O
on O O
to O O
develop O O
acute B-ADR O
renal I-ADR O
failure I-ADR O
with O O
life-threatening O B-ADR
hyperkalemia O I-ADR
29 O O
hours O O
later O O

in O O
case O O
no O O
. O O
2 O O
, O O
the O O
pathogenic O O
mechanism O O
seemed O O
to O O
be O O
persistent O O
light O O
reaction O O
preceded O O
by O O
systemic O O
photoallergy O O
, O O
as O O
he O O
had O O
taken O O
mequitazine B-DRUG B-DRUG
for O O
6 O O
months O O
, O O
and O O
there O O
were O O
strong O O
positive O O
photopatch O O
test O O
results O O
with O O
immediate O O
erythema O O
reaction O O
, O O
cross-reaction O O
to O O
promethazine O B-DRUG
, O O
decreased B-ADR O
med I-ADR O
to I-ADR O
both I-ADR O
uva I-ADR O
and I-ADR O
uvb I-ADR O
, O O
and O O
persistence O O
of O O
the O O
photosensitivity O O
over O O
a O O
3-year O O
follow-up O O
period O O
after O O
discontinuation O O
of O O
the O O
mequitazine B-DRUG B-DRUG

flutamide B-DRUG B-ADR
withdrawal O I-ADR
syndrome O I-ADR
is O O
characterized O O
by O O
a O O
decrease B-ADR O
in I-ADR O
prostate-specific I-ADR O
antigen I-ADR O
( O O
psa O O
) O O
after O O
flutamide O B-DRUG
withdrawal O O
in O O
a O O
subset O O
of O O
patients O O
with O O
progressing O O
metastatic O O
carcinoma O O
of O O
the O O
prostate O O

pulmonary O B-ADR
hemorrhage O I-ADR
is O O
an O O
uncommon O O
feature O O
in O O
the O O
hus B-ADR O
, O O
and O O
seems O O
to O O
appear O O
especially O O
in O O
the O O
hus B-ADR B-ADR
associated O O
with O O
mmc B-DRUG B-DRUG
therapy O O

gynecomastia B-ADR B-ADR
developed O O
in O O
two O O
epileptic O O
patients O O
some O O
months O O
after O O
the O O
addition O O
of O O
oral O O
fluoresone O B-DRUG
750 O O
mg O O
daily O O
to O O
the O O
phenobarbital B-DRUG B-DRUG
and O O
phenytoin O B-DRUG
already O O
being O O
administered O O

quinine B-DRUG B-DRUG
induced O O
coagulopathy B-ADR B-ADR
-- O O
a O O
near O O
fatal O O
experience O O

in O O
patients O O
with O O
cirrhosis O O
, O O
the O O
metabolism O O
of O O
meperidine B-DRUG B-DRUG
is O O
decreased O O
, O O
leading O O
to O O
accumulation O O
of O O
the O O
parent O O
drug O O
and O O
possible O O
cns B-ADR O
depressive I-ADR O
effects I-ADR O
similar O O
to O O
hepatic O B-ADR
encephalopathy O I-ADR

after O O
seven O O
months' O O
continuous O O
treatment O O
for O O
suspected O O
tuberculosis O O
with O O
rifampicin O B-DRUG
and O O
ethambutol B-DRUG B-DRUG
a O O
nine-year-old O O
boy O O
developed O O
polyarthritis O O
, O O
rash O O
and O O
hepatitis O O
in O O
association O O
with O O
anti-native B-ADR O
dna I-ADR O
antibodies I-ADR O
and O O
positive O O
antinuclear O O
factor O O

zidovudine B-DRUG B-DRUG
use O O
in O O
pregnancy O O
: O O
a O O
report O O
on O O
104 O O
cases O O
and O O
the O O
occurrence O O
of O O
birth B-ADR B-ADR
defects I-ADR I-ADR

fixed B-ADR B-ADR
drug I-ADR I-ADR
eruption I-ADR I-ADR
to O O
rofecoxib B-DRUG B-DRUG

discussion O O
: O O
the O O
naranjo O O
probability O O
scale O O
indicated O O
a O O
probable O O
relationship O O
between O O
sertraline B-DRUG B-DRUG
treatment O O
and O O
the O O
onset O O
of O O
rhabdomyolysis B-ADR B-ADR

neonatal O B-ADR
mydriasis B-ADR I-ADR
: O O
intravenous O O
lidocaine B-DRUG B-DRUG
adverse O O
reaction O O

a O O
macrophage O B-ADR
activation O I-ADR
syndrome O I-ADR
, O O
possibly O O
related O O
to O O
methotrexate B-ADR B-DRUG
toxicity I-ADR O
, O O
developed O O
in O O
a O O
boy O O
with O O
systemic O O
juvenile O O
rheumatoid O O
arthritis O O

transient O O
trazodone-induced O O
hypomanic B-ADR B-ADR
symptoms I-ADR I-ADR
occurred O O
in O O
three O O
depressed O O
patients O O

background O O
: O O
interferon O O
( O O
ifn B-DRUG B-DRUG
)- O O
associated O O
retinopathy O O
is O O
typically O O
characterized O O
by O O
retinal B-ADR O
hemorrhages I-ADR O
and O O
cotton O B-ADR
wool O I-ADR
spots O I-ADR
at O O
the O O
posterior O O
fundus O O
, O O
but O O
visual O O
function O O
is O O
usually O O
maintained O O

venlafaxine-induced O O
urinary B-ADR B-ADR
incontinence I-ADR I-ADR
resolved O O
after O O
switching O O
to O O
sertraline O B-DRUG

he O O
had O O
an O O
immediate O O
hypersensitivity B-ADR O
reaction I-ADR O
during O O
the O O
initiation O O
of O O
the O O
mtx B-DRUG B-DRUG
infusion O O
with O O
diffuse O O
urticaria O O
, O O
facial O O
swelling O O
, O O
cough O O
, O O
and O O
chest O O
tightness O O

clinical O O
course O O
of O O
macular O B-ADR
edema O I-ADR
in O O
two O O
cases O O
of O O
interferon-associated O O
retinopathy B-ADR B-ADR
observed O O
by O O
optical O O
coherence O O
tomography O O

conclusion O O
: O O
during O O
and O O
after O O
ifn B-DRUG B-DRUG
therapy O O
, O O
oct O O
is O O
a O O
useful O O
examination O O
technique O O
for O O
revealing O O
macular O B-ADR
edema O I-ADR
in O O
patients O O
who O O
have O O
decreased B-ADR B-ADR
vision I-ADR I-ADR

he O O
was O O
started O O
on O O
digoxin B-DRUG B-DRUG
, O O
0.25 O O
mg O O
daily O O
, O O
because O O
of O O
echocardiographically O O
demonstrated O O
left O O
ventricular O O
dilatation O O
and O O
functional B-ADR O
impairment I-ADR O
; O O
he O O
died O O
of O O
ventricular O B-ADR
fibrillation O I-ADR
15 O O
days O O
later O O

rifampin B-DRUG B-DRUG
( O O
rfp O B-DRUG
) O O
increases O O
hepatic O O
microsomal O O
enzyme O O
activity O O
, O O
and O O
there O O
are O O
case O O
reports O O
of O O
rfp-induced O O
hypothyroidism O B-ADR
, O O
all O O
associated O O
with O O
hashimoto B-ADR B-DRUG
's I-ADR O
thyroiditis I-ADR O

although O O
they O O
had O O
only O O
a O O
few O O
nodules B-ADR O
at O O
diagnosis O O
, O O
the O O
nodules B-ADR B-ADR
increased O I-ADR
in O O
number O O
and O O
size O O
3 O O
to O O
4 O O
months O O
after O O
the O O
start O O
of O O
methotrexate B-DRUG B-DRUG
therapy O O
in O O
both O O
patients O O

the O O
bleeding B-ADR B-ADR
resolved O O
on O O
discontinuation O O
of O O
apv B-DRUG B-DRUG

multiple O O
complications O O
of O O
propylthiouracil B-DRUG B-DRUG
treatment O O
: O O
granulocytopenia B-ADR O
, O O
eosinophilia O O
, O O
skin O O
reaction O O
and O O
hepatitis O O
with O O
lymphocyte O O
sensitization O O

angioedema O B-ADR
and O O
maculopapular B-ADR B-ADR
eruptions I-ADR I-ADR
associated O O
with O O
carbamazepine B-DRUG B-DRUG
administration O O

videopolysomnographic O O
and O O
pharmacokinetic O O
studies O O
with O O
monitoring O O
of O O
plasma O O
levodopa B-DRUG B-DRUG
levels O O
demonstrated O O
marked O O
motor O O
hyperactivity O O
during O O
augmentation O O
, O O
with O O
anarchic O O
discharges O O
of O O
motor O O
unit O O
potentials O O
, O O
tonic O O
grouped O O
discharges O O
and O O
flexor O B-ADR
spasms O I-ADR
, O O
associated O O
with O O
painful B-ADR B-ADR
dysesthesia I-ADR I-ADR

a O O
36-y-o O O
patient O O
with O O
schizophrenia O O
, O O
who O O
had O O
consumed O O
gradually O O
increasing O O
quantities O O
of O O
oolong B-DRUG B-DRUG
tea I-DRUG I-DRUG
that O O
eventually O O
reached O O
15 O O
l O O
each O O
day O O
, O O
became O O
delirious B-ADR B-ADR
and O O
was O O
admitted O O
to O O
a O O
psychiatric O O
hospital O O

pulmonary B-ADR B-ADR
fibrosis I-ADR I-ADR
is O O
a O O
severe O O
complication O O
associated O O
with O O
bis-chloronitrosourea B-DRUG B-DRUG
( O O
bcnu O B-DRUG
) O O
therapy O O

after O O
1 O O
week O O
of O O
nefazodone B-DRUG B-DRUG
therapy O O
the O O
patient O O
experienced O O
headache O O
, O O
confusion O O
, O O
and O O
" O O
gray B-ADR O
areas I-ADR O
" O O
in O O
her O O
vision O O
, O O
without O O
abnormal O O
ophthalmologic O O
findings O O

the O O
favourable O O
outcome O O
in O O
these O O
two O O
patients O O
contrasts O O
with O O
the O O
fatal O O
outcome O O
of O O
the O O
two O O
other O O
reported O O
cases O O
of O O
nitrofurantoin B-ADR B-DRUG
induced I-ADR O
boop I-ADR B-ADR

disseminated B-ADR O
cellulitic I-ADR B-ADR
cryptococcosis I-ADR I-ADR
in O O
the O O
setting O O
of O O
prednisone B-DRUG B-DRUG
monotherapy O O
for O O
pemphigus O O
vulgaris O O

interferon-alpha-induced O O
focal B-ADR B-ADR
segmental I-ADR I-ADR
glomerulosclerosis I-ADR I-ADR
in O O
chronic O O
myelogenous O O
leukemia O O
: O O
a O O
case O O
report O O
and O O
review O O
of O O
the O O
literature O O

based O O
upon O O
the O O
observed O O
fall O O
of O O
the O O
filtration O O
fraction O O
, O O
the O O
rise O O
in O O
the O O
relative O O
clearance O O
of O O
99tc-dimercaptosuccinic O B-DRUG
acid O I-DRUG
and O O
the O O
increase B-ADR O
in I-ADR O
proteinuria I-ADR O
, O O
we O O
suggest O O
that O O
in O O
this O O
case O O
the O O
tubules O O
and O O
/ O O
or O O
interstitium O O
are O O
the O O
main O O
targets O O
for O O
cyclosporine B-DRUG B-DRUG
a I-DRUG O
nephrotoxicity O B-ADR

diagnosis O O
: O O
severe O O
temozolomide-induced O O
immunosuppression B-ADR O
, O O
exacerbated O O
by O O
corticosteroids O O
, O O
with O O
profound O O
t-cell O O
lymphocytopenia O O
and O O
simultaneous O O
opportunistic O O
infections O O
with O O
pneumocystis O O
jiroveci O O
pneumonia O O
, O O
brain O O
abscess O O
with O O
listeria O O
monocytogenes O O
, O O
and O O
cutaneous O O
kaposi O O
's O O
sarcoma O O

a O O
patient O O
who O O
had O O
been O O
treated O O
with O O
large O O
doses O O
of O O
thyroid B-DRUG O
hormone I-DRUG O
for O O
several O O
years O O
developed O O
features O O
of O O
secondary O B-ADR
hypothyroidism B-ADR I-ADR
after O O
thyroid B-DRUG O
hormone I-DRUG O
withdrawal O O

objectives O O
: O O
a O O
delayed O O
stroke-like B-ADR B-ADR
leukoencephalopathy I-ADR I-ADR
has O O
been O O
observed O O
in O O
patients O O
receiving O O
methotrexate B-DRUG B-DRUG
( O O
mtx O B-DRUG
) O O
for O O
childhood O O
leukemia O O

the O O
diagnosis O O
was O O
based O O
on O O
the O O
rapid O O
onset O O
of O O
renal O O
failure O O
, O O
presence O O
of O O
eosinophilia B-ADR O
, O O
skin O O
rash O O
, O O
and O O
characteristic O O
renal O O
biopsy O O
finding O O
, O O
following O O
the O O
administration O O
of O O
ampicillin B-DRUG B-DRUG

a O O
69-year-old O O
man O O
developed O O
pure B-ADR B-ADR
red I-ADR I-ADR
cell I-ADR I-ADR
aplasia I-ADR I-ADR
after O O
taking O O
fenoprofen B-DRUG B-DRUG
for O O
ten O O
months O O

morphine B-DRUG B-DRUG
, O O
an O O
opium O O
alkaloid O O
, O O
frequently O O
causes O O
side O O
effects O O
such O O
as O O
hyperhidrosis B-ADR O
and O O
facial O O
flushing O O
, O O
but O O
serious O O
cutaneous O O
adverse O O
drug O O
reactions O O
are O O
seldom O O
observed O O

teicoplanin-induced O O
agranulocytosis B-ADR B-ADR
that O O
followed O O
vancomycin-induced O O
agranulocytosis B-ADR B-ADR
suggests O O
a O O
possible O O
cross-reactivity O O
between O O
the O O
2 O O
drugs O O

atrial B-ADR B-ADR
fibrillation I-ADR I-ADR
occurring O O
in O O
a O O
patient O O
taking O O
etanercept O B-DRUG
plus O O
methotrexate B-DRUG B-DRUG
for O O
rheumatoid O O
arthritis O O

nephrogenic O B-ADR
diabetes O I-ADR
insipidus O I-ADR
( O O
ndi B-ADR O
) O O
is O O
a O O
well-documented O O
complication O O
of O O
lithium B-DRUG B-DRUG
use O O

ncse B-ADR B-ADR
, O O
an O O
epileptic O O
disorder O O
in O O
which O O
typical O O
convulsive O B-ADR
activity O I-ADR
is O O
absent O O
, O O
has O O
previously O O
been O O
reported O O
in O O
only O O
4 O O
patients O O
receiving O O
ifosfamide B-DRUG B-DRUG

patients O O
receiving O O
neutral O O
protamine O O
hagedorn O O
( O O
nph O O
) O O
insulin O O
are O O
at O O
increased O O
risk O O
for O O
the O O
development O O
of O O
protamine B-ADR B-DRUG
hypersensitivity I-ADR B-ADR

a O O
52-year-old O O
black O O
woman O O
on O O
phenytoin B-DRUG B-DRUG
therapy O O
for O O
post-traumatic O O
epilepsy O O
developed O O
transient B-ADR B-ADR
hemiparesis I-ADR I-ADR
contralateral O O
to O O
the O O
injury O O

methylphenidate B-DRUG O
and O O
dextroamphetamine-induced O O
peripheral B-ADR B-ADR
vasculopathy I-ADR I-ADR

severe B-ADR B-ADR
acute I-ADR I-ADR
encephalopathy I-ADR I-ADR
following O O
inadvertent O O
intrathecal O O
doxorubicin B-DRUG B-DRUG
administration O O

after O O
a O O
six-week O O
course O O
of O O
low-dose O O
cyclosporine B-DRUG B-DRUG
a I-DRUG I-DRUG
, O O
she O O
developed O O
a O O
severe O O
but O O
reversible O O
loss O B-ADR
of O I-ADR
glomerular O I-ADR
filtration O I-ADR
rate O I-ADR
and O O
effective B-ADR O
renal I-ADR O
plasma I-ADR O
flow I-ADR O
despite O O
of O O
low O O
cyclosporine B-DRUG B-DRUG
a I-DRUG O
plasma O O
levels O O

case O O
1 O O
, O O
a O O
62-year-old O O
woman O O
, O O
developed O O
bilateral O O
optic O O
neuritis O O
with O O
decreased B-ADR O
sensation I-ADR O
of I-ADR O
vibration I-ADR O
and O O
increased O B-ADR
deep O I-ADR
tendon O I-ADR
reflex O I-ADR
in O I-ADR
the O I-ADR
lower O I-ADR
extremities O I-ADR
after O O
a O O
seven-month O O
use O O
of O O
recombinant B-DRUG B-DRUG
interferon I-DRUG I-DRUG
alpha-2a I-DRUG I-DRUG
for O O
chronic O O
active O O
hepatitis O O
c O O

we O O
report O O
a O O
case O O
of O O
a O O
patient O O
with O O
ciprofloxacin-induced O O
sjs B-ADR B-ADR
and O O
acute O O
onset O O
of O O
vbds O O
, O O
and O O
reviewed O O
the O O
related O O
literature O O

ibuprofen B-DRUG B-DRUG
overdose O O
is O O
usually O O
characterized O O
by O O
gi O O
upset O O
, O O
dizziness O O
, O O
and O O
mild B-ADR O
sedation I-ADR O

although O O
both O O
the O O
spontaneous O O
occurrence O O
of O O
sle B-ADR B-ADR
and O O
the O O
psychosis O O
as O O
a O O
sign O O
of O O
cns O O
involvement O O
of O O
sle B-ADR B-ADR
cannot O O
be O O
excluded O O
, O O
sle B-ADR B-ADR
could O O
be O O
considered O O
as O O
an O O
adverse O O
effect O O
of O O
carbamazepine B-DRUG B-DRUG

we O O
report O O
a O O
43-year-old O O
woman O O
who O O
developed O O
sore O O
throat O O
, O O
swelling B-ADR B-ADR
of I-ADR I-ADR
the I-ADR I-ADR
lips I-ADR I-ADR
and I-ADR O
oral I-ADR O
cavity I-ADR O
and O O
dysphagia O O
, O O
2 O O
weeks O O
after O O
the O O
use O O
of O O
budesonide B-DRUG B-DRUG
spray O O
( O O
budefat O O
) O O
for O O
treatment O O
of O O
bronchial O O
asthma O O

we O O
describe O O
the O O
development O O
of O O
cutaneous B-ADR B-ADR
scleroderma I-ADR I-ADR
in O O
3 O O
patients O O
coincident O O
with O O
the O O
use O O
of O O
bleomycin B-DRUG B-DRUG
in O O
low O O
cumulative O O
doses O O
of O O
less O O
than O O
100 O O
u O O

drug B-ADR B-ADR
eruption I-ADR I-ADR
caused O O
by O O
azathioprine B-DRUG B-DRUG
: O O
value O O
of O O
using O O
the O O
drug-induced O O
lymphocytes O O
stimulation O O
test O O
for O O
diagnosis O O

despite O O
a O O
response O O
of O O
the O O
meningeal O O
tumor O O
the O O
patient O O
developed O O
in O O
the O O
third O O
week O O
of O O
mtx B-DRUG B-DRUG
treatment O O
a O O
progressive B-ADR O
visual I-ADR B-ADR
loss I-ADR I-ADR
and O O
loss O B-ADR
of O I-ADR
consciousness O I-ADR
which O O
worsened O O
during O O
subsequent O O
ara-c O B-DRUG
treatment O O
and O O
led O O
to O O
death O B-ADR
within O O
3 O O
weeks O O

type B-ADR O
i I-ADR O
second-degree I-ADR O
av I-ADR O
block I-ADR O
( O O
mobitz O O
type O O
i O O
, O O
wenckebach O B-ADR
av O I-ADR
block O I-ADR
) O O
during O O
ritodrine B-DRUG B-DRUG
therapy O O
for O O
preterm O O
labor O O

we O O
report O O
the O O
case O O
of O O
an O O
87-year-old O O
white O O
woman O O
with O O
myasthenia O O
gravis O O
who O O
presented O O
with O O
nausea B-ADR O
, O O
shortness O B-ADR
of O I-ADR
breath O I-ADR
, O O
azotemia O O
, O O
and O O
hyperkalemia O O
shortly O O
after O O
completing O O
a O O
course O O
of O O
intravenous O O
immunoglobulin B-DRUG B-DRUG
( O O
ivig O B-DRUG

we O O
report O O
a O O
patient O O
of O O
organic O O
bipolar O O
affective O O
disorder O O
who O O
developed O O
hiccups B-ADR B-ADR
with O O
the O O
atypical O O
antipsychotic O O
aripiprazole B-DRUG B-DRUG

leflunomide-induced O O
toxic B-ADR B-ADR
epidermal I-ADR I-ADR
necrolysis I-ADR I-ADR
in O O
a O O
patient O O
with O O
rheumatoid O O
arthritis O O

this O O
patient O O
developed O O
sequential O O
symptoms O O
including O O
alternative O O
hemiparesis O O
, O O
dysarthria O O
and O O
altered B-ADR O
consciousness I-ADR O
5 O O
days O O
after O O
the O O
second O O
course O O
of O O
hd-mtx B-DRUG B-DRUG
( O O
8 O O
gm O O
/ O O
m2 O O
by O O
6 O O
h O O
continuous O O
infusion O O
) O O
with O O
leucovorin O B-DRUG
rescue O O

it O O
should O O
be O O
recognized O O
that O O
ibuprofen B-DRUG B-DRUG
may O O
be O O
associated O O
with O O
salt B-ADR B-ADR
and I-ADR I-ADR
water I-ADR I-ADR
retention I-ADR I-ADR
in O O
the O O
same O O
fashion O O
as O O
previously O O
described O O
with O O
phenylbutazone O B-DRUG
and O O
indomethacin O B-DRUG

here O O
, O O
we O O
report O O
a O O
case O O
of O O
angio-oedema B-ADR B-ADR
associated O O
with O O
vrc B-DRUG B-DRUG
therapy O O

it O O
should O O
be O O
emphasized O O
that O O
the O O
recurrence O O
of O O
nephrotic B-ADR B-ADR
syndrome I-ADR I-ADR
was O O
observed O O
after O O
the O O
following O O
chemotherapy O O
, O O
including O O
m-csf B-DRUG B-DRUG
, O O
whereas O O
the O O
bone O B-ADR
marrow O I-ADR
still O O
remained O O
completely O O
remitted O O

a O O
fatal B-ADR B-ADR
massive I-ADR I-ADR
pulmonary I-ADR I-ADR
embolus I-ADR I-ADR
developed O O
in O O
a O O
patient O O
treated O O
with O O
streptokinase B-DRUG B-DRUG
for O O
acute O O
deep O O
vein O O
thrombosis O O

acetazolamide B-DRUG B-DRUG
may O O
have O O
accelerated O O
the O O
development O O
of O O
osteomalacia B-ADR B-ADR
by O O
several O O
mechanisms O O
, O O
including O O
increased O B-ADR
renal O I-ADR
calcium O I-ADR
excretion O I-ADR

hyperammonemia B-ADR B-ADR
has O O
been O O
described O O
as O O
a O O
complication O O
of O O
valproic B-DRUG B-DRUG
acid I-DRUG I-DRUG
therapy O O
but O O
may O O
often O O
be O O
overlooked O O
as O O
a O O
cause O O
of O O
lethargy O B-ADR
in O O
the O O
postictal O O
patient O O
who O O
presents O O
to O O
the O O
emergency O O
department O O

quinine-induced O O
hearing B-ADR B-ADR
loss I-ADR I-ADR

in O O
this O O
case O O
, O O
unlike O O
those O O
previously O O
reported O O
, O O
hyponatremia B-ADR B-ADR
recurred O O
5 O O
months O O
after O O
switching O O
from O O
citalopram B-DRUG B-DRUG
to O O
mirtazapine O B-DRUG
, O O
which O O
is O O
believed O O
to O O
be O O
a O O
safe O O
antidepressant O O

a O O
36-year-old O O
man O O
being O O
treated O O
with O O
cisplatinum B-DRUG O
, O O
vinblastine O O
, O O
and O O
bleomycin O B-DRUG
for O O
testicular O O
carcinoma O O
developed O O
a O O
dense O O
left O O
homonymous O O
hemianopsia O O
, O O
encephalopathy B-ADR O
, O O
and O O
a O O
partial O B-ADR
nondominant O I-ADR
parietal O I-ADR
lobe O I-ADR
syndrome O I-ADR

conclusion O O
: O O
squamous B-ADR B-ADR
metaplasia I-ADR I-ADR
in O O
these O O
cases O O
appears O O
to O O
be O O
a O O
consequence O O
of O O
progestin B-DRUG B-DRUG
therapy O O

by O O
means O O
of O O
the O O
in O O
vitro O O
heparin-induced O O
platelet B-ADR O
activation I-ADR O
( O O
hipa O O
) O O
assay O O
it O O
was O O
shown O O
that O O
standard O O
heparin B-DRUG O
and O O
the O O
lmw O O
heparins O O
fragmin O O
and O O
fraxiparin O O
( O O
sanofi O O
labaz O O
, O O
munich O O
, O O
frg O O
) O O
, O O
as O O
well O O
as O O
the O O
enoxaparine O O
clexane O O
( O O
nattermann O O
, O O
cologne O O
, O O
frg O O
) O O
, O O
all O O
induced O O
platelet B-ADR B-ADR
activation I-ADR I-ADR
with O O
the O O
patient O O
's O O
serum O O

we O O
report O O
a O O
patient O O
with O O
pulmonary O O
adenocarcinoma O O
complicated O O
by O O
the O O
syndrome B-ADR O
of I-ADR O
inappropriate I-ADR O
secretion I-ADR O
of I-ADR O
antidiuretic I-ADR O
hormone I-ADR O
( O O
siadh O B-ADR
) O O
following O O
systemic O O
chemotherapy O O
with O O
cisplatin B-DRUG O
( O O
cddp O O
) O O
and O O
vindesine O O
( O O
vds O O

three O O
patients O O
who O O
had O O
experienced O O
neuroleptic-induced O O
akathisia B-ADR B-ADR
in O O
the O O
past O O
reported O O
that O O
the O O
symptoms O O
of O O
fluoxetine-induced O O
akathisia B-ADR B-ADR
were O O
identical O O
, O O
although O O
somewhat O O
milder O O

a O O
10-year-old O O
asthmatic O O
boy O O
began O O
to O O
suffer O O
from O O
urticarial B-ADR B-ADR
rash I-ADR I-ADR
and O O
moderately O O
severe O B-ADR
bronchospasm O I-ADR
after O O
8 O O
weeks' O O
treatment O O
with O O
disodium B-DRUG B-DRUG
cromoglycate I-DRUG I-DRUG

however O O
, O O
each O O
infant O O
demonstrated O O
hemodynamic B-ADR B-ADR
decompensation I-ADR I-ADR
shortly O O
after O O
verapamil B-DRUG B-DRUG
administration O O
and O O
required O O
cardiopulmonary O B-ADR
resuscitation O I-ADR

dental B-ADR O
and I-ADR O
gingival I-ADR B-ADR
pain I-ADR I-ADR
as O O
side O O
effects O O
of O O
niacin B-DRUG B-DRUG
therapy O O

fulminant O O
metoclopramide B-DRUG B-DRUG
induced O O
neuroleptic B-ADR B-ADR
malignant I-ADR I-ADR
syndrome I-ADR I-ADR
rapidly O O
responsive O O
to O O
intravenous O O
dantrolene O B-DRUG

we O O
report O O
a O O
case O O
of O O
acute B-ADR B-ADR
generalized I-ADR I-ADR
exanthematous I-ADR I-ADR
pustulosis I-ADR I-ADR
( O O
agep O B-ADR
) O O
in O O
a O O
50-year-old O O
woman O O
that O O
was O O
attributed O O
to O O
the O O
ingestion O O
of O O
nimesulide B-DRUG B-DRUG

we O O
present O O
two O O
cases O O
of O O
anaphylaxis B-ADR B-ADR
under O O
anaesthesia O O
where O O
return O O
of O O
spontaneous O O
circulation O O
was O O
refractory O O
to O O
epinephrine O B-DRUG
, O O
but O O
occurred O O
following O O
the O O
administration O O
of O O
the O O
alpha-agonist O O
metaraminol B-DRUG B-DRUG

the O O
noted O O
increase B-ADR B-ADR
in I-ADR I-ADR
the I-ADR I-ADR
theophylline I-ADR I-ADR
level I-ADR I-ADR
after O O
zafirlukast O B-DRUG
administration O O
is O O
in O O
contrast O O
to O O
the O O
original O O
reports O O
by O O
the O O
manufacturer O O

sertraline-induced O O
rhabdomyolysis B-ADR B-ADR
in O O
an O O
elderly O O
patient O O
with O O
dementia O O
and O O
comorbidities O O

rapid O O
onset O O
of O O
quetiapine-induced O O
diabetic B-ADR B-ADR
ketoacidosis I-ADR I-ADR
in O O
an O O
elderly O O
patient O O
: O O
a O O
case O O
report O O

anaphylaxis B-ADR B-ADR
to O O
intravenous O O
cyclosporine B-DRUG B-DRUG
and O O
tolerance O O
to O O
oral O O
cyclosporine B-DRUG B-DRUG
: O O
case O O
report O O
and O O
review O O

severe B-ADR B-ADR
diffuse I-ADR I-ADR
interstitial I-ADR I-ADR
pneumonitis I-ADR I-ADR
induced O O
by O O
carmustine O B-DRUG
( O O
bcnu B-DRUG B-DRUG

several O O
such O O
hbv B-ADR B-ADR
reactivations I-ADR I-ADR
were O O
reported O O
after O O
combined O O
rituximab B-DRUG B-DRUG
and O O
multiagent O O
chemotherapy O O
for O O
b-cell O O
lymphomas O O

patient O O
and O O
method O O
: O O
a O O
34-year-old O O
woman O O
with O O
chronic O O
hepatitis O O
c O O
, O O
genotype O O
3 O O
, O O
receiving O O
pegylated O O
interferon O O
alpha-2a O O
and O O
ribavirin B-DRUG B-DRUG
for O O
6 O O
months O O
, O O
developed O O
progressive B-ADR B-ADR
malaise I-ADR I-ADR
and O O
anemia O O
6 O O
months O O
after O O
the O O
end O O
of O O
treatment O O

thus O O
, O O
tacrolimus-induced O O
hus O B-ADR
is O O
a O O
rare O O
cause O O
of O O
arf B-ADR B-ADR
in O O
nephrotic O O
syndrome O O

we O O
describe O O
a O O
patient O O
with O O
acute O O
myeloblastic O O
leukemia O O
( O O
aml O O
) O O
who O O
developed O O
nephrotic B-ADR B-ADR
syndrome I-ADR I-ADR
after O O
receiving O O
several O O
courses O O
of O O
chemotherapy O O
, O O
including O O
macrophage-colony-stimulating B-DRUG O
factor I-DRUG O
( O O
m-csf O B-DRUG

codeine B-ADR B-ADR
intoxication I-ADR I-ADR
in O O
the O O
neonate O O

a O O
healthy O O
, O O
30-year-old O O
man O O
, O O
exposed O O
to O O
sulindac B-DRUG B-DRUG
on O O
two O O
separate O O
occasions O O
, O O
had O O
an O O
incapacitating O O
isolated B-ADR B-ADR
idential I-ADR I-ADR
sensory I-ADR I-ADR
neuropathy I-ADR I-ADR

new O O
onset O O
of O O
cd B-ADR B-ADR
may O O
be O O
considered O O
as O O
an O O
immune-mediated O B-ADR
injury O I-ADR
induced O O
by O O
etanercept B-DRUG B-DRUG

we O O
report O O
the O O
development O O
of O O
scrotal B-ADR B-ADR
ulcer I-ADR I-ADR
in O O
a O O
patient O O
with O O
acute O O
promyleocytic O O
leukemia O O
( O O
apl O B-ADR
) O O
within O O
10 O O
days O O
of O O
treatment O O
with O O
atra B-DRUG B-DRUG
at O O
a O O
dose O O
of O O
40 O O
mg O O
orally O O
twice O O
daily O O

we O O
report O O
a O O
case O O
of O O
an O O
infant O O
with O O
complex O O
congenital O O
heart O O
disease O O
who O O
was O O
placed O O
on O O
captopril B-DRUG B-DRUG
for O O
afterload O O
reduction O O
following O O
cardiac O O
surgery O O
and O O
subsequently O O
developed O O
pulmonary B-ADR B-ADR
infiltrates I-ADR I-ADR
with I-ADR O
eosinophilia I-ADR O

autopsy O O
findings O O
were O O
consistent O O
with O O
bleomycin B-DRUG B-DRUG
and O O
oxygen-induced O O
pulmonary B-ADR B-ADR
damage I-ADR I-ADR

